(6121,2,'2020-06-12 17:22:29','2020-06-12 17:22:29','We live in a world full of options. From food to places and apps, from sports tohobbies, studies to career options, houses to restaurants, buying to renting, homeremedies to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Homeopathy\">homeopathy medicines,</a></span> from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Ayurveda\">Ayurvedic</a></span> to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Allopathic_medicine\">allopathic medicines</a></span>. Be ititems, applications, eatables, clothes, places to visit, etc., everythingoffers a variety of options to choose from. However, we cannot afford to experiment with each of our choices or go by a hit and trial method especially when it comes to our health. One such significant, yetlightly side-lined choice is that of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a> </span>laboratories.\n<p style=\"text-align: right;\">It is not the easiest of decisions to choose a satisfactory and efficient diagnostic laboratory. It is natural to get a bit confused about what factors should be kept in mind before selecting a lab for testing the specimens of our blood/ urine/ body fluid/ stool, etc. Some of you might wonder why it is necessary to think before going to a <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a></span> laboratory, and should you really be that careful. The answer to that is yes! You have to be careful because decisions about your health and further treatment are madebased on the results provided by these laboratories. A laboratory has to follow certain regulatory guidelines when setting up.<img class=\"alignnone size-medium wp-image-6120\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/AA-300x289.png\" alt=\"\" width=\"300\" height=\"289\" /></p>\n&nbsp;\n\n<span style=\"text-decoration: underline;\">Here are fiveessential parameters that can be considered before choosing the appropriate diagnostic laboratory:</span>\n<strong>1.Laboratory setup and workflow:</strong>\n\n<img class=\"alignnone wp-image-6110\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/microbiology-laboratory-design-1024x683-1-300x200.jpg\" alt=\"\" width=\"422\" height=\"281\" />\n\nA laboratory should be appropriately designed, clearly demarcating collection area and work stations. The collection areas must be designed to impart privacy during collection and the laboratory must also ensure that the specimens are safe, spill-free and not damaged during transport. A good way these days to know aboutcollection practicesof a laboratory is to check customer reviews online.\n\n<strong>2. Availability of tests and advanced technologies:</strong>\n\n<img class=\" wp-image-6106\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/4228589276-healthcare-communications-unified-doctor-telehealth-mobile-tablet-supersize-300x167.jpg\" alt=\"\" width=\"435\" height=\"242\" />\n\nIn the current era of highest technological innovation and dependency, it goes without saying that advanced testing instruments are a must in a laboratory. This also increases the chances of accurate and precise health reports. Also, all the basic tests must be available at the laboratory because the effectiveness of a diagnostic laboratory is indicated by the availability of wide-ranged tests. Not all laboratories are equipped to perform all the tests on their premises due to the cost and infrastructure-related limitations.\n\n<strong>3. Laboratory employees:</strong>\n\n<img class=\"alignnone wp-image-6111\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/scientists-women-or-laboratory-employees-flat-vector-28925717-300x201.jpg\" alt=\"\" width=\"478\" height=\"320\" />\n\nAll the employees of the laboratory must be well informed, well aware and helpful towards the patients about their needs and queries. The experience, as well as the skills of the staff and the medical practitioner, are basic necessities. This experience is garnered if the lab has been established for a substantial period of time.\n\n<strong>4. Accreditation and standard of reporting:</strong>The laboratory must also have appropriate certification and accreditation to its name. Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) and NABH (National Accreditation Board for Hospitals) is standard practice for well-functioning laboratories. It also instils a sense of faith and confidence in the customers about the laboratory’s services.\n\n<strong>5.Availability of information:</strong>All the information that the patient needs to knowshould be made available in the laboratory. Be it through a brochure with test descriptions and their prices at the front desk as per the patient’s requirements. If there are discrepancies with reports, the laboratory must clearly communicate and work towards resolution.\n\nA laboratory report is very crucial for the patient’s health. If the accuracy is compromised it can have repercussions in the form of treatment modifications based on inaccurate reportswith effects ranging from minimal to severe impact on health\n\nThe digital world has given us many choices, it is our duty to make the most informed ones. When it comes to choosing the best laboratory for ourselves, rationality is emphasized. With this information, make the best choice for yourself and take care!','Here’s what you must know before you visit a diagnostic laboratory','','inherit','closed','closed','','6105-autosave-v1','','','2020-06-12 17:22:29','2020-06-12 17:22:29','',6105,'https://microbiozindia.com/uncategorized/6105-autosave-v1/',0,'revision','',0),(6122,2,'2020-06-12 17:22:55','2020-06-12 17:22:55','We live in a world full of options. From food to places and apps, from sports tohobbies, studies to career options, houses to restaurants, buying to renting, homeremedies to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Homeopathy\">homeopathy medicines,</a></span> from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Ayurveda\">Ayurvedic</a></span> to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Allopathic_medicine\">allopathic medicines</a></span>. Be ititems, applications, eatables, clothes, places to visit, etc., everythingoffers a variety of options to choose from. However, we cannot afford to experiment with each of our choices or go by a hit and trial method especially when it comes to our health. One such significant, yetlightly side-lined choice is that of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a> </span>laboratories.\r\n\r\nIt is not the easiest of decisions to choose a satisfactory and efficient diagnostic laboratory. It is natural to get a bit confused about what factors should be kept in mind before selecting a lab for testing the specimens of our blood/ urine/ body fluid/ stool, etc. Some of you might wonder why it is necessary to think before going to a <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a></span> laboratory, and should you really be that careful. The answer to that is yes! You have to be careful because decisions about your health and further treatment are madebased on the results provided by these laboratories. A laboratory has to follow certain regulatory guidelines when setting up.\r\n\r\n<img class=\"size-medium wp-image-6120 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/AA-300x289.png\" alt=\"\" width=\"300\" height=\"289\" /><span style=\"text-decoration: underline;\">Here are fiveessential parameters that can be considered before choosing the appropriate diagnostic laboratory:</span>\r\n<strong>1.Laboratory setup and workflow:</strong>\r\n\r\n<img class=\"alignnone wp-image-6110\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/microbiology-laboratory-design-1024x683-1-300x200.jpg\" alt=\"\" width=\"422\" height=\"281\" />\r\n\r\nA laboratory should be appropriately designed, clearly demarcating collection area and work stations. The collection areas must be designed to impart privacy during collection and the laboratory must also ensure that the specimens are safe, spill-free and not damaged during transport. A good way these days to know aboutcollection practicesof a laboratory is to check customer reviews online.\r\n\r\n<strong>2. Availability of tests and advanced technologies:</strong>\r\n\r\n<img class=\" wp-image-6106\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/4228589276-healthcare-communications-unified-doctor-telehealth-mobile-tablet-supersize-300x167.jpg\" alt=\"\" width=\"435\" height=\"242\" />\r\n\r\nIn the current era of highest technological innovation and dependency, it goes without saying that advanced testing instruments are a must in a laboratory. This also increases the chances of accurate and precise health reports. Also, all the basic tests must be available at the laboratory because the effectiveness of a diagnostic laboratory is indicated by the availability of wide-ranged tests. Not all laboratories are equipped to perform all the tests on their premises due to the cost and infrastructure-related limitations.\r\n\r\n<strong>3. Laboratory employees:</strong>\r\n\r\n<img class=\"alignnone wp-image-6111\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/scientists-women-or-laboratory-employees-flat-vector-28925717-300x201.jpg\" alt=\"\" width=\"478\" height=\"320\" />\r\n\r\nAll the employees of the laboratory must be well informed, well aware and helpful towards the patients about their needs and queries. The experience, as well as the skills of the staff and the medical practitioner, are basic necessities. This experience is garnered if the lab has been established for a substantial period of time.\r\n\r\n<strong>4. Accreditation and standard of reporting:</strong>The laboratory must also have appropriate certification and accreditation to its name. Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) and NABH (National Accreditation Board for Hospitals) is standard practice for well-functioning laboratories. It also instils a sense of faith and confidence in the customers about the laboratory’s services.\r\n\r\n<strong>5.Availability of information:</strong>All the information that the patient needs to knowshould be made available in the laboratory. Be it through a brochure with test descriptions and their prices at the front desk as per the patient’s requirements. If there are discrepancies with reports, the laboratory must clearly communicate and work towards resolution.\r\n\r\nA laboratory report is very crucial for the patient’s health. If the accuracy is compromised it can have repercussions in the form of treatment modifications based on inaccurate reportswith effects ranging from minimal to severe impact on health\r\n\r\nThe digital world has given us many choices, it is our duty to make the most informed ones. When it comes to choosing the best laboratory for ourselves, rationality is emphasized. With this information, make the best choice for yourself and take care!','Here’s what you must know before you visit a diagnostic laboratory','','inherit','closed','closed','','6105-revision-v1','','','2020-06-12 17:22:55','2020-06-12 17:22:55','',6105,'https://microbiozindia.com/uncategorized/6105-revision-v1/',0,'revision','',0),(6123,2,'2020-06-12 17:34:55','2020-06-12 17:34:55','','Untitled','','inherit','open','closed','','untitled-3','','','2020-06-12 17:34:55','2020-06-12 17:34:55','',6105,'https://microbiozindia.com/wp-content/uploads/2020/06/Untitled.png',0,'attachment','image/png',0),(6124,2,'2020-06-12 17:35:13','2020-06-12 17:35:13','We live in a world full of options. From food to places and apps, from sports tohobbies, studies to career options, houses to restaurants, buying to renting, homeremedies to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Homeopathy\">homeopathy medicines,</a></span> from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Ayurveda\">Ayurvedic</a></span> to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Allopathic_medicine\">allopathic medicines</a></span>. Be ititems, applications, eatables, clothes, places to visit, etc., everythingoffers a variety of options to choose from. However, we cannot afford to experiment with each of our choices or go by a hit and trial method especially when it comes to our health. One such significant, yetlightly side-lined choice is that of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a> </span>laboratories.<img class=\" wp-image-6123 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/Untitled-300x256.png\" alt=\"\" width=\"371\" height=\"317\" />\r\n\r\nIt is not the easiest of decisions to choose a satisfactory and efficient diagnostic laboratory. It is natural to get a bit confused about what factors should be kept in mind before selecting a lab for testing the specimens of our blood/ urine/ body fluid/ stool, etc. Some of you might wonder why it is necessary to think before going to a <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a></span> laboratory, and should you really be that careful. The answer to that is yes! You have to be careful because decisions about your health and further treatment are madebased on the results provided by these laboratories. A laboratory has to follow certain regulatory guidelines when setting up.\r\n\r\n<span style=\"text-decoration: underline;\">Here are fiveessential parameters that can be considered before choosing the appropriate diagnostic laboratory:</span>\r\n<strong>1.Laboratory setup and workflow:</strong>\r\n\r\n<img class=\"alignnone wp-image-6110\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/microbiology-laboratory-design-1024x683-1-300x200.jpg\" alt=\"\" width=\"422\" height=\"281\" />\r\n\r\nA laboratory should be appropriately designed, clearly demarcating collection area and work stations. The collection areas must be designed to impart privacy during collection and the laboratory must also ensure that the specimens are safe, spill-free and not damaged during transport. A good way these days to know aboutcollection practicesof a laboratory is to check customer reviews online.\r\n\r\n<strong>2. Availability of tests and advanced technologies:</strong>\r\n\r\n<img class=\" wp-image-6106\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/4228589276-healthcare-communications-unified-doctor-telehealth-mobile-tablet-supersize-300x167.jpg\" alt=\"\" width=\"435\" height=\"242\" />\r\n\r\nIn the current era of highest technological innovation and dependency, it goes without saying that advanced testing instruments are a must in a laboratory. This also increases the chances of accurate and precise health reports. Also, all the basic tests must be available at the laboratory because the effectiveness of a diagnostic laboratory is indicated by the availability of wide-ranged tests. Not all laboratories are equipped to perform all the tests on their premises due to the cost and infrastructure-related limitations.\r\n\r\n<strong>3. Laboratory employees:</strong>\r\n\r\n<img class=\"alignnone wp-image-6111\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/scientists-women-or-laboratory-employees-flat-vector-28925717-300x201.jpg\" alt=\"\" width=\"478\" height=\"320\" />\r\n\r\nAll the employees of the laboratory must be well informed, well aware and helpful towards the patients about their needs and queries. The experience, as well as the skills of the staff and the medical practitioner, are basic necessities. This experience is garnered if the lab has been established for a substantial period of time.\r\n\r\n<strong>4. Accreditation and standard of reporting:</strong>The laboratory must also have appropriate certification and accreditation to its name. Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) and NABH (National Accreditation Board for Hospitals) is standard practice for well-functioning laboratories. It also instils a sense of faith and confidence in the customers about the laboratory’s services.\r\n\r\n<strong>5.Availability of information:</strong>All the information that the patient needs to knowshould be made available in the laboratory. Be it through a brochure with test descriptions and their prices at the front desk as per the patient’s requirements. If there are discrepancies with reports, the laboratory must clearly communicate and work towards resolution.\r\n\r\nA laboratory report is very crucial for the patient’s health. If the accuracy is compromised it can have repercussions in the form of treatment modifications based on inaccurate reportswith effects ranging from minimal to severe impact on health\r\n\r\nThe digital world has given us many choices, it is our duty to make the most informed ones. When it comes to choosing the best laboratory for ourselves, rationality is emphasized. With this information, make the best choice for yourself and take care!','Here’s what you must know before you visit a diagnostic laboratory','','inherit','closed','closed','','6105-revision-v1','','','2020-06-12 17:35:13','2020-06-12 17:35:13','',6105,'https://microbiozindia.com/uncategorized/6105-revision-v1/',0,'revision','',0),(6125,2,'2020-06-12 17:35:59','2020-06-12 17:35:59','We live in a world full of options. From food to places and apps, from sports tohobbies, studies to career options, houses to restaurants, buying to renting, homeremedies to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Homeopathy\">homeopathy medicines,</a></span> from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Ayurveda\">Ayurvedic</a></span> to <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Allopathic_medicine\">allopathic medicines</a></span>. Be ititems, applications, eatables, clothes, places to visit, etc., everythingoffers a variety of options to choose from. However, we cannot afford to experiment with each of our choices or go by a hit and trial method especially when it comes to our health. One such significant, yetlightly side-lined choice is that of <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a> </span>laboratories.<img class=\"wp-image-6123 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/Untitled-300x256.png\" alt=\"\" width=\"371\" height=\"317\" />\r\n\r\nIt is not the easiest of decisions to choose a satisfactory and efficient diagnostic laboratory. It is natural to get a bit confused about what factors should be kept in mind before selecting a lab for testing the specimens of our blood/ urine/ body fluid/ stool, etc. Some of you might wonder why it is necessary to think before going to a <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.merriam-webster.com/dictionary/diagnostic\">diagnostic</a></span> laboratory, and should you really be that careful. The answer to that is yes! You have to be careful because decisions about your health and further treatment are madebased on the results provided by these laboratories. A laboratory has to follow certain regulatory guidelines when setting up.\r\n\r\n<span style=\"text-decoration: underline;\">Here are fiveessential parameters that can be considered before choosing the appropriate diagnostic laboratory:</span>\r\n<strong>1.Laboratory setup and workflow:</strong>\r\n\r\n<img class=\"alignnone wp-image-6110\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/microbiology-laboratory-design-1024x683-1-300x200.jpg\" alt=\"\" width=\"422\" height=\"281\" />\r\n\r\nA laboratory should be appropriately designed, clearly demarcating collection area and work stations. The collection areas must be designed to impart privacy during collection and the laboratory must also ensure that the specimens are safe, spill-free and not damaged during transport. A good way these days to know aboutcollection practicesof a laboratory is to check customer reviews online.\r\n\r\n<strong>2. Availability of tests and advanced technologies:</strong>\r\n\r\n<img class=\" wp-image-6106\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/4228589276-healthcare-communications-unified-doctor-telehealth-mobile-tablet-supersize-300x167.jpg\" alt=\"\" width=\"435\" height=\"242\" />\r\n\r\nIn the current era of highest technological innovation and dependency, it goes without saying that advanced testing instruments are a must in a laboratory. This also increases the chances of accurate and precise health reports. Also, all the basic tests must be available at the laboratory because the effectiveness of a diagnostic laboratory is indicated by the availability of wide-ranged tests. Not all laboratories are equipped to perform all the tests on their premises due to the cost and infrastructure-related limitations.\r\n\r\n<strong>3. Laboratory employees:</strong>\r\n\r\n<img class=\"alignnone wp-image-6111\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/scientists-women-or-laboratory-employees-flat-vector-28925717-300x201.jpg\" alt=\"\" width=\"478\" height=\"320\" />\r\n\r\nAll the employees of the laboratory must be well informed, well aware and helpful towards the patients about their needs and queries. The experience, as well as the skills of the staff and the medical practitioner, are basic necessities. This experience is garnered if the lab has been established for a substantial period of time.\r\n\r\n<strong>4. Accreditation and standard of reporting:</strong>The laboratory must also have appropriate certification and accreditation to its name. Accreditation by NABL (National Accreditation Board for Testing and Calibration Laboratories) and NABH (National Accreditation Board for Hospitals) is standard practice for well-functioning laboratories. It also instils a sense of faith and confidence in the customers about the laboratory’s services.\r\n\r\n<strong>5.Availability of information:</strong>All the information that the patient needs to knowshould be made available in the laboratory. Be it through a brochure with test descriptions and their prices at the front desk as per the patient’s requirements. If there are discrepancies with reports, the laboratory must clearly communicate and work towards resolution.\r\n\r\nA laboratory report is very crucial for the patient’s health. If the accuracy is compromised it can have repercussions in the form of treatment modifications based on inaccurate reportswith effects ranging from minimal to severe impact on health\r\n\r\nThe digital world has given us many choices, it is our duty to make the most informed ones. When it comes to choosing the best laboratory for ourselves, rationality is emphasized. With this information, make the best choice for yourself and take care!','Here’s what you must know before you visit a diagnostic laboratory','','inherit','closed','closed','','6105-revision-v1','','','2020-06-12 17:35:59','2020-06-12 17:35:59','',6105,'https://microbiozindia.com/uncategorized/6105-revision-v1/',0,'revision','',0),(6126,2,'2020-06-13 05:18:22','2020-06-13 05:18:22','Biocon Ltd and Mylan NV on Friday reported that they have gotten endorsement from the United States Food and Drug Administration (FDA) for the dispatch of its insulin glargine infusion Semglee which is intended to control high glucose in grown-ups with diabetes\r\n\r\n\"The US FDA has affirmed the New Drug Application (NDA) for Semglee (insulin glargine infusion), in vial and pre-filled pen introductions, to control high glucose in grown-ups with Type-2 diabetes and grown-up and pediatric patients with Type-1 diabetes. Semglee has an indistinguishable amino corrosive arrangement to Sanofi\'s Lantus and is endorsed for similar signs,\" the organizations said in an announcement.\r\n\r\nSemglee has been created by the India-based Biocon Biologics in association with Mylan. It was affirmed by the USFDA as a medication item under the 505(b)(2) NDA pathway.\r\n\r\nWith the item being esteemed as a biologic under segment 351(a) as per the Biologics Price Competition and Innovation Act in accordance with other insulin items, it turns into the third biologics propelled by Biocon in the US.\r\n\r\nThe endorsement for the item was looked for dependent on a \"thorough explanatory, preclinical and clinical programmeme (counting the INSTRIDE considers).\" This program affirmed the PK/PD, viability, security and immunogenicity of the infusion in patients with Type-1 and Type-2 diabetes.\r\n\r\nKiran Mazumdar Shaw, Chairperson, Biocon, stated: \"The endorsement of our insulin glargine by the US FDA denotes the perfection of a long excursion. As an association focused on making insulin-based treatment progressively available for individuals with diabetes comprehensively, I am happy this endorsement will empower us to serve the requirements of patients in the US The endorsement is likewise an underwriting of our science, scale and skill to grow excellent, increasingly reasonable insulins and move the entrance worldview for patients, taking us closer to understanding our desire of coming to \'one of every five\' insulin-subordinate individuals with diabetes around the world.\"\r\n\r\nThe commercialisation of this insulin glargine infusion in the US will additionally grow the moderateness and openness of such items for diabetic patients according to the organization.\r\n\r\n\"This endorsement is a significant achievement, most importantly for the a large number of patients living with diabetes in the US as we try to extend their entrance to insulin through increasingly reasonable treatment choices,\" said Mylan CEO Heather Bresch.','Biocon, Mylan get USFDA endorsement for the dispatch of their insulin glargine infusion','','publish','open','open','','biocon-mylan-get-usfda-endorsement-for-the-dispatch-of-their-insulin-glargine-infusion','','','2020-06-13 05:18:22','2020-06-13 05:18:22','',0,'https://microbiozindia.com/?p=6126',0,'post','',0),(6127,2,'2020-06-13 05:18:22','2020-06-13 05:18:22','Biocon Ltd and Mylan NV on Friday reported that they have gotten endorsement from the United States Food and Drug Administration (FDA) for the dispatch of its insulin glargine infusion Semglee which is intended to control high glucose in grown-ups with diabetes\r\n\r\n\"The US FDA has affirmed the New Drug Application (NDA) for Semglee (insulin glargine infusion), in vial and pre-filled pen introductions, to control high glucose in grown-ups with Type-2 diabetes and grown-up and pediatric patients with Type-1 diabetes. Semglee has an indistinguishable amino corrosive arrangement to Sanofi\'s Lantus and is endorsed for similar signs,\" the organizations said in an announcement.\r\n\r\nSemglee has been created by the India-based Biocon Biologics in association with Mylan. It was affirmed by the USFDA as a medication item under the 505(b)(2) NDA pathway.\r\n\r\nWith the item being esteemed as a biologic under segment 351(a) as per the Biologics Price Competition and Innovation Act in accordance with other insulin items, it turns into the third biologics propelled by Biocon in the US.\r\n\r\nThe endorsement for the item was looked for dependent on a \"thorough explanatory, preclinical and clinical programmeme (counting the INSTRIDE considers).\" This program affirmed the PK/PD, viability, security and immunogenicity of the infusion in patients with Type-1 and Type-2 diabetes.\r\n\r\nKiran Mazumdar Shaw, Chairperson, Biocon, stated: \"The endorsement of our insulin glargine by the US FDA denotes the perfection of a long excursion. As an association focused on making insulin-based treatment progressively available for individuals with diabetes comprehensively, I am happy this endorsement will empower us to serve the requirements of patients in the US The endorsement is likewise an underwriting of our science, scale and skill to grow excellent, increasingly reasonable insulins and move the entrance worldview for patients, taking us closer to understanding our desire of coming to \'one of every five\' insulin-subordinate individuals with diabetes around the world.\"\r\n\r\nThe commercialisation of this insulin glargine infusion in the US will additionally grow the moderateness and openness of such items for diabetic patients according to the organization.\r\n\r\n\"This endorsement is a significant achievement, most importantly for the a large number of patients living with diabetes in the US as we try to extend their entrance to insulin through increasingly reasonable treatment choices,\" said Mylan CEO Heather Bresch.','Biocon, Mylan get USFDA endorsement for the dispatch of their insulin glargine infusion','','inherit','closed','closed','','6126-revision-v1','','','2020-06-13 05:18:22','2020-06-13 05:18:22','',6126,'https://microbiozindia.com/uncategorized/6126-revision-v1/',0,'revision','',0),(6128,2,'2020-06-13 06:08:22','2020-06-13 06:08:22','A gathering of specialists at IIT-Kharagpur has built up a digital physical framework dependent on computerized reasoning for checking social removing in broad daylight puts, an authority said on Saturday.\r\n\r\nThe group, under the authority of teacher Debashish Chakravarty and educator Aditya Bandopadhyay, has designed a minimal effort gadget which can recognize the hole between people, a representative of IIT-KGP said.\r\n\r\n\"The gadget will play a vicinity ready sound through sound yield, at whatever point any infringement of the social removing standards happens. It catches pictures of the field see and registers the separation according to rules set by the Ministry of Health and Family Welfare,\" an individual from the examination bunch said.\r\n\r\nThe specialists had concentrated on the simplicity of organization of such a gadget in remote places and diminishing the expense by utilizing cheap and effectively open equipment materials, he said.\r\n\r\nUnderstudies have thought of the gadget utilizing promptly accessible equipment while the lockdown was set up, the representative said.\r\n\r\nThe framework has been effectively tried by introducing three models of the gadget inside the IIT-Kharagpur grounds.','IIT-KGP specialists create AI-based framework to follow social distancing','','publish','open','open','','iit-kgp-specialists-create-ai-based-framework-to-follow-social-distancing','','','2020-06-13 06:08:22','2020-06-13 06:08:22','',0,'https://microbiozindia.com/?p=6128',0,'post','',0),(6129,2,'2020-06-13 06:06:06','2020-06-13 06:06:06','','covid-19-5224065_640','','inherit','open','closed','','covid-19-5224065_640','','','2020-06-13 06:06:06','2020-06-13 06:06:06','',6128,'https://microbiozindia.com/wp-content/uploads/2020/06/covid-19-5224065_640.jpg',0,'attachment','image/jpeg',0),(6130,2,'2020-06-13 06:08:22','2020-06-13 06:08:22','A gathering of specialists at IIT-Kharagpur has built up a digital physical framework dependent on computerized reasoning for checking social removing in broad daylight puts, an authority said on Saturday.\r\n\r\nThe group, under the authority of teacher Debashish Chakravarty and educator Aditya Bandopadhyay, has designed a minimal effort gadget which can recognize the hole between people, a representative of IIT-KGP said.\r\n\r\n\"The gadget will play a vicinity ready sound through sound yield, at whatever point any infringement of the social removing standards happens. It catches pictures of the field see and registers the separation according to rules set by the Ministry of Health and Family Welfare,\" an individual from the examination bunch said.\r\n\r\nThe specialists had concentrated on the simplicity of organization of such a gadget in remote places and diminishing the expense by utilizing cheap and effectively open equipment materials, he said.\r\n\r\nUnderstudies have thought of the gadget utilizing promptly accessible equipment while the lockdown was set up, the representative said.\r\n\r\nThe framework has been effectively tried by introducing three models of the gadget inside the IIT-Kharagpur grounds.','IIT-KGP specialists create AI-based framework to follow social distancing','','inherit','closed','closed','','6128-revision-v1','','','2020-06-13 06:08:22','2020-06-13 06:08:22','',6128,'https://microbiozindia.com/uncategorized/6128-revision-v1/',0,'revision','',0),(6131,2,'2020-06-13 08:22:39','2020-06-13 08:22:39','The U.S. Food and Drug Administration has endorsed a medication to treat newborn children and kids with HIV, with the medication having been created by drugmaker GlaxoSmithKline\'s HIV drugs division ViiV Healthcare, the FDA and the GSK unit said.\r\n\r\nThe FDA said on Friday it was conceding Viiv the endorsement of Tivicay and Tivicay PD tablets \"for suspension to treat HIV-1 disease in pediatric patients at any rate a month old and weighing in any event 3 kgs in blend with other antiretroviral medicines\".\r\n\r\nThe medication is at present under audit by the European Medicines Agency, ViiV, in which Pfizer and Shionogi have little stakes, said in a different articulation.','U.S. FDA favors GSK unit\'s medication to treat newborn children and kids with HIV','','publish','open','open','','u-s-fda-favors-gsk-units-medication-to-treat-newborn-children-and-kids-with-hiv','','','2020-06-13 08:22:39','2020-06-13 08:22:39','',0,'https://microbiozindia.com/?p=6131',0,'post','',0),(6132,2,'2020-06-13 08:22:39','2020-06-13 08:22:39','The U.S. Food and Drug Administration has endorsed a medication to treat newborn children and kids with HIV, with the medication having been created by drugmaker GlaxoSmithKline\'s HIV drugs division ViiV Healthcare, the FDA and the GSK unit said.\r\n\r\nThe FDA said on Friday it was conceding Viiv the endorsement of Tivicay and Tivicay PD tablets \"for suspension to treat HIV-1 disease in pediatric patients at any rate a month old and weighing in any event 3 kgs in blend with other antiretroviral medicines\".\r\n\r\nThe medication is at present under audit by the European Medicines Agency, ViiV, in which Pfizer and Shionogi have little stakes, said in a different articulation.','U.S. FDA favors GSK unit\'s medication to treat newborn children and kids with HIV','','inherit','closed','closed','','6131-revision-v1','','','2020-06-13 08:22:39','2020-06-13 08:22:39','',6131,'https://microbiozindia.com/uncategorized/6131-revision-v1/',0,'revision','',0),(6133,2,'2020-06-13 08:24:49','2020-06-13 08:24:49','Indian drugmaker Zydus Cadila said on Friday it marked a non-selective permitting agreement with Gilead Sciences Inc to make and market antiviral medication remdesivir, the main treatment to show improvement in COVID-19 preliminaries.\r\n\r\nZydus, recorded as Cadila Healthcare, joins other Indian pharmaceutical organizations Cipla Ltd, Jubilant Sciences Ltd and secretly held Hetero Labs Ltd in marking non-selective settlements with Gilead for the medication.\r\n\r\nClinical investigations including the medication are by and large firmly looked as countries search for medicines for the sickness that has tainted in excess of 7 million individuals and executed more than 400,000 comprehensively.','India\'s Zydus Cadila to make Gilead\'s potential COVID-19 medication remdesivir','','publish','open','open','','indias-zydus-cadila-to-make-gileads-potential-covid-19-medication-remdesivir','','','2020-06-13 08:24:49','2020-06-13 08:24:49','',0,'https://microbiozindia.com/?p=6133',0,'post','',0),(6134,2,'2020-06-13 08:24:49','2020-06-13 08:24:49','Indian drugmaker Zydus Cadila said on Friday it marked a non-selective permitting agreement with Gilead Sciences Inc to make and market antiviral medication remdesivir, the main treatment to show improvement in COVID-19 preliminaries.\r\n\r\nZydus, recorded as Cadila Healthcare, joins other Indian pharmaceutical organizations Cipla Ltd, Jubilant Sciences Ltd and secretly held Hetero Labs Ltd in marking non-selective settlements with Gilead for the medication.\r\n\r\nClinical investigations including the medication are by and large firmly looked as countries search for medicines for the sickness that has tainted in excess of 7 million individuals and executed more than 400,000 comprehensively.','India\'s Zydus Cadila to make Gilead\'s potential COVID-19 medication remdesivir','','inherit','closed','closed','','6133-revision-v1','','','2020-06-13 08:24:49','2020-06-13 08:24:49','',6133,'https://microbiozindia.com/uncategorized/6133-revision-v1/',0,'revision','',0),(6136,2,'2020-06-13 08:37:53','2020-06-13 08:37:53','Upgradation of framework at a Government Medical College Hospital close here proved to be useful to oversee plasma to a coronavirus tolerant from a benefactor restored of COVID-19, utilizing apheresis strategy without precedent for Kerala.\r\n\r\nA clinical hardware that does the apheresis system was introduced at the GMCH at close by Thrissur a month ago and the method was utilized without precedent for Kerala to oversee plasma to a 51-year elderly person, authorities said on Friday.\r\n\r\nThey communicated certainty that the system, which has been finished effectively would help spare the patient. \"This is the main occurrence of utilization of such a real existence sparing cure in the state,\" Health specialists said here in an announcement. The apheresis method was done by GMC\'s technologists working with the divisions of medication, transfusion medication and sedation.\r\n\r\nUnder the method, blood of the contributor, Davis Antony was gone through the gadget which isolated plasma and let that part alone into the circulatory system of the patient intravenously and sent the other blood constituents again into the blood arrangement of the giver. The giver was relieved of COVID-19.\r\n\r\nThe strategy started on Thursday night and was finished on Friday, they said including the fundamentally sick infection tormented man kept on being in the clinic for treatment. \"We welcome the signal and expectation that all the more such volunteers will move toward us to give plasma in the countries battle against COVID-19, Dr M An Andrews, head, GMC said.','In a first in Kerala, Apheresis strategy used to manage plasma to COVID-19 patient','','publish','open','open','','in-a-first-in-kerala-apheresis-strategy-used-to-manage-plasma-to-covid-19-patient','','','2020-06-13 08:37:53','2020-06-13 08:37:53','',0,'https://microbiozindia.com/?p=6136',0,'post','',0),(6137,2,'2020-06-13 08:37:53','2020-06-13 08:37:53','Upgradation of framework at a Government Medical College Hospital close here proved to be useful to oversee plasma to a coronavirus tolerant from a benefactor restored of COVID-19, utilizing apheresis strategy without precedent for Kerala.\r\n\r\nA clinical hardware that does the apheresis system was introduced at the GMCH at close by Thrissur a month ago and the method was utilized without precedent for Kerala to oversee plasma to a 51-year elderly person, authorities said on Friday.\r\n\r\nThey communicated certainty that the system, which has been finished effectively would help spare the patient. \"This is the main occurrence of utilization of such a real existence sparing cure in the state,\" Health specialists said here in an announcement. The apheresis method was done by GMC\'s technologists working with the divisions of medication, transfusion medication and sedation.\r\n\r\nUnder the method, blood of the contributor, Davis Antony was gone through the gadget which isolated plasma and let that part alone into the circulatory system of the patient intravenously and sent the other blood constituents again into the blood arrangement of the giver. The giver was relieved of COVID-19.\r\n\r\nThe strategy started on Thursday night and was finished on Friday, they said including the fundamentally sick infection tormented man kept on being in the clinic for treatment. \"We welcome the signal and expectation that all the more such volunteers will move toward us to give plasma in the countries battle against COVID-19, Dr M An Andrews, head, GMC said.','In a first in Kerala, Apheresis strategy used to manage plasma to COVID-19 patient','','inherit','closed','closed','','6136-revision-v1','','','2020-06-13 08:37:53','2020-06-13 08:37:53','',6136,'https://microbiozindia.com/uncategorized/6136-revision-v1/',0,'revision','',0),(6138,2,'2020-06-13 08:51:30','2020-06-13 08:51:30','Analysts from North Carolina State University have built up an in a general sense new way to deal with DNA information stockpiling frameworks, enabling clients to peruse or adjust information records without decimating them and making the frameworks simpler to scale up for functional use.\r\n\r\n\"The greater part of the current DNA information stockpiling frameworks depend on polymerase chain response (PCR) to get to put away documents, which is exceptionally productive at replicating data yet presents some critical difficulties,\" says Albert Keung, co-relating creator of a paper on the work. \"We\'ve built up a framework called Dynamic Operations and Reusable Information Storage, or DORIS, that doesn\'t depend on PCR. That has helped us address a portion of the key hindrances confronting handy execution of DNA information stockpiling innovations.\" Keung is an associate teacher of substance and biomolecular building at NC State.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">DNA information stockpiling frameworks can possibly hold significant degrees more data than existing frameworks of tantamount size. In any case, existing advancements have battled to address a scope of concerns identified with functional usage.</a></span>\r\n\r\nCurrent frameworks depend on groupings of DNA called groundwork restricting successions that are added to the closures of DNA strands that store data. To put it plainly, the groundwork restricting succession of DNA fills in as a record name. At the point when you need a given record, you recover the strands of DNA bearing that arrangement.\r\n\r\nA significant number of the reasonable obstructions to DNA information stockpiling advancements rotate around the utilization of PCR to recover put away information. Frameworks that depend on PCR need to definitely raise and lower the temperature of the put away hereditary material so as to tear the twofold abandoned DNA separated and uncover the groundwork restricting grouping. This outcomes in the entirety of the DNA - the preliminary restricting groupings and the information stockpiling arrangements - swimming free in a sort of hereditary soup. Existing advancements would then be able to figure out the soup to discover, recover and duplicate the applicable DNA utilizing PCR. The temperature swings are hazardous for creating handy advancements, and the PCR method itself bit by bit expends - or goes through - the first form of the document that is being recovered.\r\n\r\nDORIS adopts an alternate strategy. Rather than utilizing twofold abandoned DNA as a preliminary restricting succession, DORIS utilizes an \"overhang\" that comprises of a solitary strand of DNA - like a tail that streams behind the twofold abandoned DNA that really stores information. While customary procedures required temperature vacillations to tear open the DNA so as to locate the pertinent groundwork restricting groupings, utilizing a solitary abandoned shade implies that DORIS can locate the fitting preliminary restricting successions without upsetting the twofold abandoned DNA.\r\n\r\n\"As it were, DORIS can work at room temperature, making it considerably more possible to create DNA information the board advances that are practical in genuine situations,\" says James Tuck, co-comparing creator of the paper and an educator of electrical and PC building at NC State.\r\n\r\nThe other advantage of not tearing separated the DNA strands is that the DNA succession in the shade can be equivalent to an arrangement found in the twofold abandoned district of the information document itself. That is hard to accomplish in PCR-based frameworks without giving up data thickness - in light of the fact that the framework wouldn\'t have the option to separate between preliminary restricting groupings and information stockpiling successions.\r\n\r\n\"DORIS permits us to altogether expand the data thickness of the framework, and furthermore makes it simpler to scale up to deal with extremely enormous databases,\" says Kevin Lin, first creator of the paper and a Ph.D. understudy at NC State.\r\n\r\nWhat\'s more, when DORIS has distinguished the right DNA grouping, it doesn\'t depend on PCR to make duplicates. Rather, DORIS translates the DNA to RNA, which is then converse deciphered go into DNA which the information stockpiling framework can peruse. At the end of the day, DORIS doesn\'t need to devour the first document so as to understand it.\r\n\r\nThe single-abandoned shades can likewise be altered, permitting clients to rename records, erase documents or \"lock\" them - adequately making them imperceptible to different clients.\r\n\r\n\"We\'ve built up a practical model of DORIS, so we realize it works,\" Keung says. \"We\'re currently keen on scaling it up, speeding it up and placing it into a gadget that robotizes the procedure - making it easy to use.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">Materials</a></span> provided by North Carolina State University and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nKevin N. Lin, Kevin Volkel, James M. Tuck, Albert J. Keung. Dynamic and scalable DNA-based information storage. Nature Communications, 2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">11 (1) DOI: 10.1038/s41467-020-16797-2</a></span>','New way to deal with DNA data stockpiling makes framework progressively powerful, adaptable','','publish','open','open','','new-way-to-deal-with-dna-data-stockpiling-makes-framework-progressively-powerful-adaptable','','','2020-06-13 08:51:30','2020-06-13 08:51:30','',0,'https://microbiozindia.com/?p=6138',0,'post','',0),(6139,2,'2020-06-13 08:51:13','2020-06-13 08:51:13','','dna-308919_640','','inherit','open','closed','','dna-308919_640','','','2020-06-13 08:51:13','2020-06-13 08:51:13','',6138,'https://microbiozindia.com/wp-content/uploads/2020/06/dna-308919_640.png',0,'attachment','image/png',0),(6140,2,'2020-06-13 08:51:30','2020-06-13 08:51:30','Analysts from North Carolina State University have built up an in a general sense new way to deal with DNA information stockpiling frameworks, enabling clients to peruse or adjust information records without decimating them and making the frameworks simpler to scale up for functional use.\r\n\r\n\"The greater part of the current DNA information stockpiling frameworks depend on polymerase chain response (PCR) to get to put away documents, which is exceptionally productive at replicating data yet presents some critical difficulties,\" says Albert Keung, co-relating creator of a paper on the work. \"We\'ve built up a framework called Dynamic Operations and Reusable Information Storage, or DORIS, that doesn\'t depend on PCR. That has helped us address a portion of the key hindrances confronting handy execution of DNA information stockpiling innovations.\" Keung is an associate teacher of substance and biomolecular building at NC State.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">DNA information stockpiling frameworks can possibly hold significant degrees more data than existing frameworks of tantamount size. In any case, existing advancements have battled to address a scope of concerns identified with functional usage.</a></span>\r\n\r\nCurrent frameworks depend on groupings of DNA called groundwork restricting successions that are added to the closures of DNA strands that store data. To put it plainly, the groundwork restricting succession of DNA fills in as a record name. At the point when you need a given record, you recover the strands of DNA bearing that arrangement.\r\n\r\nA significant number of the reasonable obstructions to DNA information stockpiling advancements rotate around the utilization of PCR to recover put away information. Frameworks that depend on PCR need to definitely raise and lower the temperature of the put away hereditary material so as to tear the twofold abandoned DNA separated and uncover the groundwork restricting grouping. This outcomes in the entirety of the DNA - the preliminary restricting groupings and the information stockpiling arrangements - swimming free in a sort of hereditary soup. Existing advancements would then be able to figure out the soup to discover, recover and duplicate the applicable DNA utilizing PCR. The temperature swings are hazardous for creating handy advancements, and the PCR method itself bit by bit expends - or goes through - the first form of the document that is being recovered.\r\n\r\nDORIS adopts an alternate strategy. Rather than utilizing twofold abandoned DNA as a preliminary restricting succession, DORIS utilizes an \"overhang\" that comprises of a solitary strand of DNA - like a tail that streams behind the twofold abandoned DNA that really stores information. While customary procedures required temperature vacillations to tear open the DNA so as to locate the pertinent groundwork restricting groupings, utilizing a solitary abandoned shade implies that DORIS can locate the fitting preliminary restricting successions without upsetting the twofold abandoned DNA.\r\n\r\n\"As it were, DORIS can work at room temperature, making it considerably more possible to create DNA information the board advances that are practical in genuine situations,\" says James Tuck, co-comparing creator of the paper and an educator of electrical and PC building at NC State.\r\n\r\nThe other advantage of not tearing separated the DNA strands is that the DNA succession in the shade can be equivalent to an arrangement found in the twofold abandoned district of the information document itself. That is hard to accomplish in PCR-based frameworks without giving up data thickness - in light of the fact that the framework wouldn\'t have the option to separate between preliminary restricting groupings and information stockpiling successions.\r\n\r\n\"DORIS permits us to altogether expand the data thickness of the framework, and furthermore makes it simpler to scale up to deal with extremely enormous databases,\" says Kevin Lin, first creator of the paper and a Ph.D. understudy at NC State.\r\n\r\nWhat\'s more, when DORIS has distinguished the right DNA grouping, it doesn\'t depend on PCR to make duplicates. Rather, DORIS translates the DNA to RNA, which is then converse deciphered go into DNA which the information stockpiling framework can peruse. At the end of the day, DORIS doesn\'t need to devour the first document so as to understand it.\r\n\r\nThe single-abandoned shades can likewise be altered, permitting clients to rename records, erase documents or \"lock\" them - adequately making them imperceptible to different clients.\r\n\r\n\"We\'ve built up a practical model of DORIS, so we realize it works,\" Keung says. \"We\'re currently keen on scaling it up, speeding it up and placing it into a gadget that robotizes the procedure - making it easy to use.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">Materials</a></span> provided by North Carolina State University and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nKevin N. Lin, Kevin Volkel, James M. Tuck, Albert J. Keung. Dynamic and scalable DNA-based information storage. Nature Communications, 2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.ncsu.edu/2020/06/dynamic-scalable-dna-data/\">11 (1) DOI: 10.1038/s41467-020-16797-2</a></span>','New way to deal with DNA data stockpiling makes framework progressively powerful, adaptable','','inherit','closed','closed','','6138-revision-v1','','','2020-06-13 08:51:30','2020-06-13 08:51:30','',6138,'https://microbiozindia.com/uncategorized/6138-revision-v1/',0,'revision','',0),(6141,2,'2020-06-13 08:54:48','2020-06-13 08:54:48','In excess of 3 million Americans have glaucoma, a genuine eye condition causing vision misfortune. Utilizing human immature microorganism models, analysts at Indiana University School of Medicine discovered they could break down shortfalls inside cells harmed by glaucoma, with the possibility to utilize this data to grow new procedures to slow the sickness procedure.\r\n\r\nThe examination, distributed June 11 in Stem Cell Reports, concentrated on focusing on hereditary transformations inside retinal ganglion cells, which fill in as the association between the eye and the mind. Scientists found that while separating pluripotent human undifferentiated cells into retinal ganglion cells, they had the option to distinguish qualities related with neurodegeneration in glaucoma.\r\n\r\n\"When you\'ve recognized an objective like this - what\'s turning out badly in the cells - this opens up various opportunities for the inevitable advancement of restorative methodologies, particularly pharmacology ways to deal with delayed down and converse these degenerative phenotypes,\" said Jason Meyer, PhD, partner teacher of clinical and atomic hereditary qualities at IU School of Medicine.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">The group of scientists was driven by Meyer, alongside the co-first creators of the distribution, Kirstin VanderWall and Kang-Chieh Huang, graduate understudies from the School of Science at IUPUI in Meyer\'s lab, which is situated inside Stark Neurosciences Research Institute.</a> </span>Meyer\'s lab had recently been situated inside the School of Science.\r\n\r\nAt the point when retinal ganglion cells degenerate through glaucoma, it prompts the loss of vision and possible visual impairment. Analysts in this examination got pluripotent undifferentiated cells from a patient that had a hereditary type of glaucoma, Meyer said. They at that point separated the foundational microorganisms into retinal ganglion cells to look for neurodegeneration shortages.\r\n\r\n\"An incredible aspect regarding (undifferentiated cell research) is the point at which you get the cells from a patient that has a hereditary reason for an ailment, the entirety of the plans are there in the cell\'s DNA to create highlights of the illness,\" Meyer said.\r\n\r\nThey likewise utilized quality altering innovation - CRISPR-Cas9 - to present a hereditary transformation regularly connected with glaucoma into existing lines of the immature microorganisms for illness displaying, just as to address the quality deformity in understanding inferred cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">\"CRISPR/Cas9 quality altering approaches permitted us to contemplate the sickness, however utilizing this methodology we were additionally ready to show how remedying the quality transformation switched the infection, exhibiting the potential for quality treatment approaches also,\" Huang said.</a></span>\r\n\r\nMeyer said the group found brokenness during the time spent autophagy, the body\'s method of evacuating harmed cells to recover solid cells.\r\n\r\n\"We found that in the glaucoma quiet cells, there are a few deficiencies in this autophagy procedure, so you had an excessive amount of cell garbage that was being developed,\" Meyer stated, including that those shortfalls related with the degeneration of the cells, which would wilt up and in the long beyond words.\r\n\r\nUtilizing a pharmaceutical compound called rapamycin - which is known to help the procedure of autophagy - Meyer said they found that huge numbers of the neurodegenerative qualities they had recently distinguished eased back down and the phones appeared to recuperate and show up progressively ordinary.\r\n\r\nMeyer said human foundational microorganisms are instrumental in contemplating human ailment, particularly neurodegeneration. Past investigations on retinal ganglion cells and glaucoma as a degenerative infection utilizing creature models propose contrasts in how cells react between species.\r\n\r\n\"Since they are human cells, it gives fairly a progressively delegate model for us to test pharmacological mixes,\" VanderWall included, \"and it gives us a superior thought of how it might be poisonous or nontoxic to human cells contrasted with testing mixes in creatures.\"\r\n\r\nMeyer said including distinguished an objective inside the cells - the procedure of autophagy - the lab\'s continuous work will concentrate on examining approaches to utilize various sorts of pharmaceutical mixes for treatment of glaucoma. Just like the case for some neurodegenerative ailments, for example, Alzheimer\'s and Parkinson\'s maladies, there are not very many medicines, assuming any, and no fixes.\r\n\r\n\"There is a desperate need to attempt to recognize new ways to deal with treat these maladies,\" Meyer said. Award support for this examination was given by the National Eye Institute, the Indiana Department of Health Spinal Cord and Brain Injury Research Fund and the Indiana Clinical and Translational Sciences Institute.\r\n\r\nStory source:\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">Materials</a></span> provided by Indiana University School of Medicine and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nKirstin B. VanderWall, Kang-Chieh Huang, Yanling Pan, Sailee S. Lavekar, Clarisse M. Fligor, Anna R. Allsop, Kelly A. Lentsch, Pengtao Dang, Chi Zhang, Henry C. Tseng, Theodore R. Cummins, Jason S. Meyer. Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids. Stem Cell Reports,<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\"> 2020; DOI: 10.1016/j.stemcr.2020.05.009</a></span>','Scientists model human stem cells to recognize degeneration in glaucoma','','publish','open','open','','scientists-model-human-stem-cells-to-recognize-degeneration-in-glaucoma','','','2020-06-13 08:54:48','2020-06-13 08:54:48','',0,'https://microbiozindia.com/?p=6141',0,'post','',0),(6142,2,'2020-06-13 08:54:48','2020-06-13 08:54:48','In excess of 3 million Americans have glaucoma, a genuine eye condition causing vision misfortune. Utilizing human immature microorganism models, analysts at Indiana University School of Medicine discovered they could break down shortfalls inside cells harmed by glaucoma, with the possibility to utilize this data to grow new procedures to slow the sickness procedure.\r\n\r\nThe examination, distributed June 11 in Stem Cell Reports, concentrated on focusing on hereditary transformations inside retinal ganglion cells, which fill in as the association between the eye and the mind. Scientists found that while separating pluripotent human undifferentiated cells into retinal ganglion cells, they had the option to distinguish qualities related with neurodegeneration in glaucoma.\r\n\r\n\"When you\'ve recognized an objective like this - what\'s turning out badly in the cells - this opens up various opportunities for the inevitable advancement of restorative methodologies, particularly pharmacology ways to deal with delayed down and converse these degenerative phenotypes,\" said Jason Meyer, PhD, partner teacher of clinical and atomic hereditary qualities at IU School of Medicine.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">The group of scientists was driven by Meyer, alongside the co-first creators of the distribution, Kirstin VanderWall and Kang-Chieh Huang, graduate understudies from the School of Science at IUPUI in Meyer\'s lab, which is situated inside Stark Neurosciences Research Institute.</a> </span>Meyer\'s lab had recently been situated inside the School of Science.\r\n\r\nAt the point when retinal ganglion cells degenerate through glaucoma, it prompts the loss of vision and possible visual impairment. Analysts in this examination got pluripotent undifferentiated cells from a patient that had a hereditary type of glaucoma, Meyer said. They at that point separated the foundational microorganisms into retinal ganglion cells to look for neurodegeneration shortages.\r\n\r\n\"An incredible aspect regarding (undifferentiated cell research) is the point at which you get the cells from a patient that has a hereditary reason for an ailment, the entirety of the plans are there in the cell\'s DNA to create highlights of the illness,\" Meyer said.\r\n\r\nThey likewise utilized quality altering innovation - CRISPR-Cas9 - to present a hereditary transformation regularly connected with glaucoma into existing lines of the immature microorganisms for illness displaying, just as to address the quality deformity in understanding inferred cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">\"CRISPR/Cas9 quality altering approaches permitted us to contemplate the sickness, however utilizing this methodology we were additionally ready to show how remedying the quality transformation switched the infection, exhibiting the potential for quality treatment approaches also,\" Huang said.</a></span>\r\n\r\nMeyer said the group found brokenness during the time spent autophagy, the body\'s method of evacuating harmed cells to recover solid cells.\r\n\r\n\"We found that in the glaucoma quiet cells, there are a few deficiencies in this autophagy procedure, so you had an excessive amount of cell garbage that was being developed,\" Meyer stated, including that those shortfalls related with the degeneration of the cells, which would wilt up and in the long beyond words.\r\n\r\nUtilizing a pharmaceutical compound called rapamycin - which is known to help the procedure of autophagy - Meyer said they found that huge numbers of the neurodegenerative qualities they had recently distinguished eased back down and the phones appeared to recuperate and show up progressively ordinary.\r\n\r\nMeyer said human foundational microorganisms are instrumental in contemplating human ailment, particularly neurodegeneration. Past investigations on retinal ganglion cells and glaucoma as a degenerative infection utilizing creature models propose contrasts in how cells react between species.\r\n\r\n\"Since they are human cells, it gives fairly a progressively delegate model for us to test pharmacological mixes,\" VanderWall included, \"and it gives us a superior thought of how it might be poisonous or nontoxic to human cells contrasted with testing mixes in creatures.\"\r\n\r\nMeyer said including distinguished an objective inside the cells - the procedure of autophagy - the lab\'s continuous work will concentrate on examining approaches to utilize various sorts of pharmaceutical mixes for treatment of glaucoma. Just like the case for some neurodegenerative ailments, for example, Alzheimer\'s and Parkinson\'s maladies, there are not very many medicines, assuming any, and no fixes.\r\n\r\n\"There is a desperate need to attempt to recognize new ways to deal with treat these maladies,\" Meyer said. Award support for this examination was given by the National Eye Institute, the Indiana Department of Health Spinal Cord and Brain Injury Research Fund and the Indiana Clinical and Translational Sciences Institute.\r\n\r\nStory source:\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\">Materials</a></span> provided by Indiana University School of Medicine and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nKirstin B. VanderWall, Kang-Chieh Huang, Yanling Pan, Sailee S. Lavekar, Clarisse M. Fligor, Anna R. Allsop, Kelly A. Lentsch, Pengtao Dang, Chi Zhang, Henry C. Tseng, Theodore R. Cummins, Jason S. Meyer. Retinal Ganglion Cells With a Glaucoma OPTN(E50K) Mutation Exhibit Neurodegenerative Phenotypes when Derived from Three-Dimensional Retinal Organoids. Stem Cell Reports,<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.iu.edu/news/2020/06/human-stem-cells-used-to-identify-degeneration-in-glaucoma\"> 2020; DOI: 10.1016/j.stemcr.2020.05.009</a></span>','Scientists model human stem cells to recognize degeneration in glaucoma','','inherit','closed','closed','','6141-revision-v1','','','2020-06-13 08:54:48','2020-06-13 08:54:48','',6141,'https://microbiozindia.com/uncategorized/6141-revision-v1/',0,'revision','',0),(6143,2,'2020-06-13 11:57:37','2020-06-13 11:57:37','Dr Reddy\'s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bloombergquint.com/business/dr-reddy-s-inks-pact-with-gilead-sciences-for-remdesivir\">Gilead Sciences to fabricate and advertise remdesivir - a potential COVID-19 medication in 127 nations, including India.</a></span>\r\n<iframe src=\"https://www.youtube.com/embed/ZJ6Ol-T6f18\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nAccording to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy\'s Laboratories said in an announcement.\r\n\r\nThe organization will get innovation move from Gilead for assembling of the medication, it included.\r\n\r\nDr Reddy\'s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.\r\n\r\nRemdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.','Dr Reddy\'s inks agreement with Gilead Sciences to produce remdesivir','','publish','open','open','','dr-reddys-inks-agreement-with-gilead-sciences-to-produce-remdesivir','','','2020-06-13 13:06:17','2020-06-13 13:06:17','',0,'https://microbiozindia.com/?p=6143',0,'post','',0),(6144,2,'2020-06-13 11:57:37','2020-06-13 11:57:37','Dr Reddy\'s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bloombergquint.com/business/dr-reddy-s-inks-pact-with-gilead-sciences-for-remdesivir\">Gilead Sciences to fabricate and advertise remdesivir - a potential COVID-19 medication in 127 nations, including India.</a></span>\r\n\r\nAccording to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy\'s Laboratories said in an announcement.\r\n\r\nThe organization will get innovation move from Gilead for assembling of the medication, it included.\r\n\r\nDr Reddy\'s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.\r\n\r\nRemdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.','Dr Reddy\'s inks agreement with Gilead Sciences to produce remdesivir','','inherit','closed','closed','','6143-revision-v1','','','2020-06-13 11:57:37','2020-06-13 11:57:37','',6143,'https://microbiozindia.com/uncategorized/6143-revision-v1/',0,'revision','',0),(6145,2,'2020-06-13 13:06:07','2020-06-13 13:06:07','Dr Reddy\'s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bloombergquint.com/business/dr-reddy-s-inks-pact-with-gilead-sciences-for-remdesivir\">Gilead Sciences to fabricate and advertise remdesivir - a potential COVID-19 medication in 127 nations, including India.</a></span>\n<iframe width=\"560\" height=\"315\" src=\"https://www.youtube.com/embed/ZJ6Ol-T6f18\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen></iframe>\n\nAccording to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy\'s Laboratories said in an announcement.\n\nThe organization will get innovation move from Gilead for assembling of the medication, it included.\n\nDr Reddy\'s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.\n\nRemdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.','Dr Reddy\'s inks agreement with Gilead Sciences to produce remdesivir','','inherit','closed','closed','','6143-autosave-v1','','','2020-06-13 13:06:07','2020-06-13 13:06:07','',6143,'https://microbiozindia.com/uncategorized/6143-autosave-v1/',0,'revision','',0),(6146,2,'2020-06-13 13:06:17','2020-06-13 13:06:17','Dr Reddy\'s Laboratories on June 13 said that it has inked agreement with US-based biopharmaceutical organization <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.bloombergquint.com/business/dr-reddy-s-inks-pact-with-gilead-sciences-for-remdesivir\">Gilead Sciences to fabricate and advertise remdesivir - a potential COVID-19 medication in 127 nations, including India.</a></span>\r\n<iframe src=\"https://www.youtube.com/embed/ZJ6Ol-T6f18\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nAccording to the non-selective authorizing understanding, Gilead will allow the Hyderabad-based medication creator the option to enroll and fabricate its investigational tranquilize remdesivir in 127 nations, Dr Reddy\'s Laboratories said in an announcement.\r\n\r\nThe organization will get innovation move from Gilead for assembling of the medication, it included.\r\n\r\nDr Reddy\'s would need to scale up assembling and get administrative endorsement for showcasing of this medication in particular nations, the organization said.\r\n\r\nRemdesivir, an investigational antiviral treatment created by Gilead, has gotten Emergency Use Authorisation (EUA) by the US Food and Drug Administration (USFDA) to treat COVID-19.','Dr Reddy\'s inks agreement with Gilead Sciences to produce remdesivir','','inherit','closed','closed','','6143-revision-v1','','','2020-06-13 13:06:17','2020-06-13 13:06:17','',6143,'https://microbiozindia.com/uncategorized/6143-revision-v1/',0,'revision','',0),(6147,2,'2020-06-14 05:58:21','2020-06-14 05:58:21','British drugmaker AstraZeneca Plc said on Saturday it marked an agreement with Italy, Germany, France and the Netherlands to flexibly Europe with an immunization against the coronavirus, with conveyances beginning before the finish of 2020.\r\nThe agreement is for up to 400 million dosages of the immunization, created by the University of Oxford, the organization stated, adding that it was hoping to extend assembling of the antibody, which it promised to accommodate no benefit during the pandemic.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://foxbaltimore.com/news/coronavirus/european-nations-sign-400-million-dose-vaccine-deal\">\"With our European gracefully bind because of start creation before long, we would like to make the antibody accessible broadly and quickly,\" Chief Executive Pascal Soriot said in an announcement.</a> </span>\r\nThe experimentation period of the antibody is as of now progressed and expected to end in the harvest time, Italian Health Minister Roberto Speranza said in a Facebook post.\r\nAstraZeneca has concurred fabricating bargains all around to meet its objective of creating 2 billion portions of the antibody, incorporating with two endeavors supported by Bill Gates and a $1.2 billion concurrence with the U.S. government.\r\nThere are no affirmed antibodies or medicines for COVID-19, the exceptionally infectious respiratory disease brought about by the novel coronavirus.\r\n\"Numerous nations on the planet have just made sure about immunizations, Europe has not yet. The quick planned activity of a gathering of part states will make included an incentive for all EU residents in this emergency,\" German Health Minister Jens Spahn said.\r\nThe European Commission got a command from EU governments on Friday to arrange advance acquisition of promising coronavirus immunizations, the EU\'s top wellbeing official stated, yet it was muddled whether there would be sufficient cash accessible.\r\n\r\nDetailing by Giuseppe Fonte in ROME, Rama Venkat in BANGALORE, extra announcing by Madeline Chambers in BERLIN, composing by Giulia Segreti; altering by John Stonestreet and Louise Heavens.','AstraZeneca consents to gracefully Europe with 400 million dosages of COVID-19 antibody','','publish','open','open','','astrazeneca-consents-to-gracefully-europe-with-400-million-dosages-of-covid-19-antibody','','','2020-06-14 05:58:21','2020-06-14 05:58:21','',0,'https://microbiozindia.com/?p=6147',0,'post','',0),(6148,2,'2020-06-14 05:58:21','2020-06-14 05:58:21','British drugmaker AstraZeneca Plc said on Saturday it marked an agreement with Italy, Germany, France and the Netherlands to flexibly Europe with an immunization against the coronavirus, with conveyances beginning before the finish of 2020.\r\nThe agreement is for up to 400 million dosages of the immunization, created by the University of Oxford, the organization stated, adding that it was hoping to extend assembling of the antibody, which it promised to accommodate no benefit during the pandemic.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://foxbaltimore.com/news/coronavirus/european-nations-sign-400-million-dose-vaccine-deal\">\"With our European gracefully bind because of start creation before long, we would like to make the antibody accessible broadly and quickly,\" Chief Executive Pascal Soriot said in an announcement.</a> </span>\r\nThe experimentation period of the antibody is as of now progressed and expected to end in the harvest time, Italian Health Minister Roberto Speranza said in a Facebook post.\r\nAstraZeneca has concurred fabricating bargains all around to meet its objective of creating 2 billion portions of the antibody, incorporating with two endeavors supported by Bill Gates and a $1.2 billion concurrence with the U.S. government.\r\nThere are no affirmed antibodies or medicines for COVID-19, the exceptionally infectious respiratory disease brought about by the novel coronavirus.\r\n\"Numerous nations on the planet have just made sure about immunizations, Europe has not yet. The quick planned activity of a gathering of part states will make included an incentive for all EU residents in this emergency,\" German Health Minister Jens Spahn said.\r\nThe European Commission got a command from EU governments on Friday to arrange advance acquisition of promising coronavirus immunizations, the EU\'s top wellbeing official stated, yet it was muddled whether there would be sufficient cash accessible.\r\n\r\nDetailing by Giuseppe Fonte in ROME, Rama Venkat in BANGALORE, extra announcing by Madeline Chambers in BERLIN, composing by Giulia Segreti; altering by John Stonestreet and Louise Heavens.','AstraZeneca consents to gracefully Europe with 400 million dosages of COVID-19 antibody','','inherit','closed','closed','','6147-revision-v1','','','2020-06-14 05:58:21','2020-06-14 05:58:21','',6147,'https://microbiozindia.com/uncategorized/6147-revision-v1/',0,'revision','',0),(6149,2,'2020-06-14 12:17:28','2020-06-14 12:17:28','A group headed by Hideharu Mikami from the University of Tokyo as of late decided an imaging technique dependent on optomechanics that conquers the exhibition and utility of imaging stream cytometry (IFC).\r\nThe strategy empowers high throughput imaging of single cells going at &gt;10,000 cells sec-1 without trading off affectability or goals and empowering strong measurable investigation and a precise grouping of cells.\r\nConventional IFC offers a few points of interest over customary stream cytometry by giving quantitative picture information. This information allows the portrayal of single cells across heterogeneous populaces. The huge information coming about because of IFC technique is pertinent in a period where profound learning important to improve clinical dynamic in the biomedical and clinical settings.\r\n\r\n<strong>The impediments of conventional imaging stream cytometry</strong>\r\n\r\nIFC is especially successful for the identification of a scope of macromolecules including proteins, nucleic acids, the examination of cell-cell cooperation, and the portrayal of DNA harm and fix. Be that as it may, the presentation and utility of IFC endure because of endeavors to expand throughput, spatial goals, and affectability.\r\n\r\nBy speeding up with the end goal of high-throughput, an abbreviated combination period results, empowering the assortment of obscure free pictures; be that as it may, the impact is diminished affectability or pixel goals to battle this.\r\n\r\nTo defeat this, time postponement and coordination (TDI) with a picture sensor dependent on a charged couple gadget (CCD) has been utilized. TDI gathers a few exposures of cells in stream, with a few lines of CCD photosensitive components. Nonetheless, this cutoff points throughput as the CCD readout rate is diminished.\r\n\r\nAn extra issue endured by CCD is readout commotion, which restrains its affectability of identification. A few endeavors to defeat the exchange off are single-pixel imaging and utilization of an integral metal oxide semiconductor (CMOS) picture sensor – however these, thus, limit affectability.\r\n\r\nThe binding together characteristic of these compensatory strategies is the trade off of one of the key boundaries for other people. This forestalls applying IFC to specialty applications, which rouses the investigation by the group at the University of Tokyo.\r\n\r\n<strong>A tale optomechanical imaging technique</strong>\r\n\r\nMikami et al. allude to their improved imaging strategy as virtual freezing fluorescence imaging (VIFFI). Significantly, tradeoffs are bypassed while high throughput (&gt;10,000 cells sec-1), spatial goals at around 700nm, and high affectability are guaranteed.\r\n\r\n<a href=\"https://www.nature.com/articles/s41467-020-14929-2\">The strategy depends on freezing a streaming cell on the picture sensor by dropping the movement of a solitary cell to build the presentation time of the picture sensor. This creates a fluorescence picture with a high sign to-clamor proportion (SNR).</a>\r\n\r\nThe basic components of VIFFI stream cytometry is an excitation bar scanner that look over the field of view (FOV) and concurrent planning of the picture detects presentation and the excitation shafts light. In mix, virtual freezing means multiple times more prominent occasions for signal joining on the picture sensor. This outcomes in microscopy-level fluorescence imaging of cells at 1 m s-1.\r\n\r\nThe philosophy behind the gathering\'s method included the optical structure of the VIFI stream cytometer, the presentation of an excitation pillar examine to expand the introduction time for the quick streaming cells, procurement of information, and the preparing of the computerized pictures and profound learning.\r\n\r\n<strong>Applying virtual freezing fluorescence imaging</strong>\r\n\r\nThe gathering utilized two hues. The group brought up that few hues can be utilized with the end goal of fluorescence imaging when dichroic beamsplitters are utilized. The gathering likewise comment on the similarity of VIFFI stream cytometry with cutting edge picture sensor-based fluorescence microscopy method – empowering super-goals fluorescence.\r\n\r\nAlso, the strategy empowers the stream speed to be differed insofar as it fits in with the tradeoff connection between the FOV, introduction time, and stream speed. Alongside this progression, AI will permit the profundity of information investigation accomplished to be extended. So also, as advances in picture sensor innovation are accomplished, high-throughput and number of fluorescence shading alternatives are would have liked to be expanded. VIFFI likewise empowers the profundity of field to be extended. This is valuable for FSIH imaging and imaging of huge cells.\r\n\r\nInferable from affectability spatial goals on high throughput of this fluorescence imaging, the applications in science, drug store, and medication are extended. Right off the bat, high throughput FISH examination is able; this procedure is particularly helpful in determination, distinguishing proof, and discovery of negligible remaining malady. Customary microscopy is deficient as screening of huge populaces of cells is preposterous.\r\n\r\nAs a proof of idea, the group showed enormous scope examination dependent on morphological phenotype. This proposes this procedure is priceless while deciding genotype-phenotype connection. In particular, the high spatial goals empowers exact portrayal of key highlights, for example, territory and edge of every cell and intracellular organelles.\r\n\r\nThe gathering additionally showed through imaging of freaks of C. reinhardtii, VIFF I stream cytometry can be utilized for assessing mutagenesis.\r\n\r\nAt long last, VIFFI stream cytometry can both distinguish and check coursing tumor cells (CTCs) from heterogeneous blood tests. Single CTC\'s and groups can be imagined and tallied; this is relied upon to help the investigation of the connection between\'s bunch size and metastatic potential/spread of CTCS.\r\n\r\n<em>Note: The content may be editor depending upon length and style.</em>\r\n\r\n<strong>S</strong><strong>ource</strong>\r\n<span style=\"text-decoration: underline;\"><em><strong>Mikami, H. et al (2020) Virtual-freezing fluorescence imaging flow cytometry.</strong> </em></span>Nature Communications. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41467-020-14929-2\">DOI: 10.1038/s41467-020-14929-2</a></span>','Imaging method that overcomes the performance and utility of imaging flow cytometry','','publish','open','open','','imaging-method-that-overcomes-the-performance-and-utility-of-imaging-flow-cytometry','','','2020-06-14 12:17:28','2020-06-14 12:17:28','',0,'https://microbiozindia.com/?p=6149',0,'post','',0),(6150,2,'2020-06-14 12:16:39','2020-06-14 12:16:39','','digital illustration antibodies','','inherit','open','closed','','digital-illustration-antibodies','','','2020-06-14 12:16:39','2020-06-14 12:16:39','',6149,'https://microbiozindia.com/wp-content/uploads/2020/06/antibodies.jpg',0,'attachment','image/jpeg',0),(6151,2,'2020-06-14 12:16:40','2020-06-14 12:16:40','','glowing-2245832_640','','inherit','open','closed','','glowing-2245832_640','','','2020-06-14 12:16:40','2020-06-14 12:16:40','',6149,'https://microbiozindia.com/wp-content/uploads/2020/06/glowing-2245832_640.jpg',0,'attachment','image/jpeg',0),(6152,2,'2020-06-14 12:17:28','2020-06-14 12:17:28','A group headed by Hideharu Mikami from the University of Tokyo as of late decided an imaging technique dependent on optomechanics that conquers the exhibition and utility of imaging stream cytometry (IFC).\r\nThe strategy empowers high throughput imaging of single cells going at &gt;10,000 cells sec-1 without trading off affectability or goals and empowering strong measurable investigation and a precise grouping of cells.\r\nConventional IFC offers a few points of interest over customary stream cytometry by giving quantitative picture information. This information allows the portrayal of single cells across heterogeneous populaces. The huge information coming about because of IFC technique is pertinent in a period where profound learning important to improve clinical dynamic in the biomedical and clinical settings.\r\n\r\n<strong>The impediments of conventional imaging stream cytometry</strong>\r\n\r\nIFC is especially successful for the identification of a scope of macromolecules including proteins, nucleic acids, the examination of cell-cell cooperation, and the portrayal of DNA harm and fix. Be that as it may, the presentation and utility of IFC endure because of endeavors to expand throughput, spatial goals, and affectability.\r\n\r\nBy speeding up with the end goal of high-throughput, an abbreviated combination period results, empowering the assortment of obscure free pictures; be that as it may, the impact is diminished affectability or pixel goals to battle this.\r\n\r\nTo defeat this, time postponement and coordination (TDI) with a picture sensor dependent on a charged couple gadget (CCD) has been utilized. TDI gathers a few exposures of cells in stream, with a few lines of CCD photosensitive components. Nonetheless, this cutoff points throughput as the CCD readout rate is diminished.\r\n\r\nAn extra issue endured by CCD is readout commotion, which restrains its affectability of identification. A few endeavors to defeat the exchange off are single-pixel imaging and utilization of an integral metal oxide semiconductor (CMOS) picture sensor – however these, thus, limit affectability.\r\n\r\nThe binding together characteristic of these compensatory strategies is the trade off of one of the key boundaries for other people. This forestalls applying IFC to specialty applications, which rouses the investigation by the group at the University of Tokyo.\r\n\r\n<strong>A tale optomechanical imaging technique</strong>\r\n\r\nMikami et al. allude to their improved imaging strategy as virtual freezing fluorescence imaging (VIFFI). Significantly, tradeoffs are bypassed while high throughput (&gt;10,000 cells sec-1), spatial goals at around 700nm, and high affectability are guaranteed.\r\n\r\n<a href=\"https://www.nature.com/articles/s41467-020-14929-2\">The strategy depends on freezing a streaming cell on the picture sensor by dropping the movement of a solitary cell to build the presentation time of the picture sensor. This creates a fluorescence picture with a high sign to-clamor proportion (SNR).</a>\r\n\r\nThe basic components of VIFFI stream cytometry is an excitation bar scanner that look over the field of view (FOV) and concurrent planning of the picture detects presentation and the excitation shafts light. In mix, virtual freezing means multiple times more prominent occasions for signal joining on the picture sensor. This outcomes in microscopy-level fluorescence imaging of cells at 1 m s-1.\r\n\r\nThe philosophy behind the gathering\'s method included the optical structure of the VIFI stream cytometer, the presentation of an excitation pillar examine to expand the introduction time for the quick streaming cells, procurement of information, and the preparing of the computerized pictures and profound learning.\r\n\r\n<strong>Applying virtual freezing fluorescence imaging</strong>\r\n\r\nThe gathering utilized two hues. The group brought up that few hues can be utilized with the end goal of fluorescence imaging when dichroic beamsplitters are utilized. The gathering likewise comment on the similarity of VIFFI stream cytometry with cutting edge picture sensor-based fluorescence microscopy method – empowering super-goals fluorescence.\r\n\r\nAlso, the strategy empowers the stream speed to be differed insofar as it fits in with the tradeoff connection between the FOV, introduction time, and stream speed. Alongside this progression, AI will permit the profundity of information investigation accomplished to be extended. So also, as advances in picture sensor innovation are accomplished, high-throughput and number of fluorescence shading alternatives are would have liked to be expanded. VIFFI likewise empowers the profundity of field to be extended. This is valuable for FSIH imaging and imaging of huge cells.\r\n\r\nInferable from affectability spatial goals on high throughput of this fluorescence imaging, the applications in science, drug store, and medication are extended. Right off the bat, high throughput FISH examination is able; this procedure is particularly helpful in determination, distinguishing proof, and discovery of negligible remaining malady. Customary microscopy is deficient as screening of huge populaces of cells is preposterous.\r\n\r\nAs a proof of idea, the group showed enormous scope examination dependent on morphological phenotype. This proposes this procedure is priceless while deciding genotype-phenotype connection. In particular, the high spatial goals empowers exact portrayal of key highlights, for example, territory and edge of every cell and intracellular organelles.\r\n\r\nThe gathering additionally showed through imaging of freaks of C. reinhardtii, VIFF I stream cytometry can be utilized for assessing mutagenesis.\r\n\r\nAt long last, VIFFI stream cytometry can both distinguish and check coursing tumor cells (CTCs) from heterogeneous blood tests. Single CTC\'s and groups can be imagined and tallied; this is relied upon to help the investigation of the connection between\'s bunch size and metastatic potential/spread of CTCS.\r\n\r\n<em>Note: The content may be editor depending upon length and style.</em>\r\n\r\n<strong>S</strong><strong>ource</strong>\r\n<span style=\"text-decoration: underline;\"><em><strong>Mikami, H. et al (2020) Virtual-freezing fluorescence imaging flow cytometry.</strong> </em></span>Nature Communications. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41467-020-14929-2\">DOI: 10.1038/s41467-020-14929-2</a></span>','Imaging method that overcomes the performance and utility of imaging flow cytometry','','inherit','closed','closed','','6149-revision-v1','','','2020-06-14 12:17:28','2020-06-14 12:17:28','',6149,'https://microbiozindia.com/uncategorized/6149-revision-v1/',0,'revision','',0),(6153,2,'2020-06-14 12:19:59','0000-00-00 00:00:00','Flow cytometry (FC) is a broadly applied investigative method that uses, commonly with frequencies of either 488, 642, 532 or 405 nanometers (nm), lasers to check and assess suspended cells and other molecule types. Normally, fluorescent antibodies and additionally colors are utilized to treat the cell tests and take into consideration the recognizable proof and partition of cells labeled with explicit surface proteins, intracellular markers or other cell targets.\n\nAt the point when stream cytometry is utilized for blood examination, a few distinctive recoloring steps are typically required, which incorporate white platelet (WBC) isolation, red platelet (RBC) lysis and test obsession. Though clinical blood investigations will regularly use specific hematology instruments to procure total blood tallies (CBC), stream cytometry for cell culture examination can be utilized to quantify different degrees of invulnerable cell work.\n\nHow the resistant framework capacities\n\nAny invulnerable reaction is accomplished by the various cell types that contain the insusceptible framework that capacity to ensure a creature against conceivably destructive pathogens like microscopic organisms and infections. The main line of guard is given by both the physical and synthetic sythesis of obstructions like the skin and bodily fluid and the proteins and acidic synthetics that include them.\n\nSimilarly, the second line of protection, in any case alluded to as the natural resistant framework, is comprised of invulnerable cells known as phagocytes that are available inside different body tissues and basically capacity to wipe out pathogenic species from the body.\n\nInsusceptible dysregulation with spaceflight\n\nSince the primary Apollo strategic 1969, over half of space travelers setting out on outings to space have experienced some kind of bacterial or viral contamination. The horde of elements adding to careless invulnerable reactions, which incorporate pressure, microgravity and radiation presentation, have been found to add to this marvel.\n\nRegardless of its proceeded with repeat in space explorers, little work has been fruitful in explaining the clinical essentialness of this insusceptible dysregulation.\n\nChecking adjustments in resistant framework work\n\nA few distinctive stream cytometry procedures have been utilized to decide any distinctions that may exist in the resistant cell estimations of space explorers earlier, during and quickly following spaceflight. Stream cytometry has been demonstrated to be a perfect logical procedure for these kinds of studies has a consequence of its overall simplicity of activity for learned clients, high dependability and wide scope of appropriate measures.\n\nOne of the most widely recognized uses of stream cytometry for such spaceflight considers has included estimating the appropriation of fringe blood leukocyte cell populaces. Commonly, such adjustments in leukocyte appropriation can be clinically critical.\n\nFor instance, increments in these levels can reflect safe framework initiation, extension, and additionally multiplication, while diminishes can reflect safe cell movement out of the blood or potentially limitation of these cells to indicated locales of aggravation.\n\nUntil now, stream cytometry fluorochromes and channel abilities of stream cytometry instruments have essentially extended to incorporate a wide scope of resistant cell subsets, some of which incorporate granulocytes, lymphocytes, monocytes, cytotoxic impact cells like CD8+ and various memory T cell markers, for example, CD3, CD8, CD45RA, CD62L and CD11a, to give some examples.\n\nLater progressions have permitted scientists to now use stream cytometry for the distinguishing proof of all the more fine leukocyte subtypes, for example, B cells, NK cells and monocytes, every one of which are related with their own clinically huge impacts.\n\nSpaceflight applications\n\nThe absolute soonest uses of stream cytometry for spaceflight invulnerable checking happened in 1999, when a gathering of specialists estimated changes in the WBC and granulocyte levels of space travelers following the Space Shuttle strategic. In their work, space travelers were found to have fundamentally more significant levels of both safe cell populaces following landing, which has been proposed to be the aftereffect of reemergence stress.\n\nAnother examination on a gathering of Space Shuttle space travelers was directed to decide the impacts that fluctuating strategic have on their resistant framework. In their work, WBC, granulocyte, monocyte, B cell and CD4+ T cells were totally seen as altogether raised postflight, while NK cells were seen as lower.\n\nWhen looking at the impact that diverse strategic have on these levels, specialists found that space travelers on 1-week missions showed increasingly articulated changes in their safe cell levels when contrasted with those on 2-week missions.\n\nA few different examinations have additionally explored how changes in the degrees of intracellular cytokines might be results from spaceflight.\n\nTo this end, a recent report found that both IFNγ and IL-2 from both CD4+ and CD8+ T cells in Shuttle and ISS space explorers subsequent to landing were fundamentally lower when contrasted with controls. Another comparative investigation found that the intracellular creation of IL-6 and IL-8 in monocytes was decreased postflight, while IL-1β and IL-1ra levels were raised.\n\nEnd\n\nStream cytometry has shown its flexibility to screen and evaluate safe dysregulation in space travelers all through the spaceflight procedure. By seeing how the invulnerable framework reacts to spaceflight, national associations like the National Aeronautics and Space Administration (NASA) inside the United States can be increasingly arranged to alleviate clinical dangers for space explorers and other group individuals during spaceflight.\nSources\n• Crucian, B., Makedonas, G., &amp; Sams, C. Chapter 27 Flow Cytometry Methods to Monitor Immune Dysregulation Associated with Spaceflight. In: Stress Challenges and Immunity Space. 2nd ed. Munich, Germany: 2020;499-418. DOI:10.1007/978-3-030-16996-1.\n• Crucian, B., Chouker, A. Chapter 11 Immune System in Space: General Introduction and Observations on Stress-Sensitive Regulations. In: Stress Challenges and Immunity Space. 2nd ed. Munich, Germany: 2020;205-220. DOI:10.1007/978-3-030-16996-1.','Stream Cytometry in Monitoring Post-Spaceflight Immune Dysregulation','','draft','open','open','','','','','2020-06-14 12:19:59','2020-06-14 12:19:59','',0,'https://microbiozindia.com/?p=6153',0,'post','',0),(6155,2,'2020-06-14 12:48:52','2020-06-14 12:48:52','Specialists in the US are taking a gander at the chance of utilizing tuberculosis and polio immunizations in giving insurance from the savage coronavirus, as indicated by a media report.\r\n\r\nTests are in progress to check whether the tuberculosis immunization can slow the novel coronavirus, The Washington Post provided details regarding Thursday.\r\n\r\n\"This is the main immunization on the planet that can be given to battle COVID-19 at the present time,\" Jeffrey D Cirillo, a teacher of microbial pathogenesis and immunology at Texas A&amp;M Health Science Center, was cited as saying by the Post.\r\n\r\nAs indicated by Johns Hopkins Coronavirus Resource Center, the disease has tainted more than 75,00,000 individuals and executed more than 4,20,000 over the world. The US is the most noticeably terrible influenced nation with over 2.02 million cases and in excess of 1,13,000 passings.\r\n<iframe src=\"https://www.youtube.com/embed/9i4_G5ESzkk\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nThe COVID-19, which started in China\'s\' Wuhan city in December a year ago, has likewise battered the world economy with the International Monetary Fund saying that the worldwide economy will undoubtedly endure a \"serious downturn\".\r\n\r\nResearchers are attempting to beat the clock to discover an antibody or medication for its treatment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.ncbi.nlm.nih.gov/books/NBK538185/\">Dr Cirillo is driving a preliminary of the tuberculosis immunization, called bacillus Calmette-Guérin and known by the shorthand BCG.</a></span>\r\n\r\nThe BCG immunization, he stated, is as of now affirmed by the Food and Drug Administration (FDA) and has a protracted record of being utilized securely.\r\n\r\nAnother gathering of researchers, as indicated by report, have proposed utilizing the polio antibody to slow the COVID-19.\r\n\r\n\"Immunizations created against TB (tuberculosis) and polio have just been utilized in a huge number of individuals and could offer a generally safe approach to fire up the body\'s first line of guard — the natural resistant framework — against an expansive exhibit of pathogens, including the coronavirus,\" the gathering said.\r\n\r\nPakistani-American Azra Raza, a teacher of medication at Columbia University Medical Center, told the every day that BCG can improve individuals\' capacity to ward off different pathogens, in any event, for patients who are given the antibody for another affirmed use, against bladder malignant growth.','Researchers taking a gander at tuberculosis, polio immunizations to avert coronavirus: report','','publish','open','open','','researchers-taking-a-gander-at-tuberculosis-polio-immunizations-to-avert-coronavirus-report','','','2020-06-14 13:54:54','2020-06-14 13:54:54','',0,'https://microbiozindia.com/?p=6155',0,'post','',0),(6156,2,'2020-06-14 12:48:52','2020-06-14 12:48:52','Specialists in the US are taking a gander at the chance of utilizing tuberculosis and polio immunizations in giving insurance from the savage coronavirus, as indicated by a media report.\r\n\r\nTests are in progress to check whether the tuberculosis immunization can slow the novel coronavirus, The Washington Post provided details regarding Thursday.\r\n\r\n\"This is the main immunization on the planet that can be given to battle COVID-19 at the present time,\" Jeffrey D Cirillo, a teacher of microbial pathogenesis and immunology at Texas A&amp;M Health Science Center, was cited as saying by the Post.\r\n\r\nAs indicated by Johns Hopkins Coronavirus Resource Center, the disease has tainted more than 75,00,000 individuals and executed more than 4,20,000 over the world. The US is the most noticeably terrible influenced nation with over 2.02 million cases and in excess of 1,13,000 passings.\r\n\r\nThe COVID-19, which started in China\'s\' Wuhan city in December a year ago, has likewise battered the world economy with the International Monetary Fund saying that the worldwide economy will undoubtedly endure a \"serious downturn\".\r\n\r\nResearchers are attempting to beat the clock to discover an antibody or medication for its treatment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.ncbi.nlm.nih.gov/books/NBK538185/\">Dr Cirillo is driving a preliminary of the tuberculosis immunization, called bacillus Calmette-Guérin and known by the shorthand BCG.</a></span>\r\n\r\nThe BCG immunization, he stated, is as of now affirmed by the Food and Drug Administration (FDA) and has a protracted record of being utilized securely.\r\n\r\nAnother gathering of researchers, as indicated by report, have proposed utilizing the polio antibody to slow the COVID-19.\r\n\r\n\"Immunizations created against TB (tuberculosis) and polio have just been utilized in a huge number of individuals and could offer a generally safe approach to fire up the body\'s first line of guard — the natural resistant framework — against an expansive exhibit of pathogens, including the coronavirus,\" the gathering said.\r\n\r\nPakistani-American Azra Raza, a teacher of medication at Columbia University Medical Center, told the every day that BCG can improve individuals\' capacity to ward off different pathogens, in any event, for patients who are given the antibody for another affirmed use, against bladder malignant growth.','Researchers taking a gander at tuberculosis, polio immunizations to avert coronavirus: report','','inherit','closed','closed','','6155-revision-v1','','','2020-06-14 12:48:52','2020-06-14 12:48:52','',6155,'https://microbiozindia.com/uncategorized/6155-revision-v1/',0,'revision','',0),(6157,2,'2020-06-14 13:48:17','2020-06-14 13:48:17','Specialists in the US are taking a gander at the chance of utilizing tuberculosis and polio immunizations in giving insurance from the savage coronavirus, as indicated by a media report.\r\n\r\nTests are in progress to check whether the tuberculosis immunization can slow the novel coronavirus, The Washington Post provided details regarding Thursday.\r\n\r\n\"This is the main immunization on the planet that can be given to battle COVID-19 at the present time,\" Jeffrey D Cirillo, a teacher of microbial pathogenesis and immunology at Texas A&amp;M Health Science Center, was cited as saying by the Post.\r\n\r\nAs indicated by Johns Hopkins Coronavirus Resource Center, the disease has tainted more than 75,00,000 individuals and executed more than 4,20,000 over the world. The US is the most noticeably terrible influenced nation with over 2.02 million cases and in excess of 1,13,000 passings.\r\n<iframe src=\"https://www.youtube.com/embed/9i4_G5ESzkk\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nThe COVID-19, which started in China\'s\' Wuhan city in December a year ago, has likewise battered the world economy with the International Monetary Fund saying that the worldwide economy will undoubtedly endure a \"serious downturn\".\r\n\r\nResearchers are attempting to beat the clock to discover an antibody or medication for its treatment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.ncbi.nlm.nih.gov/books/NBK538185/\">Dr Cirillo is driving a preliminary of the tuberculosis immunization, called bacillus Calmette-Guérin and known by the shorthand BCG.</a></span>\r\n\r\nThe BCG immunization, he stated, is as of now affirmed by the Food and Drug Administration (FDA) and has a protracted record of being utilized securely.\r\n\r\nAnother gathering of researchers, as indicated by report, have proposed utilizing the polio antibody to slow the COVID-19.\r\n\r\n\"Immunizations created against TB (tuberculosis) and polio have just been utilized in a huge number of individuals and could offer a generally safe approach to fire up the body\'s first line of guard — the natural resistant framework — against an expansive exhibit of pathogens, including the coronavirus,\" the gathering said.\r\n\r\nPakistani-American Azra Raza, a teacher of medication at Columbia University Medical Center, told the every day that BCG can improve individuals\' capacity to ward off different pathogens, in any event, for patients who are given the antibody for another affirmed use, against bladder malignant growth.','Researchers taking a gander at tuberculosis, polio immunizations to avert coronavirus: report','','inherit','closed','closed','','6155-revision-v1','','','2020-06-14 13:48:17','2020-06-14 13:48:17','',6155,'https://microbiozindia.com/uncategorized/6155-revision-v1/',0,'revision','',0),(6158,2,'2020-06-15 09:36:02','2020-06-15 09:36:02','Breastfeeding moms don\'t appear to be giving the new coronavirus to their newborn children, and dependent on current proof the advantages exceed any likely dangers of transmission, the World Health Organization (WHO) said on Friday.\r\n\r\n<a href=\"https://www.news18.com/news/world/who-rcommends-breastfeeding-of-infants-says-no-live-coronavirus-found-in-mothers-milk-2667237.html\">WHO Director general <strong><u>Tedros Adhanom Ghebreyesus</u></strong> said that it had painstakingly researched the dangers of ladies transmitting COVID-19 to their kids during breastfeeding.</a>\r\n\r\n\"We realize that kids are at generally safe of COVID-19, yet are at high danger of various different sicknesses and conditions that breastfeeding forestalls,\" Tedros told a news meeting.\r\n\r\n<strong>\"In view of the accessible proof, WHO\'s recommendation is that the advantages of breastfeeding exceed any likely dangers of transmission of COVID-19,\" he said. </strong>\r\n\r\nAnshu Banerjee, a senior counselor in WHO\'s Department of Reproductive Health and Research, said that solitary \"sections\" of the Virus had been distinguished in bosom milk, not live Virus.\r\n\r\n\"So far we have not had the option to identify live infection in bosom milk,\" he said. \"So the danger of transmission from mother to baby so far has not been set up.\"','WHO suggests breastfeeding of infants, says no live coronavirus found in moms\' milk','','publish','open','open','','who-suggests-breastfeeding-of-infants-says-no-live-coronavirus-found-in-moms-milk','','','2020-06-15 09:36:24','2020-06-15 09:36:24','',0,'https://microbiozindia.com/?p=6158',0,'post','',0),(6159,2,'2020-06-15 09:36:02','2020-06-15 09:36:02','Breastfeeding moms don\'t appear to be giving the new coronavirus to their newborn children, and dependent on current proof the advantages exceed any likely dangers of transmission, the World Health Organization (WHO) said on Friday.\r\n\r\n<a href=\"https://www.news18.com/news/world/who-rcommends-breastfeeding-of-infants-says-no-live-coronavirus-found-in-mothers-milk-2667237.html\">WHO Director general <strong><u>Tedros Adhanom Ghebreyesus</u></strong> said that it had painstakingly researched the dangers of ladies transmitting COVID-19 to their kids during breastfeeding.</a>\r\n\r\n\"We realize that kids are at generally safe of COVID-19, yet are at high danger of various different sicknesses and conditions that breastfeeding forestalls,\" Tedros told a news meeting.\r\n\r\n<strong>\"In view of the accessible proof, WHO\'s recommendation is that the advantages of breastfeeding exceed any likely dangers of transmission of COVID-19,\" he said. </strong>\r\n\r\nAnshu Banerjee, a senior counselor in WHO\'s Department of Reproductive Health and Research, said that solitary \"sections\" of the Virus had been distinguished in bosom milk, not live Virus.\r\n\r\n\"So far we have not had the option to identify live infection in bosom milk,\" he said. \"So the danger of transmission from mother to baby so far has not been set up.\"','WHO suggests breastfeeding of infants, says no live coronavirus found in moms\' milk','','inherit','closed','closed','','6158-revision-v1','','','2020-06-15 09:36:02','2020-06-15 09:36:02','',6158,'https://microbiozindia.com/uncategorized/6158-revision-v1/',0,'revision','',0),(6160,2,'2020-06-15 09:36:24','2020-06-15 09:36:24','Breastfeeding moms don\'t appear to be giving the new coronavirus to their newborn children, and dependent on current proof the advantages exceed any likely dangers of transmission, the World Health Organization (WHO) said on Friday.\r\n\r\n<a href=\"https://www.news18.com/news/world/who-rcommends-breastfeeding-of-infants-says-no-live-coronavirus-found-in-mothers-milk-2667237.html\">WHO Director general <strong><u>Tedros Adhanom Ghebreyesus</u></strong> said that it had painstakingly researched the dangers of ladies transmitting COVID-19 to their kids during breastfeeding.</a>\r\n\r\n\"We realize that kids are at generally safe of COVID-19, yet are at high danger of various different sicknesses and conditions that breastfeeding forestalls,\" Tedros told a news meeting.\r\n\r\n<strong>\"In view of the accessible proof, WHO\'s recommendation is that the advantages of breastfeeding exceed any likely dangers of transmission of COVID-19,\" he said. </strong>\r\n\r\nAnshu Banerjee, a senior counselor in WHO\'s Department of Reproductive Health and Research, said that solitary \"sections\" of the Virus had been distinguished in bosom milk, not live Virus.\r\n\r\n\"So far we have not had the option to identify live infection in bosom milk,\" he said. \"So the danger of transmission from mother to baby so far has not been set up.\"','WHO suggests breastfeeding of infants, says no live coronavirus found in moms\' milk','','inherit','closed','closed','','6158-revision-v1','','','2020-06-15 09:36:24','2020-06-15 09:36:24','',6158,'https://microbiozindia.com/uncategorized/6158-revision-v1/',0,'revision','',0),(6161,2,'2020-06-15 09:59:43','2020-06-15 09:59:43','Chinese vaccine manufacturer Sinovac Biotech has reported \"positive starter\" aftereffects of stage I and II clinical preliminaries for its COVID-19 immunization up-and-comer, CoronaVac, saying it can incite a positive resistant reaction.\r\n\r\nThe stage I/II clinical preliminaries was planned as randomized, twofold visually impaired and fake treatment controlled examinations.\r\n\r\nAltogether, 743 solid volunteers, matured from 18 to 59 years of age, took on the preliminaries.\r\n\r\nOf those, 143 volunteers are in stage I and 600 volunteers are in stage II, the Beijing-based organization said in an announcement.\r\n\r\nThe immunization prompted killing antibodies in \"over 90 percent\" of individuals who were tried 14 days in the wake of getting two infusions, fourteen days separated. There were no serious reactions detailed, the organization said in an announcement.\r\n\r\nThe organization hopes to present a stage II clinical investigation report and a stage III clinical examination convention to China\'s National Medical Products Administration (NMPA) soon and start use of stage III clinical preliminaries outside of China.\r\n\r\nSinovac is working together with Instituto Butantan in Brazil to get ready and direct a stage III clinical examination.\r\n\r\nThe organization hopes to share the full information on our clinical preliminaries with general society through scholastic distributions.\r\n\r\nWeidong Yin, Chairman, President and CEO of Sinovac, stated, \"Our stage I/II study shows CoronaVac is protected and can instigate a resistant reaction.\r\n\r\n\"Closing our stage I/II clinical examinations with these empowering results is another noteworthy achievement we have accomplished in the battle against COVID-19,\" Weidong said.\r\n\r\n\"We have begun to put resources into building an assembling office with the goal that we can amplify the quantity of portions accessible to shield individuals from COVID-19. Like with our different immunizations, we are focused on creating CoronaVac for worldwide use as a feature of our strategic providing antibodies to take out human maladies,\" he said.\r\n\r\nSinovac\'s improvement of an immunization against COVID-19 started in January 2020 in organization with driving scholarly exploration foundations in China.\r\n\r\nThe organization got endorsement from China\'s NMPA on April 13 to direct stage I/II preliminaries on its inactivated immunization up-and-comer against COVID-19 in China.\r\n\r\nThere are right now in excess of two dozen examination endeavors in progress to create defensive antibodies against the novel coronavirus that causes COVID-19.\r\n\r\nIn May, Moderna, a Cambridge, Mass.- based biotech firm, declared early and empowering resistant reaction results for its test COVID-19 antibody.','China\'s\' Sinovac says its coronavirus antibody demonstrated positive outcomes in preliminaries','','publish','open','open','','chinas-sinovac-says-its-coronavirus-antibody-demonstrated-positive-outcomes-in-preliminaries','','','2020-06-15 09:59:43','2020-06-15 09:59:43','',0,'https://microbiozindia.com/?p=6161',0,'post','',0),(6162,2,'2020-06-15 09:59:43','2020-06-15 09:59:43','Chinese vaccine manufacturer Sinovac Biotech has reported \"positive starter\" aftereffects of stage I and II clinical preliminaries for its COVID-19 immunization up-and-comer, CoronaVac, saying it can incite a positive resistant reaction.\r\n\r\nThe stage I/II clinical preliminaries was planned as randomized, twofold visually impaired and fake treatment controlled examinations.\r\n\r\nAltogether, 743 solid volunteers, matured from 18 to 59 years of age, took on the preliminaries.\r\n\r\nOf those, 143 volunteers are in stage I and 600 volunteers are in stage II, the Beijing-based organization said in an announcement.\r\n\r\nThe immunization prompted killing antibodies in \"over 90 percent\" of individuals who were tried 14 days in the wake of getting two infusions, fourteen days separated. There were no serious reactions detailed, the organization said in an announcement.\r\n\r\nThe organization hopes to present a stage II clinical investigation report and a stage III clinical examination convention to China\'s National Medical Products Administration (NMPA) soon and start use of stage III clinical preliminaries outside of China.\r\n\r\nSinovac is working together with Instituto Butantan in Brazil to get ready and direct a stage III clinical examination.\r\n\r\nThe organization hopes to share the full information on our clinical preliminaries with general society through scholastic distributions.\r\n\r\nWeidong Yin, Chairman, President and CEO of Sinovac, stated, \"Our stage I/II study shows CoronaVac is protected and can instigate a resistant reaction.\r\n\r\n\"Closing our stage I/II clinical examinations with these empowering results is another noteworthy achievement we have accomplished in the battle against COVID-19,\" Weidong said.\r\n\r\n\"We have begun to put resources into building an assembling office with the goal that we can amplify the quantity of portions accessible to shield individuals from COVID-19. Like with our different immunizations, we are focused on creating CoronaVac for worldwide use as a feature of our strategic providing antibodies to take out human maladies,\" he said.\r\n\r\nSinovac\'s improvement of an immunization against COVID-19 started in January 2020 in organization with driving scholarly exploration foundations in China.\r\n\r\nThe organization got endorsement from China\'s NMPA on April 13 to direct stage I/II preliminaries on its inactivated immunization up-and-comer against COVID-19 in China.\r\n\r\nThere are right now in excess of two dozen examination endeavors in progress to create defensive antibodies against the novel coronavirus that causes COVID-19.\r\n\r\nIn May, Moderna, a Cambridge, Mass.- based biotech firm, declared early and empowering resistant reaction results for its test COVID-19 antibody.','China\'s\' Sinovac says its coronavirus antibody demonstrated positive outcomes in preliminaries','','inherit','closed','closed','','6161-revision-v1','','','2020-06-15 09:59:43','2020-06-15 09:59:43','',6161,'https://microbiozindia.com/uncategorized/6161-revision-v1/',0,'revision','',0),(6168,2,'2020-06-15 11:27:45','2020-06-15 11:27:45','Medication significant Sun Pharma on Monday said it has gone into an elite permitting and appropriation concurrence with Hikma Pharmaceuticals for plaque psoriasis medication, Ilumya, for the Middle East and North Africa (MENA) area.\r\n\r\nOne of the organization\'s\' completely possessed auxiliaries and Hikma Pharmaceuticals have gone into the understanding for Ilumya, Sun Pharma said in a documenting to BSE.\r\n\r\nUnder the details of the permitting understanding, Hikma will be answerable for the enlistment and commercialisation of the item in all MENA markets and Sun Pharma will be liable for item gracefully, it included.\r\n\r\n\"Sun Pharma is qualified for forthright and achievement installments from Hikma. The term of this understanding is 15 years from first deal, with two years\'\' programmed reestablishment periods,\" the documenting said.\r\n\r\nSun Pharma, be that as it may, didn\'t give any budgetary subtleties of the understanding.\r\n\r\n\"Hikma\'s\' solid nearness in the MENA district will empower access to another treatment alternative for individuals who can\'t deal with their moderate-to-serious plaque psoriasis,\" Sun Pharma Emerging Markets Senior VP Aalok Shanghvi said.\r\n\r\nIlumya (tildrakizumab) is a United States Food and Drug Administration (USFDA)- affirmed inventive monoclonal immunizer utilized for the treatment of grown-ups with moderate-to-extreme plaque psoriasis who are contender for fundamental treatment or phototherapy, Sun Pharma said.\r\n\r\nPortions of Sun Pharma were exchanging at Rs 478.55 per scrip on BSE, down 0.26 percent from their past close.','Sun Pharma, Hikma ink restrictive settlement for plaque psoriasis sedate for MENA locale','','publish','open','open','','sun-pharma-hikma-ink-restrictive-settlement-for-plaque-psoriasis-sedate-for-mena-locale','','','2020-06-15 11:27:58','2020-06-15 11:27:58','',0,'https://microbiozindia.com/?p=6168',0,'post','',0),(6169,2,'2020-06-15 11:27:45','2020-06-15 11:27:45','Medication significant Sun Pharma on Monday said it has gone into an elite permitting and appropriation concurrence with Hikma Pharmaceuticals for plaque psoriasis medication, Ilumya, for the Middle East and North Africa (MENA) area.\r\n\r\nOne of the organization\'s\' completely possessed auxiliaries and Hikma Pharmaceuticals have gone into the understanding for Ilumya, Sun Pharma said in a documenting to BSE.\r\n\r\nUnder the details of the permitting understanding, Hikma will be answerable for the enlistment and commercialisation of the item in all MENA markets and Sun Pharma will be liable for item gracefully, it included.\r\n\r\n\"Sun Pharma is qualified for forthright and achievement installments from Hikma. The term of this understanding is 15 years from first deal, with two years\'\' programmed reestablishment periods,\" the documenting said.\r\n\r\nSun Pharma, be that as it may, didn\'t give any budgetary subtleties of the understanding.\r\n\r\n\"Hikma\'s\' solid nearness in the MENA district will empower access to another treatment alternative for individuals who can\'t deal with their moderate-to-serious plaque psoriasis,\" Sun Pharma Emerging Markets Senior VP Aalok Shanghvi said.\r\n\r\nIlumya (tildrakizumab) is a United States Food and Drug Administration (USFDA)- affirmed inventive monoclonal immunizer utilized for the treatment of grown-ups with moderate-to-extreme plaque psoriasis who are contender for fundamental treatment or phototherapy, Sun Pharma said.\r\n\r\nPortions of Sun Pharma were exchanging at Rs 478.55 per scrip on BSE, down 0.26 percent from their past close.','Sun Pharma, Hikma ink restrictive settlement for plaque psoriasis sedate for MENA locale','','inherit','closed','closed','','6168-revision-v1','','','2020-06-15 11:27:45','2020-06-15 11:27:45','',6168,'https://microbiozindia.com/uncategorized/6168-revision-v1/',0,'revision','',0),(6173,2,'2020-06-15 12:49:37','2020-06-15 12:49:37','a:15:{s:4:\"type\";s:10:\"true_false\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";i:0;s:17:\"conditional_logic\";i:0;s:7:\"wrapper\";a:3:{s:5:\"width\";s:0:\"\";s:5:\"class\";s:0:\"\";s:2:\"id\";s:0:\"\";}s:7:\"message\";s:0:\"\";s:13:\"default_value\";i:0;s:2:\"ui\";i:1;s:10:\"ui_on_text\";s:0:\"\";s:11:\"ui_off_text\";s:0:\"\";s:11:\"show_column\";i:0;s:20:\"show_column_sortable\";i:0;s:18:\"show_column_weight\";i:1000;s:15:\"allow_quickedit\";i:0;s:14:\"allow_bulkedit\";i:0;}','Active','pop_active','publish','closed','closed','','field_5ee76e0336659','','','2020-06-15 12:54:57','2020-06-15 12:54:57','',4063,'https://microbiozindia.com/?post_type=acf-field&#038;p=6173',1,'acf-field','',0),(6174,2,'2020-06-15 13:42:35','2020-06-15 13:42:35','a:7:{s:8:\"location\";a:1:{i:0;a:1:{i:0;a:3:{s:5:\"param\";s:9:\"post_type\";s:8:\"operator\";s:2:\"==\";s:5:\"value\";s:16:\"newsletter_popup\";}}}s:8:\"position\";s:6:\"normal\";s:5:\"style\";s:7:\"default\";s:15:\"label_placement\";s:3:\"top\";s:21:\"instruction_placement\";s:5:\"label\";s:14:\"hide_on_screen\";s:0:\"\";s:11:\"description\";s:0:\"\";}','Newsletter Popup','newsletter-popup','publish','closed','closed','','group_5ee77a88b3ded','','','2020-06-15 13:42:35','2020-06-15 13:42:35','',0,'https://microbiozindia.com/?post_type=acf-field-group&#038;p=6174',0,'acf-field-group','',0),(6175,2,'2020-06-15 13:42:35','2020-06-15 13:42:35','a:10:{s:4:\"type\";s:10:\"true_false\";s:12:\"instructions\";s:0:\"\";s:8:\"required\";i:0;s:17:\"conditional_logic\";i:0;s:7:\"wrapper\";a:3:{s:5:\"width\";s:0:\"\";s:5:\"class\";s:0:\"\";s:2:\"id\";s:0:\"\";}s:7:\"message\";s:0:\"\";s:13:\"default_value\";i:0;s:2:\"ui\";i:1;s:10:\"ui_on_text\";s:0:\"\";s:11:\"ui_off_text\";s:0:\"\";}','Active','activate_newsletter_popup','publish','closed','closed','','field_5ee77a928c46e','','','2020-06-15 13:42:35','2020-06-15 13:42:35','',6174,'https://microbiozindia.com/?post_type=acf-field&p=6175',0,'acf-field','',0),(6176,2,'2020-06-15 13:43:49','2020-06-15 13:43:49','','Auto Draft','','publish','closed','closed','','auto-draft','','','2020-06-16 11:52:36','2020-06-16 11:52:36','',0,'https://microbiozindia.com/?post_type=newsletter_popup&#038;p=6176',0,'newsletter_popup','',0),(6177,2,'2020-06-16 05:52:51','2020-06-16 05:52:51','Some facilitate frameworks are more helpful than others for speaking to data. To speak to an area on Earth, for instance, we may utilize an Earth-focused arrange framework, for example, scope and longitude. In such an Earth-focused facilitate framework, an area -, for example, your home - is consistent after some time. Yet, you could likewise speak to where you live as an area comparative with the sun utilizing a sun-focused organize framework. Such a framework would unmistakably not be valuable for individuals attempting to discover where you live, as your location in sun-focused directions would change ceaselessly as the Earth pivots comparative with the sun.\r\n\r\nThe human cerebrum faces this equivalent issue of speaking to data with proper organize frameworks and moving between arrange frameworks to manage your activities. This is incompletely on the grounds that tactile data is encoded in various reference outlines: visual data is at first encoded comparative with the eye with eye-focused directions, sound-related data is at first encoded comparative with the head with head-focused directions, etc. An intriguing arrangement of calculations must happen in the cerebrum all together for these tactile signs to be joined to permit an individual to see a whole scene.\r\n\r\n<strong>Be that as it may, how do neurons speak to objects in various reference outlines while you travel through a domain?</strong>\r\n\r\nIn a paper distributed in the diary Nature Neuroscience, analysts from the University of Rochester, including Greg DeAngelis, a teacher of mind and intellectual sciences, analyzed how neurons in the cerebrum speak to the movement of an item while the onlooker is additionally moving.\r\n\r\nIn particular, the analysts concentrated how spectators judge an item\'s movement comparative with the onlooker\'s head or comparative with the world.\r\n\r\nTheir discoveries - that neurons in a particular cerebrum locale are increasingly adaptable in exchanging between reference outlines - offer significant data about the inward activities of the mind and might be utilized in neural prosthetics and treatments to treat cerebrum issue.\r\n\r\n<strong>ARE NEURONS FIXED OR FLEXIBLE?</strong>\r\n\r\nEnvision you\'re playing soccer. In case you\'re running and need to head the ball, you would need to register the direction of the ball\'s movement comparative with your head so you can reach between your head and the ball. A head-focused facilitate framework would in this manner be valuable. On the other hand, on the off chance that you are running and viewing your colleague kick the ball toward the objective, you would need to register the direction of the ball comparative with the objective to decide if your partner scored. This would require a world-focused organize framework since the objective is fixed comparative with the world.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">\"Contingent upon the errand being played out, the cerebrum needs to speak to protest movement in various organize frameworks to be fruitful,\" DeAngelis says. \"The unavoidable issue is: how does the cerebrum do this?\"</a></span>\r\n\r\nThe analysts needed to decide whether the mind needs to switch between various neurons that each have an alternate fixed reference outline - for instance, exchanging between head-focused neurons and world-focused neurons - or if the neurons are adaptable and update their reference outlines as per the prompt requests of the undertaking of speaking to question movement.\r\n\r\nThe analysts prepared subjects to pass judgment on object movement in either head-focused or world-focused directions and to switch between them from preliminary to preliminary dependent on a prompt.\r\n\r\nThe specialists recorded signs from neurons in two unique territories of the cerebrum and found that neurons in the ventral intraparietal (VIP) zone of the mind have an exceptional property: their reactions to protest movement change contingent upon the assignment.\r\n\r\nThat is, the neurons don\'t have fixed reference outlines, yet rather deftly adjust to the requests of the undertaking and change their reference outlines in like manner.\r\n\r\nNeurons in VIP will speak to protest movement in head-focused directions when the subjects are required to report object movement comparative with their head. They speak to protest movement in world-focused directions when the subject was required to report object movement comparative with the world.\r\n\r\nSince the neurons have such adaptable reactions, this implies the cerebrum may enormously streamline the way toward going along the data it needs to manage activities.\r\n\r\n\"This is the main investigation to show that neurons can deftly speak to spatial data, for example, object movement, in various arrange frameworks dependent on the guidelines given to the subject,\" DeAngelis says. \"This implies the cerebrum can translate - or \'read out\' - data from this single populace of neurons and have the option to have the data it requirements for either task circumstance.\"\r\n\r\nThe VIP zone is situated in the parietal flap of the mind and gets contributions from visual, sound-related, and vestibular (inward ear) detects. This is the primary investigation to test for adaptable reference outlines, so the VIP region is the main region known to have this property. The scientists suspect, in any case, that neurons in different territories of the cerebrum may have this property too.\r\n\r\n<strong>APPLICATIONS FOR NEURAL PROSTHETICS AND BRAIN DISORDERS</strong>\r\n\r\nThe examination offers significant data about the inward functions of the mind and possibly could be utilized for applications, for example, neural prosthetics, in which cerebrum movement is utilized to control counterfeit appendages or vehicles.\r\n\r\n\"To make a compelling neural prosthetic, you need to gather signals from the mind regions that would be generally valuable and adaptable for performing fundamental assignments,\" DeAngelis says. \"In the event that those errands include capturing moving articles, for instance, at that point taking advantage of signs from VIP may be an approach to make a prosthetic work proficiently for an assortment of assignments that would include passing judgment on movement comparative with the head or the world.\"\r\n\r\nDespite the fact that this exploration isn\'t as of now associated with a particular mind issue, analysts have recently discovered that people\'s capacity to take in tactile data and surmise which occasions on the planet caused that tangible information - a capacity known as causal derivation - is weakened in disarranges, for example, mental imbalance and schizophrenia.\r\n\r\n\"In continuous and future work, we are considering the neural systems of this causal induction process in more detail, utilizing related undertakings that include cooperations between object movement and self-movement,\" DeAngelis says.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">Materials</a></span> gave by University of Rochester. Note: Content might be altered for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\n1. Ryo Sasaki, Akiyuki Anzai, Dora E. Angelaki, Gregory C. DeAngelis. Adaptable coding of article movement in different reference outlines by parietal cortex neurons. Nature Neuroscience, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">2020; DOI: 10.1038/s41593-020-0656-0</a></span>\r\n\r\n&nbsp;','Neurons can move how they process data about movement','','publish','open','open','','neurons-can-move-how-they-process-data-about-movement','','','2020-06-16 05:53:26','2020-06-16 05:53:26','',0,'https://microbiozindia.com/?p=6177',0,'post','',0),(6178,2,'2020-06-16 05:52:51','2020-06-16 05:52:51','Some facilitate frameworks are more helpful than others for speaking to data. To speak to an area on Earth, for instance, we may utilize an Earth-focused arrange framework, for example, scope and longitude. In such an Earth-focused facilitate framework, an area -, for example, your home - is consistent after some time. Yet, you could likewise speak to where you live as an area comparative with the sun utilizing a sun-focused organize framework. Such a framework would unmistakably not be valuable for individuals attempting to discover where you live, as your location in sun-focused directions would change ceaselessly as the Earth pivots comparative with the sun.\r\n\r\nThe human cerebrum faces this equivalent issue of speaking to data with proper organize frameworks and moving between arrange frameworks to manage your activities. This is incompletely on the grounds that tactile data is encoded in various reference outlines: visual data is at first encoded comparative with the eye with eye-focused directions, sound-related data is at first encoded comparative with the head with head-focused directions, etc. An intriguing arrangement of calculations must happen in the cerebrum all together for these tactile signs to be joined to permit an individual to see a whole scene.\r\n\r\n<strong>Be that as it may, how do neurons speak to objects in various reference outlines while you travel through a domain?</strong>\r\n\r\nIn a paper distributed in the diary Nature Neuroscience, analysts from the University of Rochester, including Greg DeAngelis, a teacher of mind and intellectual sciences, analyzed how neurons in the cerebrum speak to the movement of an item while the onlooker is additionally moving.\r\n\r\nIn particular, the analysts concentrated how spectators judge an item\'s movement comparative with the onlooker\'s head or comparative with the world.\r\n\r\nTheir discoveries - that neurons in a particular cerebrum locale are increasingly adaptable in exchanging between reference outlines - offer significant data about the inward activities of the mind and might be utilized in neural prosthetics and treatments to treat cerebrum issue.\r\n\r\n<strong>ARE NEURONS FIXED OR FLEXIBLE?</strong>\r\n\r\nEnvision you\'re playing soccer. In case you\'re running and need to head the ball, you would need to register the direction of the ball\'s movement comparative with your head so you can reach between your head and the ball. A head-focused facilitate framework would in this manner be valuable. On the other hand, on the off chance that you are running and viewing your colleague kick the ball toward the objective, you would need to register the direction of the ball comparative with the objective to decide if your partner scored. This would require a world-focused organize framework since the objective is fixed comparative with the world.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">\"Contingent upon the errand being played out, the cerebrum needs to speak to protest movement in various organize frameworks to be fruitful,\" DeAngelis says. \"The unavoidable issue is: how does the cerebrum do this?\"</a></span>\r\n\r\nThe analysts needed to decide whether the mind needs to switch between various neurons that each have an alternate fixed reference outline - for instance, exchanging between head-focused neurons and world-focused neurons - or if the neurons are adaptable and update their reference outlines as per the prompt requests of the undertaking of speaking to question movement.\r\n\r\nThe analysts prepared subjects to pass judgment on object movement in either head-focused or world-focused directions and to switch between them from preliminary to preliminary dependent on a prompt.\r\n\r\nThe specialists recorded signs from neurons in two unique territories of the cerebrum and found that neurons in the ventral intraparietal (VIP) zone of the mind have an exceptional property: their reactions to protest movement change contingent upon the assignment.\r\n\r\nThat is, the neurons don\'t have fixed reference outlines, yet rather deftly adjust to the requests of the undertaking and change their reference outlines in like manner.\r\n\r\nNeurons in VIP will speak to protest movement in head-focused directions when the subjects are required to report object movement comparative with their head. They speak to protest movement in world-focused directions when the subject was required to report object movement comparative with the world.\r\n\r\nSince the neurons have such adaptable reactions, this implies the cerebrum may enormously streamline the way toward going along the data it needs to manage activities.\r\n\r\n\"This is the main investigation to show that neurons can deftly speak to spatial data, for example, object movement, in various arrange frameworks dependent on the guidelines given to the subject,\" DeAngelis says. \"This implies the cerebrum can translate - or \'read out\' - data from this single populace of neurons and have the option to have the data it requirements for either task circumstance.\"\r\n\r\nThe VIP zone is situated in the parietal flap of the mind and gets contributions from visual, sound-related, and vestibular (inward ear) detects. This is the primary investigation to test for adaptable reference outlines, so the VIP region is the main region known to have this property. The scientists suspect, in any case, that neurons in different territories of the cerebrum may have this property too.\r\n\r\n<strong>APPLICATIONS FOR NEURAL PROSTHETICS AND BRAIN DISORDERS</strong>\r\n\r\nThe examination offers significant data about the inward functions of the mind and possibly could be utilized for applications, for example, neural prosthetics, in which cerebrum movement is utilized to control counterfeit appendages or vehicles.\r\n\r\n\"To make a compelling neural prosthetic, you need to gather signals from the mind regions that would be generally valuable and adaptable for performing fundamental assignments,\" DeAngelis says. \"In the event that those errands include capturing moving articles, for instance, at that point taking advantage of signs from VIP may be an approach to make a prosthetic work proficiently for an assortment of assignments that would include passing judgment on movement comparative with the head or the world.\"\r\n\r\nDespite the fact that this exploration isn\'t as of now associated with a particular mind issue, analysts have recently discovered that people\'s capacity to take in tactile data and surmise which occasions on the planet caused that tangible information - a capacity known as causal derivation - is weakened in disarranges, for example, mental imbalance and schizophrenia.\r\n\r\n\"In continuous and future work, we are considering the neural systems of this causal induction process in more detail, utilizing related undertakings that include cooperations between object movement and self-movement,\" DeAngelis says.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">Materials</a></span> gave by University of Rochester. Note: Content might be altered for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\n1. Ryo Sasaki, Akiyuki Anzai, Dora E. Angelaki, Gregory C. DeAngelis. Adaptable coding of article movement in different reference outlines by parietal cortex neurons. Nature Neuroscience, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rochester.edu/newscenter/neurons-shift-how-they-process-motion-information-440482/\">2020; DOI: 10.1038/s41593-020-0656-0</a></span>\r\n\r\n&nbsp;','Neurons can move how they process data about movement','','inherit','closed','closed','','6177-revision-v1','','','2020-06-16 05:52:51','2020-06-16 05:52:51','',6177,'https://microbiozindia.com/uncategorized/6177-revision-v1/',0,'revision','',0),(6179,2,'2020-06-16 05:53:14','2020-06-16 05:53:14','','mind-544404_640','','inherit','open','closed','','mind-544404_640','','','2020-06-16 05:53:14','2020-06-16 05:53:14','',6177,'https://microbiozindia.com/wp-content/uploads/2020/06/mind-544404_640.png',0,'attachment','image/png',0),(6180,2,'2020-06-16 09:26:50','2020-06-16 09:26:50','AstraZeneca\'s potential coronavirus immunization is probably going to give assurance against contracting COVID-19 for about a year, the organization\'s CEO told a Belgian radio broadcast on Tuesday.\r\n\r\nThe British drugmaker has just started human preliminaries of the antibody created by the University of Oxford, with a stage I preliminary in Britain because of end soon and a stage III preliminary previously started, Pascal Soriot told supporter Bel RTL.\r\n\r\n\"We imagine that it will ensure for about a year,\" Soriot said.\r\n\r\nAstraZeneca said on Saturday that it had marked agreements with France, Germany, Italy and the Netherlands to flexibly the European Union with up to 400 million portions of the possible antibody.\r\n\r\nIt has additionally concurred manages Britain and the United States.\r\n\r\n\"In the event that all works out positively, we will have the aftereffects of the clinical preliminaries in August/September. We are producing in equal. We will be prepared to convey from October if all works out positively,\" Soriot said.','AstraZeneca COVID-19 vaccine liable to ensure for a year: CEO','','publish','open','open','','astrazeneca-covid-19-vaccine-liable-to-ensure-for-a-year-ceo','','','2020-06-16 09:26:50','2020-06-16 09:26:50','',0,'https://microbiozindia.com/?p=6180',0,'post','',0),(6181,2,'2020-06-16 09:26:50','2020-06-16 09:26:50','AstraZeneca\'s potential coronavirus immunization is probably going to give assurance against contracting COVID-19 for about a year, the organization\'s CEO told a Belgian radio broadcast on Tuesday.\r\n\r\nThe British drugmaker has just started human preliminaries of the antibody created by the University of Oxford, with a stage I preliminary in Britain because of end soon and a stage III preliminary previously started, Pascal Soriot told supporter Bel RTL.\r\n\r\n\"We imagine that it will ensure for about a year,\" Soriot said.\r\n\r\nAstraZeneca said on Saturday that it had marked agreements with France, Germany, Italy and the Netherlands to flexibly the European Union with up to 400 million portions of the possible antibody.\r\n\r\nIt has additionally concurred manages Britain and the United States.\r\n\r\n\"In the event that all works out positively, we will have the aftereffects of the clinical preliminaries in August/September. We are producing in equal. We will be prepared to convey from October if all works out positively,\" Soriot said.','AstraZeneca COVID-19 vaccine liable to ensure for a year: CEO','','inherit','closed','closed','','6180-revision-v1','','','2020-06-16 09:26:50','2020-06-16 09:26:50','',6180,'https://microbiozindia.com/uncategorized/6180-revision-v1/',0,'revision','',0),(6182,2,'2020-06-16 12:18:32','2020-06-16 12:18:32','','','','inherit','closed','closed','','6176-autosave-v1','','','2020-06-16 12:18:32','2020-06-16 12:18:32','',6176,'https://microbiozindia.com/uncategorized/6176-autosave-v1/',0,'revision','',0),(6183,2,'2020-06-16 12:47:30','2020-06-16 12:47:30','The portions of Alembic Pharmaceuticals picked up as much as 6 percent to Rs 943.80 on Tuesday.\r\n\r\nPrior today, the organization reported it had gotten last endorsement from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Deferasirox Tablets, 180 mg.\r\n\r\nThe affirmed ANDA is remedially proportionate to the reference recorded medication item, Jadenu tablets, 180 mg, of Novartis Pharmaceuticals. Deferasirox tablets are shown for the treatment of interminable iron over-burden because of blood transfusions.\r\n\r\nThe evaluated showcase size for this item is US$ 53 million for a year finishing March 2020, as indicated by IQVIA.','Alembic Pharma gains 6% on USFDA gesture for its iron tablet','','publish','open','open','','alembic-pharma-gains-6-on-usfda-gesture-for-its-iron-tablet','','','2020-06-16 12:47:30','2020-06-16 12:47:30','',0,'https://microbiozindia.com/?p=6183',0,'post','',0),(6184,2,'2020-06-16 12:47:30','2020-06-16 12:47:30','The portions of Alembic Pharmaceuticals picked up as much as 6 percent to Rs 943.80 on Tuesday.\r\n\r\nPrior today, the organization reported it had gotten last endorsement from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Deferasirox Tablets, 180 mg.\r\n\r\nThe affirmed ANDA is remedially proportionate to the reference recorded medication item, Jadenu tablets, 180 mg, of Novartis Pharmaceuticals. Deferasirox tablets are shown for the treatment of interminable iron over-burden because of blood transfusions.\r\n\r\nThe evaluated showcase size for this item is US$ 53 million for a year finishing March 2020, as indicated by IQVIA.','Alembic Pharma gains 6% on USFDA gesture for its iron tablet','','inherit','closed','closed','','6183-revision-v1','','','2020-06-16 12:47:30','2020-06-16 12:47:30','',6183,'https://microbiozindia.com/uncategorized/6183-revision-v1/',0,'revision','',0),(6185,2,'2020-06-16 15:54:59','2020-06-16 15:54:59','The ReactoMate DATUM from Asynt is a high quality, dual-rod stainless steel and aluminium support system built to ensure the stability and safety of your lab reactor. Sturdy, yet compact, the ReactoMate DATUM support system can accommodate a wide range of reaction vessels from 100 mL up to 5000 mL.\r\n\r\nDesigned with user-friendliness in mind, the ReactoMate DATUM support system incorporates a suite of innovative features.\r\n\r\nChanging a vessel supported by the ReactoMate DATUM is as simple as “Clip &amp; Click”. The novel neck clamp allows fast changeover between reactor vessel sizes thereby enabling simple reaction scale-up, whilst the ingenious mounting mechanism ensures excellent stability and alignment every time.\r\n\r\nThe Reactomate DATUM support system is fully compatible with all leading brands of overhead stirrers and circulator heating/cooling systems. Designed by chemists for chemists, low-friction polymer bearings line both the overhead stirrer alignment chuck and the neck support to ensure smooth and easy operation.\r\n\r\nIdeally suited for use within a benchtop fume hood, adjustable feet allow you to level the ReactoMate DATUM support system ensuring stability and security while you work. Each DATUM system is also supplied with a moulded drip tray that fits perfectly within the base of the support, for safely catching any drips and spills from the reaction vessel during draining.\r\n\r\nWith a wide range of accessories and upgrades available, including drain manifolds and automation packages, the ReactoMate DATUM support system really is the perfect all-rounder for laboratory scale reactions.\r\n\r\nTo watch a video introduction to the ReactoMate DATUM please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.youtube.com/watch?v=StJt4fzIl8I\">https://www.youtube.com/watch?v=StJt4fzIl8I</a></span>. For further information on the ReactoMate DATUM support system please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.asynt.com/product/reactomate-datum/\">https://www.asynt.com/product/reactomate-datum/</a></span> or contact Asynt on +44-1638-781709 / enquiries@asynt.com.\r\n\r\nAsynt is a leading supplier of affordable products, consumables and services for chemists in industry and academia. With a staff of trained chemists - Asynt can draw upon this in-depth applications knowledge to provide a high level of customer support for its DrySyn Heating Blocks, Controlled Lab Reactors, Synthesis Tools, Evaporators, Circulators, Temperature Control Systems, Vacuum Pumps and Lab Safety Equipment.','User-Friendly Support System for Laboratory Scale Reactions','','publish','open','open','','user-friendly-support-system-for-laboratory-scale-reactions','','','2020-06-16 15:54:59','2020-06-16 15:54:59','',0,'https://microbiozindia.com/?p=6185',0,'post','',0),(6186,2,'2020-06-16 15:54:16','2020-06-16 15:54:16','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-6','','','2020-06-16 15:54:16','2020-06-16 15:54:16','',6185,'https://microbiozindia.com/wp-content/uploads/2020/06/Untitled-design-1-1.png',0,'attachment','image/png',0),(6187,2,'2020-06-16 15:54:59','2020-06-16 15:54:59','The ReactoMate DATUM from Asynt is a high quality, dual-rod stainless steel and aluminium support system built to ensure the stability and safety of your lab reactor. Sturdy, yet compact, the ReactoMate DATUM support system can accommodate a wide range of reaction vessels from 100 mL up to 5000 mL.\r\n\r\nDesigned with user-friendliness in mind, the ReactoMate DATUM support system incorporates a suite of innovative features.\r\n\r\nChanging a vessel supported by the ReactoMate DATUM is as simple as “Clip &amp; Click”. The novel neck clamp allows fast changeover between reactor vessel sizes thereby enabling simple reaction scale-up, whilst the ingenious mounting mechanism ensures excellent stability and alignment every time.\r\n\r\nThe Reactomate DATUM support system is fully compatible with all leading brands of overhead stirrers and circulator heating/cooling systems. Designed by chemists for chemists, low-friction polymer bearings line both the overhead stirrer alignment chuck and the neck support to ensure smooth and easy operation.\r\n\r\nIdeally suited for use within a benchtop fume hood, adjustable feet allow you to level the ReactoMate DATUM support system ensuring stability and security while you work. Each DATUM system is also supplied with a moulded drip tray that fits perfectly within the base of the support, for safely catching any drips and spills from the reaction vessel during draining.\r\n\r\nWith a wide range of accessories and upgrades available, including drain manifolds and automation packages, the ReactoMate DATUM support system really is the perfect all-rounder for laboratory scale reactions.\r\n\r\nTo watch a video introduction to the ReactoMate DATUM please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.youtube.com/watch?v=StJt4fzIl8I\">https://www.youtube.com/watch?v=StJt4fzIl8I</a></span>. For further information on the ReactoMate DATUM support system please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.asynt.com/product/reactomate-datum/\">https://www.asynt.com/product/reactomate-datum/</a></span> or contact Asynt on +44-1638-781709 / enquiries@asynt.com.\r\n\r\nAsynt is a leading supplier of affordable products, consumables and services for chemists in industry and academia. With a staff of trained chemists - Asynt can draw upon this in-depth applications knowledge to provide a high level of customer support for its DrySyn Heating Blocks, Controlled Lab Reactors, Synthesis Tools, Evaporators, Circulators, Temperature Control Systems, Vacuum Pumps and Lab Safety Equipment.','User-Friendly Support System for Laboratory Scale Reactions','','inherit','closed','closed','','6185-revision-v1','','','2020-06-16 15:54:59','2020-06-16 15:54:59','',6185,'https://microbiozindia.com/uncategorized/6185-revision-v1/',0,'revision','',0),(6188,2,'2020-06-16 16:30:53','2020-06-16 16:30:53','Sanitizing is most important than anything to protect ourselves in this global pandemic situation. In this current Pandemic situation of COVID-19 it has made every one use hand sanitizer to get rid of any bit of virus present on our hands due to direct or indirect contact with infected one. According to WHO guidelines washing hands every 2 hours or timely sanitizing them to protect her/himself. Now washing hands on the go is not possible for everyone, hence the use of hand sanitizer has been recommended.\r\nWhile the world strives to cope with a global pandemic, the requirement of hand sanitizers has increased. FDA is allowing additional companies to manufacture alcohol-based hand sanitizers for consumer use and for use as health care personnel hand rubs for the duration of the public health emergency, But provided the following circumstances are present:\r\n\r\n1. The hand sanitizer is manufactured using only the following United States Pharmacopeia (USP) grade ingredients, consistent with World Health Organization (WHO)recommendations:\r\n\r\na. Alcohol (ethanol) (USP or Food Chemical Codex (FCC) grade) (80%,volume/volume (v/v)) in an aqueous solution or Isopropyl Alcohol (75%,v/v) in an aqueous solution.\r\n\r\nb. Glycerol (1.45% v/v).\r\n\r\nc. Hydrogen peroxide (0.125% v/v).\r\n\r\nd. Sterile distilled water or boiled cold water.\r\nWHO recommends the local production of the following two formulations as an alternative when suitable commercial products are either unavailable or too costly, the formulations are as follows.\r\n\r\n<img class=\"alignnone  wp-image-6189\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/NEW-300x56.png\" alt=\"\" width=\"654\" height=\"122\" />\r\n\r\nQuality-control pre and post production is also very important. Pre-production analysis should be made every time an analysis certificate is not available to guarantee the concentration of alcohol. Verify the alcohol concentration with the alcohol meter and make the necessary adjustments in volume in the preparation formulation to obtain the final result.\r\n\r\nPost-production analysis is mandatory if either ethanol or an isopropanol solution is used. Use the alcohol meter to control the alcohol concentration of the final use solution. The accepted limits should be fixed to ± 5% of the target concentration (75%–85% for ethanol).\r\n\r\nPre-production reagents quality can be verified in conformity of the respective monograph if an analysis certificate is not available. Density, Refractometry and Titration instrumentation are used to ensure compliance with pharmacopoeia requirements (e.g. European Pharmacopoeia).\r\n\r\n<strong>• Ethanol 96%:</strong> alcoholometry or relative density 0.805 to 0.812 and R.I. 1.3636\r\n<strong>• Isopropyl alcohol 99.8%:</strong> relative density 0.785 to 0.789 and R.I. 1.376 to 1.379\r\n<strong>• Glycerol 98%:</strong> refractive index 1.470 to 1.475\r\n<strong>• Hydrogen peroxide 3%:</strong> concentration can be determined by titration (oxidation of hydrogen peroxide using potassium permanganate).\r\n\r\nWe at Hanna instruments supply the instruments in refractometry as well as in titrometry. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://hannainst.in/hi96800-digital-refractometer-for-refractive-index-and-brix.html\">Our HI96800 refractometer and HI93X series of tiltrator series, is cost friendly as well as easy to use.</a> </span>HI96800 is easy measurement with just 3 button operation. Titrators are state of art built to sustain in adverse conditions. Saves foot-print of your lab, gives accurate results. Durable, accurate, and simple to use, our fully supported autotitrators make switching to us the right choice.\r\n\r\n<strong>Author :</strong>\r\nWith more than a decade of experience in managing sales, marketing, customer support and business of Analytical Instruments. Kondiba has a vast knowledge of Instrument sales in new and remote markets. With his expertise and foresightedness, Hanna Instruments - a worldwide leader in analytical instruments has a strong hold in Indian market and witnessing growth every year. Spearheading a team of 35 sales engineers, he ensures to achieve targets and is responsible for the accountability of sales and marketing operations in Hanna Instruments.\r\n\r\n<strong>Hanna Equipments India Pvt.Ltd.</strong>\r\nEmail :marketing@hannainst.in\r\nMob   :7045792178','Sanitizer formulations and Quality control','','publish','open','open','','sanitizer-formulations-and-quality-control','','','2020-06-16 16:30:53','2020-06-16 16:30:53','',0,'https://microbiozindia.com/?p=6188',0,'post','',0),(6189,2,'2020-06-16 16:18:03','2020-06-16 16:18:03','','NEW','','inherit','open','closed','','new-2','','','2020-06-16 16:18:03','2020-06-16 16:18:03','',6188,'https://microbiozindia.com/wp-content/uploads/2020/06/NEW.png',0,'attachment','image/png',0),(6190,2,'2020-06-16 16:25:53','2020-06-16 16:25:53','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-7','','','2020-06-16 16:25:53','2020-06-16 16:25:53','',6188,'https://microbiozindia.com/wp-content/uploads/2020/06/Untitled-design-1-2.png',0,'attachment','image/png',0),(6191,2,'2020-06-16 16:30:53','2020-06-16 16:30:53','Sanitizing is most important than anything to protect ourselves in this global pandemic situation. In this current Pandemic situation of COVID-19 it has made every one use hand sanitizer to get rid of any bit of virus present on our hands due to direct or indirect contact with infected one. According to WHO guidelines washing hands every 2 hours or timely sanitizing them to protect her/himself. Now washing hands on the go is not possible for everyone, hence the use of hand sanitizer has been recommended.\r\nWhile the world strives to cope with a global pandemic, the requirement of hand sanitizers has increased. FDA is allowing additional companies to manufacture alcohol-based hand sanitizers for consumer use and for use as health care personnel hand rubs for the duration of the public health emergency, But provided the following circumstances are present:\r\n\r\n1. The hand sanitizer is manufactured using only the following United States Pharmacopeia (USP) grade ingredients, consistent with World Health Organization (WHO)recommendations:\r\n\r\na. Alcohol (ethanol) (USP or Food Chemical Codex (FCC) grade) (80%,volume/volume (v/v)) in an aqueous solution or Isopropyl Alcohol (75%,v/v) in an aqueous solution.\r\n\r\nb. Glycerol (1.45% v/v).\r\n\r\nc. Hydrogen peroxide (0.125% v/v).\r\n\r\nd. Sterile distilled water or boiled cold water.\r\nWHO recommends the local production of the following two formulations as an alternative when suitable commercial products are either unavailable or too costly, the formulations are as follows.\r\n\r\n<img class=\"alignnone  wp-image-6189\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/NEW-300x56.png\" alt=\"\" width=\"654\" height=\"122\" />\r\n\r\nQuality-control pre and post production is also very important. Pre-production analysis should be made every time an analysis certificate is not available to guarantee the concentration of alcohol. Verify the alcohol concentration with the alcohol meter and make the necessary adjustments in volume in the preparation formulation to obtain the final result.\r\n\r\nPost-production analysis is mandatory if either ethanol or an isopropanol solution is used. Use the alcohol meter to control the alcohol concentration of the final use solution. The accepted limits should be fixed to ± 5% of the target concentration (75%–85% for ethanol).\r\n\r\nPre-production reagents quality can be verified in conformity of the respective monograph if an analysis certificate is not available. Density, Refractometry and Titration instrumentation are used to ensure compliance with pharmacopoeia requirements (e.g. European Pharmacopoeia).\r\n\r\n<strong>• Ethanol 96%:</strong> alcoholometry or relative density 0.805 to 0.812 and R.I. 1.3636\r\n<strong>• Isopropyl alcohol 99.8%:</strong> relative density 0.785 to 0.789 and R.I. 1.376 to 1.379\r\n<strong>• Glycerol 98%:</strong> refractive index 1.470 to 1.475\r\n<strong>• Hydrogen peroxide 3%:</strong> concentration can be determined by titration (oxidation of hydrogen peroxide using potassium permanganate).\r\n\r\nWe at Hanna instruments supply the instruments in refractometry as well as in titrometry. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://hannainst.in/hi96800-digital-refractometer-for-refractive-index-and-brix.html\">Our HI96800 refractometer and HI93X series of tiltrator series, is cost friendly as well as easy to use.</a> </span>HI96800 is easy measurement with just 3 button operation. Titrators are state of art built to sustain in adverse conditions. Saves foot-print of your lab, gives accurate results. Durable, accurate, and simple to use, our fully supported autotitrators make switching to us the right choice.\r\n\r\n<strong>Author :</strong>\r\nWith more than a decade of experience in managing sales, marketing, customer support and business of Analytical Instruments. Kondiba has a vast knowledge of Instrument sales in new and remote markets. With his expertise and foresightedness, Hanna Instruments - a worldwide leader in analytical instruments has a strong hold in Indian market and witnessing growth every year. Spearheading a team of 35 sales engineers, he ensures to achieve targets and is responsible for the accountability of sales and marketing operations in Hanna Instruments.\r\n\r\n<strong>Hanna Equipments India Pvt.Ltd.</strong>\r\nEmail :marketing@hannainst.in\r\nMob   :7045792178','Sanitizer formulations and Quality control','','inherit','closed','closed','','6188-revision-v1','','','2020-06-16 16:30:53','2020-06-16 16:30:53','',6188,'https://microbiozindia.com/uncategorized/6188-revision-v1/',0,'revision','',0),(6192,2,'2020-06-17 07:06:13','2020-06-17 07:06:13','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a <span style=\"color: #ff6600;\"><strong>serology-based total antibody (IgM, IgG, IgA) detection assay.</strong></span>\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"406\" height=\"290\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','publish','open','open','','total-antibody-detection-assay-kit-for-covid-19-launched-in-india-by-j-mitra','','','2020-06-17 07:14:02','2020-06-17 07:14:02','',0,'https://microbiozindia.com/?p=6192',0,'post','',0),(6193,2,'2020-06-17 07:01:47','2020-06-17 07:01:47','','JMITRA (2)','','inherit','open','closed','','jmitra-2','','','2020-06-17 07:01:47','2020-06-17 07:01:47','',6192,'https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-2.png',0,'attachment','image/png',0),(6194,2,'2020-06-17 07:01:49','2020-06-17 07:01:49','','JMITRA','','inherit','open','closed','','jmitra','','','2020-06-17 07:01:49','2020-06-17 07:01:49','',6192,'https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA.png',0,'attachment','image/png',0),(6195,2,'2020-06-17 07:06:13','2020-06-17 07:06:13','<strong><u>New Delhi, 17<sup>th</sup> June 2020</u></strong><strong>: </strong>J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as <strong>COVID-19 [IgM, IgG, IgA] MICROLISA</strong>. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\n<img class=\" wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"407\" height=\"290\" />This factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, “<em>we have deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market</em>.”\r\n\r\nTalking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “<em>The </em><em>IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.</em>”\r\n\r\nSpeaking on the production aspects, Jatin Mahajan, managing director said, “<em>We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.” </em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n\r\n<em>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</em>\r\n\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\n<strong>Prasun Peter @ 9811279008, prasun.peter@gmail.com</strong>','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:06:13','2020-06-17 07:06:13','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6196,2,'2020-06-17 07:12:29','2020-06-17 07:12:29','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a <span style=\"color: #ff6600;\"><strong>serology-based total antibody (IgM, IgG, IgA) detection assay.</strong></span>\n\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignnone\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\n\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\n\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\n\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\n\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\n\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\n<strong>About J Mitra &amp; Company</strong>\n\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\n\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\n\nFor further information please contact:\n\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-autosave-v1','','','2020-06-17 07:12:29','2020-06-17 07:12:29','',6192,'https://microbiozindia.com/uncategorized/6192-autosave-v1/',0,'revision','',0),(6197,2,'2020-06-17 07:08:24','2020-06-17 07:08:24','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\" wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:08:24','2020-06-17 07:08:24','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6198,2,'2020-06-17 07:08:59','2020-06-17 07:08:59','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignnone\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:08:59','2020-06-17 07:08:59','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6199,2,'2020-06-17 07:09:29','2020-06-17 07:09:29','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"alignright wp-image-6194\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:09:29','2020-06-17 07:09:29','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6200,2,'2020-06-17 07:10:21','2020-06-17 07:10:21','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"alignleft wp-image-6194\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:10:21','2020-06-17 07:10:21','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6201,2,'2020-06-17 07:11:07','2020-06-17 07:11:07','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a serology-based total antibody (IgM, IgG, IgA) detection assay.\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:11:07','2020-06-17 07:11:07','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6202,2,'2020-06-17 07:12:33','2020-06-17 07:12:33','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a <span style=\"color: #ff6600;\"><strong>serology-based total antibody (IgM, IgG, IgA) detection assay.</strong></span>\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignnone\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"387\" height=\"276\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:12:33','2020-06-17 07:12:33','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6203,2,'2020-06-17 07:13:26','2020-06-17 07:13:26','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a <span style=\"color: #ff6600;\"><strong>serology-based total antibody (IgM, IgG, IgA) detection assay.</strong></span>\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"362\" height=\"259\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:13:26','2020-06-17 07:13:26','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6204,2,'2020-06-17 07:14:02','2020-06-17 07:14:02','New Delhi, 17th June 2020: J Mitra &amp; Co. Pvt Ltd, India’s leading global MNC in the In-Vitro Diagnostics (IVD) industry has launched its state-of-the-art Covid-19 Test Kit in the Indian market. Based on the Double Sandwich Elisa technology, the test kit is known as COVID-19 [IgM, IgG, IgA] MICROLISA. It is a <span style=\"color: #ff6600;\"><strong>serology-based total antibody (IgM, IgG, IgA) detection assay.</strong></span>\r\n\r\nThis factor makes the J Mitra Corona Test kit superior and more accurate than other similar tests available in the market. It is a detection assay for the indirect diagnosis of past exposure to COVID-19. All the Covid-19 antibodies are detected without a differentiation in antibodies, and this is the reason contributing to the superior performance of this test. Elisa tests are highly sensitive and specific, and detect the COVID-19 antibodies in patient blood samples. 96-tests can be performed in one single go (using an instrument) and the test results are available within 90 minutes.<img class=\"wp-image-6194 alignright\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/JMITRA-300x214.png\" alt=\"\" width=\"406\" height=\"290\" />\r\n\r\nThe COVID-19 [IgM, IgG, IgA] MICROLISA Elisa test kit has cleared all government parameters and received all necessary approvals, including Indian Council of Medical Research (ICMR) and Drug Controller General of India (DCGI).\r\n\r\nSpeaking on the latest offering from the J Mitra stable, Lalit Mahajan, chairman said, <em>“we have  deployed extensive indigenous R&amp;D for the development of this unique product. There has been substantial contribution in its development by International Centre for Genetic Engineering &amp; Biotechnology (ICGEB) headed by Dr Navin Khanna. This is the first time that a total antibody detection assay kit for covid-19 has been developed in the Indian market. Using a combination of IgM, IgG and IgA antibody test increases the sensitivity, efficiency and efficacy of the test parameters, providing a more accurate diagnosis as compared to other test kits in the market.”</em>\r\n\r\n<em>Talking about the accuracy of the J Mitra covid-19 test kit, Lalit Mahajan further added, “The IgG antibody takes approximately 14 days to form after an infection, while IgM antibodies are the first antibody that the body forms after approximately 7 days when it fights a new infection. The presence of IgA antibodies in patient sample also gets detected simultaneously, in this test kit. IgA is considered a major effector in the defence mechanism against viruses and induces efficient IgA antibodies response. Its simultaneous detection along with IgM/IgG antibodies improves sensitivity of the test kit. because of this, the J Mitra covid-19 test is a more potent diagnostic kit, providing an opportunity to fight the disease during the pre-symptomatic phase and thus mitigating further risk.”</em>\r\n\r\n<em>Speaking on the production aspects, Jatin Mahajan, managing director said, “We are ready to meet the demand arising from all parts of the country. We have an immediate production capacity of 5 lakh test kits daily (or 1 crore test kits per month), but we have a dynamic production plant that can be augmented to double the production capacity in 3 days.”</em>\r\n\r\n<em>“The pricing of the kit is being worked out. We are a socially conscious company with a 50-year legacy of service to the nation –we will price it very competitive to ensure that it is available for the masses through all relevant government channels.”</em>\r\n<blockquote>“This is a completely indigenous kit – an ‘atmanirbhar’ initiative with R&amp;D done inhouse, and sourcing done from Indian manufacturers and suppliers. In keeping with the Government’s make in India initiative, we have created the most robust supply chain ecosystem for material sourcing as well as for supplying to various government agencies as per the demands”, he further added.</blockquote>\r\n<strong>About J Mitra &amp; Company</strong>\r\n\r\nIncorporated in 1969, this research-based Indian biotechnology MNC has completed 51 years towards its mission to serve mankind and is one of the leading IVD companies globally. The company manufactures a range of tests for infectious diseases like HIV, HBV, HCV, Dengue, Malaria, Typhoid, Leptospira in rapid and ELISA test formats. The other products include a range of Anti-Sera products and confirmatory tests like Western Blot for HIV. Famous for its innovation and R&amp;D, the company has over 55 patents – highest for any Indian company\r\n\r\nApart from a pan-India footprint, J Mitra &amp; Company is also the biggest exporter of diagnostics kits from India, and export to more than 45 countries across the entire globe.\r\n\r\nFor further information please contact:\r\n\r\nPrasun Peter @ 9811279008, prasun.peter@gmail.com','\"TOTAL ANTIBODY DETECTION ASSAY KIT\" for COVID -19 launched in India by  J.Mitra','','inherit','closed','closed','','6192-revision-v1','','','2020-06-17 07:14:02','2020-06-17 07:14:02','',6192,'https://microbiozindia.com/uncategorized/6192-revision-v1/',0,'revision','',0),(6205,2,'2020-06-17 08:24:59','2020-06-17 08:24:59','Dexamethasone, a modest and broadly utilized steroid, has become the primary medication demonstrated to have the option to spare lives among Covid-19 patients in what researchers hailed as a \"significant forward leap\".\r\n\r\nAftereffects of preliminaries reported on Tuesday demonstrated dexamethasone, which is utilized to decrease aggravation in different ailments, diminished demise rates by around a third among the most seriously sick Covid-19 patients admitted to emergency clinic.\r\n\r\nThe outcomes recommend the medication should promptly become standard consideration in patients with serious instances of the pandemic malady, said the specialists who drove the preliminaries.\r\n<blockquote>\"This is an outcome that shows that if patients who have Covid-19 and are on ventilators or are on oxygen are given dexamethasone, it will spare lives, and it will do as such at an amazingly minimal effort,\" said Martin Landray, an Oxford University educator co-driving the preliminary, known as the RECOVERY preliminary.</blockquote>\r\n\"It will be exceptionally hard for any medication truly to supplant this, given for under 50 pounds ($63.26), you can treat eight patients and spare an actual existence,\" he told journalists in an internet instructions.\r\n\r\nHis co-lead examiner, Peter Horby, said dexamethasone was \"the main medication that is so far appeared to lessen mortality - and it decreases it fundamentally.\"\r\n\r\n\"It is a significant forward leap,\" he said. \"Dexamethasone is cheap, on the rack, and can be utilized promptly to spare lives around the world.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-vaccine/art-20484859\">There are at present no affirmed medicines or immunizations for Covid-19, the illness brought about by the new coronavirus which has murdered more than 431,000 all inclusive.</a></span>\r\n\r\nSparing \'innumerable lives\'\r\n\r\nThe RECOVERY preliminary looked at results of around 2,100 patients who were haphazardly alloted to get the steroid, with those of around 4,300 patients who didn\'t get it.\r\n\r\nThe outcomes propose that one passing would be forestalled by treatment with dexamethasone among each eight ventilated Covid-19 patients, Landray stated, and one demise would be forestalled among each 25 Covid-19 patients that got the medication and are on oxygen.\r\n\r\nAmong patients with Covid-19 who didn\'t need respiratory help, there was no advantage from treatment with dexamethasone.\r\n\r\n\"The endurance advantage is clear and huge in those patients who are wiped out enough to require oxygen treatment, so dexamethasone should now get standard of care in these patients,\" Horby said.\r\n\r\nScratch Cammack, a master on Covid-19 at the Wellcome Trust worldwide wellbeing noble cause, said the discoveries would \"change the effect of the Covid-19 pandemic on lives and economies over the world\".\r\n\r\n\"Endless lives will be spared comprehensively,\" he said in an announcement reacting to the outcomes.\r\n\r\nThe RECOVERY preliminary was propelled in April as a randomized clinical preliminary to test a scope of likely medicines for Covid-19, including low-portion dexamethasone and the intestinal sickness sedate hydoxycholoroquine.\r\n\r\nThe hydroxychloroquine arm was ended recently after Horby and Landray said results indicated it was \"futile\" at rewarding Covid-19 patients.\r\n\r\nWorldwide instances of contamination with the novel coronavirus have reached more than 8 million, as indicated by a Reuters count, and in excess of 434,000 individuals have passed on subsequent to getting the infection, the primary case if which was accounted for in China toward the beginning of January.','Researchers hail dexamethasone as \'significant forward leap\' in rewarding coronavirus','','publish','open','open','','researchers-hail-dexamethasone-as-significant-forward-leap-in-rewarding-coronavirus','','','2020-06-17 08:24:59','2020-06-17 08:24:59','',0,'https://microbiozindia.com/?p=6205',0,'post','',0),(6206,2,'2020-06-17 08:24:59','2020-06-17 08:24:59','Dexamethasone, a modest and broadly utilized steroid, has become the primary medication demonstrated to have the option to spare lives among Covid-19 patients in what researchers hailed as a \"significant forward leap\".\r\n\r\nAftereffects of preliminaries reported on Tuesday demonstrated dexamethasone, which is utilized to decrease aggravation in different ailments, diminished demise rates by around a third among the most seriously sick Covid-19 patients admitted to emergency clinic.\r\n\r\nThe outcomes recommend the medication should promptly become standard consideration in patients with serious instances of the pandemic malady, said the specialists who drove the preliminaries.\r\n<blockquote>\"This is an outcome that shows that if patients who have Covid-19 and are on ventilators or are on oxygen are given dexamethasone, it will spare lives, and it will do as such at an amazingly minimal effort,\" said Martin Landray, an Oxford University educator co-driving the preliminary, known as the RECOVERY preliminary.</blockquote>\r\n\"It will be exceptionally hard for any medication truly to supplant this, given for under 50 pounds ($63.26), you can treat eight patients and spare an actual existence,\" he told journalists in an internet instructions.\r\n\r\nHis co-lead examiner, Peter Horby, said dexamethasone was \"the main medication that is so far appeared to lessen mortality - and it decreases it fundamentally.\"\r\n\r\n\"It is a significant forward leap,\" he said. \"Dexamethasone is cheap, on the rack, and can be utilized promptly to spare lives around the world.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-vaccine/art-20484859\">There are at present no affirmed medicines or immunizations for Covid-19, the illness brought about by the new coronavirus which has murdered more than 431,000 all inclusive.</a></span>\r\n\r\nSparing \'innumerable lives\'\r\n\r\nThe RECOVERY preliminary looked at results of around 2,100 patients who were haphazardly alloted to get the steroid, with those of around 4,300 patients who didn\'t get it.\r\n\r\nThe outcomes propose that one passing would be forestalled by treatment with dexamethasone among each eight ventilated Covid-19 patients, Landray stated, and one demise would be forestalled among each 25 Covid-19 patients that got the medication and are on oxygen.\r\n\r\nAmong patients with Covid-19 who didn\'t need respiratory help, there was no advantage from treatment with dexamethasone.\r\n\r\n\"The endurance advantage is clear and huge in those patients who are wiped out enough to require oxygen treatment, so dexamethasone should now get standard of care in these patients,\" Horby said.\r\n\r\nScratch Cammack, a master on Covid-19 at the Wellcome Trust worldwide wellbeing noble cause, said the discoveries would \"change the effect of the Covid-19 pandemic on lives and economies over the world\".\r\n\r\n\"Endless lives will be spared comprehensively,\" he said in an announcement reacting to the outcomes.\r\n\r\nThe RECOVERY preliminary was propelled in April as a randomized clinical preliminary to test a scope of likely medicines for Covid-19, including low-portion dexamethasone and the intestinal sickness sedate hydoxycholoroquine.\r\n\r\nThe hydroxychloroquine arm was ended recently after Horby and Landray said results indicated it was \"futile\" at rewarding Covid-19 patients.\r\n\r\nWorldwide instances of contamination with the novel coronavirus have reached more than 8 million, as indicated by a Reuters count, and in excess of 434,000 individuals have passed on subsequent to getting the infection, the primary case if which was accounted for in China toward the beginning of January.','Researchers hail dexamethasone as \'significant forward leap\' in rewarding coronavirus','','inherit','closed','closed','','6205-revision-v1','','','2020-06-17 08:24:59','2020-06-17 08:24:59','',6205,'https://microbiozindia.com/uncategorized/6205-revision-v1/',0,'revision','',0),(6207,2,'2020-06-17 08:29:33','2020-06-17 08:29:33','The World Health Organization (WHO) hailed as \"incredible news\" introductory clinical preliminary outcomes that demonstrated a modest and generally utilized steroid called dexamethasone can help spare the lives of fundamentally sick COVID-19 patients.\r\n<blockquote>\"This is the primary treatment to be appeared to decrease mortality in patients with COVID-19 requiring oxygen or ventilator support,\" WHO Director-General Tedros Adhanom Ghebreyesus said in an announcement late on Tuesday.\r\n\r\n\"This is incredible news and I salute the administration of the UK, the University of Oxford, and the numerous medical clinics and patients in the UK who have added to this lifesaving logical discovery.\"</blockquote>\r\nThe specialists shared introductory bits of knowledge about the consequences of the preliminary with WHO, \"and we are anticipating the full information investigation in the coming days,\" it said.\r\n\r\n\"WHO will facilitate a meta-investigation to expand our general comprehension of this intercession. WHO clinical direction will be refreshed to reflect how and when the medication ought to be utilized in COVID-19,\" the office included.','WHO sees \'incredible news\' in steroid\'s preliminary outcomes in COVID-19','','publish','open','open','','who-sees-incredible-news-in-steroids-preliminary-outcomes-in-covid-19','','','2020-06-17 08:29:33','2020-06-17 08:29:33','',0,'https://microbiozindia.com/?p=6207',0,'post','',0),(6208,2,'2020-06-17 08:29:33','2020-06-17 08:29:33','The World Health Organization (WHO) hailed as \"incredible news\" introductory clinical preliminary outcomes that demonstrated a modest and generally utilized steroid called dexamethasone can help spare the lives of fundamentally sick COVID-19 patients.\r\n<blockquote>\"This is the primary treatment to be appeared to decrease mortality in patients with COVID-19 requiring oxygen or ventilator support,\" WHO Director-General Tedros Adhanom Ghebreyesus said in an announcement late on Tuesday.\r\n\r\n\"This is incredible news and I salute the administration of the UK, the University of Oxford, and the numerous medical clinics and patients in the UK who have added to this lifesaving logical discovery.\"</blockquote>\r\nThe specialists shared introductory bits of knowledge about the consequences of the preliminary with WHO, \"and we are anticipating the full information investigation in the coming days,\" it said.\r\n\r\n\"WHO will facilitate a meta-investigation to expand our general comprehension of this intercession. WHO clinical direction will be refreshed to reflect how and when the medication ought to be utilized in COVID-19,\" the office included.','WHO sees \'incredible news\' in steroid\'s preliminary outcomes in COVID-19','','inherit','closed','closed','','6207-revision-v1','','','2020-06-17 08:29:33','2020-06-17 08:29:33','',6207,'https://microbiozindia.com/uncategorized/6207-revision-v1/',0,'revision','',0),(6209,2,'2020-06-17 10:25:35','2020-06-17 10:25:35','The Serum Institute of India will give ten million portions of the pneumococcal conjugate immunization, which assists with forestalling serious pneumonia, consistently to bring down salary nations for the following decade under another gracefully concurrence with the UNICEF that helped significantly diminished the cost of pneumonia antibody for those countries.\r\n\r\n\"Pneumonia is the greatest single enemy of kids, killing a kid at regular intervals. By having the option to give this quality-guaranteed pneumococcal conjugate antibody at such a reasonable value, we can spare a huge number of youngsters\' lives,\" Director of UNICEF\'s gracefully and obtainment central station Etleva Kadilli said.\r\n\r\nThe Pune-based Serum Institute of India is a main maker of immunobiological drugs, including immunizations.\r\n\r\n\"Our imaginative methodology has boosted industry to carry this immunization at scale to the market. The outcome implies more nations – including center salary nations – that have not yet brought this antibody into their standard inoculation because of already restrictive valuing, will have a moderate alternative to quicken access for all youngsters,\" Kadilli said.\r\n\r\nLower-pay nations over the world will currently have the option to get to life-sparing pneumococcal conjugate antibodies, which secure against the main source of pneumonia, for USD 2 for each portion, because of the gracefully understanding between UNICEF, Vaccine Alliance Gavi\'s acquirement accomplice and the Serum Institute of India.\r\n\r\nThe gracefully understanding is the eighth to occur under the Vaccine Alliance\'s AMC instrument, and the first to incorporate a creating nation maker.\r\n\r\nThe new cost speaks to a 43 percent decrease from the Gavi cost of USD 3.50 toward the beginning of the Advance Market Commitment (AMC).\r\n\r\nUnder the understanding, the Indian organization will give 10 million PCV dosages to Gavi-bolstered nations every year for the following ten years.\r\n\r\nThe pneumococcus bacterium is the main source of extreme pneumonia and is a significant reason for horribleness and mortality around the world.\r\n\r\nThe greater part of these passings happen in lower-pay nations and incorporate a lopsided number of kids younger than two, UNICEF said.\r\n\r\nGavi\'s Managing Director for Resource Mobilization, Private Sector Partnerships and Innovative Finance Marie-Ange Saraka-Yao said the fruitful system will presently be utilized as a model to help guarantee the world\'s most unfortunate nations gain admittance to COVID-19 immunizations simultaneously as the wealthiest, putting forth it essential to the worldwide attempt to crush this pandemic.\r\n\r\nThe AMC, which is set to end this year, was propelled by Gavi in 2009 – with the help of contributors Italy, the United Kingdom, Canada, Russia, Norway and the Bill and Melinda Gates Foundation – to \"understand an away from of market disappointment: complex immunizations like PCV would regularly arrive at low-pay nations, where the ailment trouble is frequently most noteworthy, ten to 15 years after their presentation in industrialized nations.\"\r\n\r\nThe PCV immunization has now been presented in 60 lower-pay nations, where inclusion rates, at 48 percent, are currently higher than the worldwide normal of 47 percent.\r\n\r\nAssessments show that in excess of 225 million youngsters will have been immunized, and that more than 700,000 passings will have been forestalled before the finish of 2020.\r\n\r\nWith the new flexibly understanding, AMC will be shutting this year having encouraged the passage of the new maker to the market just as a record-setting low cost for Gavi-upheld nations that will bring about an expected a large number of dollars in reserve funds for both Gavi and lower pay nations\' immunization spending plans, the UNICEF said.\r\n\r\nGavi\'s Managing Director for Vaccines and Sustainability Aurelia Nguyen said due to the \"visionary model\", there is a solid PCV advertise that is creating enough antibodies to gracefully both rich and poor nations and, thus, a huge number of youngsters are presently secured against one of the world\'s deadliest infections.\r\n\r\nFinally week\'s Global Vaccine Summit, Gavi propelled the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), another financing instrument planned for boosting antibody makers to deliver adequate amounts of possible COVID-19 immunizations, and to guarantee access for creating nations.','Serum Institute of India, UNICEF flexibly consent to give pneumonia immunization to low-income countries','','publish','open','open','','serum-institute-of-india-unicef-flexibly-consent-to-give-pneumonia-immunization-to-low-income-countries','','','2020-06-17 10:25:35','2020-06-17 10:25:35','',0,'https://microbiozindia.com/?p=6209',0,'post','',0),(6210,2,'2020-06-17 10:25:35','2020-06-17 10:25:35','The Serum Institute of India will give ten million portions of the pneumococcal conjugate immunization, which assists with forestalling serious pneumonia, consistently to bring down salary nations for the following decade under another gracefully concurrence with the UNICEF that helped significantly diminished the cost of pneumonia antibody for those countries.\r\n\r\n\"Pneumonia is the greatest single enemy of kids, killing a kid at regular intervals. By having the option to give this quality-guaranteed pneumococcal conjugate antibody at such a reasonable value, we can spare a huge number of youngsters\' lives,\" Director of UNICEF\'s gracefully and obtainment central station Etleva Kadilli said.\r\n\r\nThe Pune-based Serum Institute of India is a main maker of immunobiological drugs, including immunizations.\r\n\r\n\"Our imaginative methodology has boosted industry to carry this immunization at scale to the market. The outcome implies more nations – including center salary nations – that have not yet brought this antibody into their standard inoculation because of already restrictive valuing, will have a moderate alternative to quicken access for all youngsters,\" Kadilli said.\r\n\r\nLower-pay nations over the world will currently have the option to get to life-sparing pneumococcal conjugate antibodies, which secure against the main source of pneumonia, for USD 2 for each portion, because of the gracefully understanding between UNICEF, Vaccine Alliance Gavi\'s acquirement accomplice and the Serum Institute of India.\r\n\r\nThe gracefully understanding is the eighth to occur under the Vaccine Alliance\'s AMC instrument, and the first to incorporate a creating nation maker.\r\n\r\nThe new cost speaks to a 43 percent decrease from the Gavi cost of USD 3.50 toward the beginning of the Advance Market Commitment (AMC).\r\n\r\nUnder the understanding, the Indian organization will give 10 million PCV dosages to Gavi-bolstered nations every year for the following ten years.\r\n\r\nThe pneumococcus bacterium is the main source of extreme pneumonia and is a significant reason for horribleness and mortality around the world.\r\n\r\nThe greater part of these passings happen in lower-pay nations and incorporate a lopsided number of kids younger than two, UNICEF said.\r\n\r\nGavi\'s Managing Director for Resource Mobilization, Private Sector Partnerships and Innovative Finance Marie-Ange Saraka-Yao said the fruitful system will presently be utilized as a model to help guarantee the world\'s most unfortunate nations gain admittance to COVID-19 immunizations simultaneously as the wealthiest, putting forth it essential to the worldwide attempt to crush this pandemic.\r\n\r\nThe AMC, which is set to end this year, was propelled by Gavi in 2009 – with the help of contributors Italy, the United Kingdom, Canada, Russia, Norway and the Bill and Melinda Gates Foundation – to \"understand an away from of market disappointment: complex immunizations like PCV would regularly arrive at low-pay nations, where the ailment trouble is frequently most noteworthy, ten to 15 years after their presentation in industrialized nations.\"\r\n\r\nThe PCV immunization has now been presented in 60 lower-pay nations, where inclusion rates, at 48 percent, are currently higher than the worldwide normal of 47 percent.\r\n\r\nAssessments show that in excess of 225 million youngsters will have been immunized, and that more than 700,000 passings will have been forestalled before the finish of 2020.\r\n\r\nWith the new flexibly understanding, AMC will be shutting this year having encouraged the passage of the new maker to the market just as a record-setting low cost for Gavi-upheld nations that will bring about an expected a large number of dollars in reserve funds for both Gavi and lower pay nations\' immunization spending plans, the UNICEF said.\r\n\r\nGavi\'s Managing Director for Vaccines and Sustainability Aurelia Nguyen said due to the \"visionary model\", there is a solid PCV advertise that is creating enough antibodies to gracefully both rich and poor nations and, thus, a huge number of youngsters are presently secured against one of the world\'s deadliest infections.\r\n\r\nFinally week\'s Global Vaccine Summit, Gavi propelled the Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC), another financing instrument planned for boosting antibody makers to deliver adequate amounts of possible COVID-19 immunizations, and to guarantee access for creating nations.','Serum Institute of India, UNICEF flexibly consent to give pneumonia immunization to low-income countries','','inherit','closed','closed','','6209-revision-v1','','','2020-06-17 10:25:35','2020-06-17 10:25:35','',6209,'https://microbiozindia.com/uncategorized/6209-revision-v1/',0,'revision','',0),(6211,2,'2020-06-17 11:58:06','2020-06-17 11:58:06','AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle.\r\n\r\nDeveloped for immunocapture, cell stimulating, biopanning and flow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because Streptavidin has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the magnetic beads irreversibly.\r\n\r\nThe complex may be removed from the solution manually using a magnetic separator. The bound SARS-CoV-2 spike proteins can then be dissociated from the magnetic beads using an elution buffer. All magnetic bead products from AMSBIO are of uniform size, narrow size distribution with large surface area and unique surface coating, which delivers industry-leading performance and highly reproducible results. AMSBIO also offers a Custom Magnetic Beads service to provide you with the best possible tools for your specific research project.\r\n\r\nAMSBIO has also introduced new SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates optimised for ELISA Assay and Biopannning. These assay kits employ a standard Indirect-ELISA format which provide a rapid quantification of Anti-SARS-CoV-2 antibodies or ACE-2 protein in serum by binding to Spike protein S1. Key advantages of these new plates include time saving (pre-coated and blocked), flexible experimental design (detachable 8-well strips) and that they are proven to eliminate problems associated with denaturing of the protein component of a conjugate upon binding. These new coated plates are ideal for binding anti-SARS2-CoV-2 antibodies or ACE2 protein that typically exhibit poor binding to polystyrene.\r\n\r\nWith infections spread globally, COVID-19 was declared a pandemic outbreak by the World Health Organization on 11 March 2020. The development of vaccines, diagnostics, and therapeutics is vital for the ongoing control of the outbreak. AMSBIO provide an ever-expanding collection of tools for SARS-CoV-2 and Coronavirus research, including recombinant proteins, antibodies, inhibitor screening kits, and other assay kits.\r\n\r\nFor further information on ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads and SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates please visit www.amsbio.com/sars-cov-2-magnetic-beads-plates/ and www.amsbio.com/covid-19 or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.\r\n\r\nFounded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.','New Range of SARS-CoV-2 Spike Protein Products','','publish','open','open','','new-range-of-sars-cov-2-spike-protein-products','','','2020-06-19 04:09:37','2020-06-19 04:09:37','',0,'https://microbiozindia.com/?p=6211',0,'post','',0),(6212,2,'2020-06-17 11:57:41','2020-06-17 11:57:41','','amsbiopr270-image','','inherit','open','closed','','amsbiopr270-image','','','2020-06-17 11:57:41','2020-06-17 11:57:41','',6211,'https://microbiozindia.com/wp-content/uploads/2020/06/amsbiopr270-image.jpg',0,'attachment','image/jpeg',0),(6213,2,'2020-06-17 11:58:06','2020-06-17 11:58:06','AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle.\r\n\r\nDeveloped for immunocapture, cell stimulating, biopanning and flow cytometry applications these new products use biotinylated SARS-CoV-2 Spike protein pre-coupled to streptavidin conjugated magnetic beads, which can capture the Anti-SARS-CoV-2 antibody or ACE2 protein from cell or serum sample. Because Streptavidin has an extraordinarily high affinity for biotin with a dissociation constant (Kd) on the order of 10-14 mol/L, the biotinylated protein can bind to the magnetic beads irreversibly.\r\n\r\nThe complex may be removed from the solution manually using a magnetic separator. The bound SARS-CoV-2 spike proteins can then be dissociated from the magnetic beads using an elution buffer. All magnetic bead products from AMSBIO are of uniform size, narrow size distribution with large surface area and unique surface coating, which delivers industry-leading performance and highly reproducible results. AMSBIO also offers a Custom Magnetic Beads service to provide you with the best possible tools for your specific research project.\r\n\r\nAMSBIO has also introduced new SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates optimised for ELISA Assay and Biopannning. These assay kits employ a standard Indirect-ELISA format which provide a rapid quantification of Anti-SARS-CoV-2 antibodies or ACE-2 protein in serum by binding to Spike protein S1. Key advantages of these new plates include time saving (pre-coated and blocked), flexible experimental design (detachable 8-well strips) and that they are proven to eliminate problems associated with denaturing of the protein component of a conjugate upon binding. These new coated plates are ideal for binding anti-SARS2-CoV-2 antibodies or ACE2 protein that typically exhibit poor binding to polystyrene.\r\n\r\nWith infections spread globally, COVID-19 was declared a pandemic outbreak by the World Health Organization on 11 March 2020. The development of vaccines, diagnostics, and therapeutics is vital for the ongoing control of the outbreak. AMSBIO provide an ever-expanding collection of tools for SARS-CoV-2 and Coronavirus research, including recombinant proteins, antibodies, inhibitor screening kits, and other assay kits.\r\n\r\nFor further information on ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads and SARS-CoV2 Spike S1 protein-coated and SARS-CoV2 Spike protein RBD-Coated microplates please visit www.amsbio.com/sars-cov-2-magnetic-beads-plates/ and www.amsbio.com/covid-19 or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.\r\n\r\nFounded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.','New Range of SARS-CoV-2 Spike Protein Products','','inherit','closed','closed','','6211-revision-v1','','','2020-06-17 11:58:06','2020-06-17 11:58:06','',6211,'https://microbiozindia.com/uncategorized/6211-revision-v1/',0,'revision','',0),(6214,2,'2020-06-18 07:40:22','2020-06-18 07:40:22','The World Health Organization said that testing of the intestinal sickness tranquilize hydroxychloroquine in its enormous multi-nation preliminary of medicines for COVID-19 patients had been stopped after outcomes from different preliminaries demonstrated no advantage.\r\n\r\n\"The hydroxychloroquine arm of the SOLIDARITY preliminary has been halted,\" WHO master Ana Maria Henao-Restrepo told a news instructions.','WHO ends preliminary of hydroxychloroquine in COVID-19 patients','','publish','open','open','','who-ends-preliminary-of-hydroxychloroquine-in-covid-19-patients','','','2020-06-18 07:40:22','2020-06-18 07:40:22','',0,'https://microbiozindia.com/?p=6214',0,'post','',0),(6215,2,'2020-06-18 07:40:22','2020-06-18 07:40:22','The World Health Organization said that testing of the intestinal sickness tranquilize hydroxychloroquine in its enormous multi-nation preliminary of medicines for COVID-19 patients had been stopped after outcomes from different preliminaries demonstrated no advantage.\r\n\r\n\"The hydroxychloroquine arm of the SOLIDARITY preliminary has been halted,\" WHO master Ana Maria Henao-Restrepo told a news instructions.','WHO ends preliminary of hydroxychloroquine in COVID-19 patients','','inherit','closed','closed','','6214-revision-v1','','','2020-06-18 07:40:22','2020-06-18 07:40:22','',6214,'https://microbiozindia.com/uncategorized/6214-revision-v1/',0,'revision','',0),(6216,2,'2020-06-18 09:27:20','2020-06-18 09:27:20','Israel has consented to an arrangement with Moderna Inc for the future acquisition of its potential COVID-19 antibody, Prime Minister Benjamin Netanyahu said on Wednesday.\r\n\r\nThe Cambridge, Massachusetts-based biotech firm a week ago affirmed intends to begin a preliminary of 30,000 volunteers of its eagerly awaited immunization in July as the organization enters the last phases of testing.\r\n\r\nIt is one of a few antibodies being tried far and wide as drugmakers race to battle the pandemic. There are as of now no affirmed medicines or immunizations for COVID-19.\r\n\r\n\"Israel has marked with the organization Moderna a plan that will permit us to purchase immunizations,\" Netanyahu stated, as indicated by an announcement from his office.\r\n\r\n\"The organization is propelling its turn of events, they guarantee they can accomplish it by the center of one year from now, we trust that they succeed,\" he said.\r\n\r\nMoney related subtleties were not unveiled.\r\n\r\nNetanyahu included that Israel would proceed with its own endeavors to build up a COVID-19 antibody through the Israel Institute for Biological Research.\r\n\r\nIsrael - with a populace of 9 million - has detailed 19,783 novel coronavirus cases and 303 passings. It has seen a spike in new diseases since reviving schools, cafés and numerous organizations a month ago.\r\n\r\nDifferent nations, including France, Germany and Italy, have marked gracefully manages British drugmaker AstraZeneca for its potential COVID-19 immunization.','Israel consents to arrangement with Moderna for potential COVID-19 antibody','','publish','open','open','','israel-consents-to-arrangement-with-moderna-for-potential-covid-19-antibody','','','2020-06-18 09:27:20','2020-06-18 09:27:20','',0,'https://microbiozindia.com/?p=6216',0,'post','',0),(6217,2,'2020-06-18 09:27:20','2020-06-18 09:27:20','Israel has consented to an arrangement with Moderna Inc for the future acquisition of its potential COVID-19 antibody, Prime Minister Benjamin Netanyahu said on Wednesday.\r\n\r\nThe Cambridge, Massachusetts-based biotech firm a week ago affirmed intends to begin a preliminary of 30,000 volunteers of its eagerly awaited immunization in July as the organization enters the last phases of testing.\r\n\r\nIt is one of a few antibodies being tried far and wide as drugmakers race to battle the pandemic. There are as of now no affirmed medicines or immunizations for COVID-19.\r\n\r\n\"Israel has marked with the organization Moderna a plan that will permit us to purchase immunizations,\" Netanyahu stated, as indicated by an announcement from his office.\r\n\r\n\"The organization is propelling its turn of events, they guarantee they can accomplish it by the center of one year from now, we trust that they succeed,\" he said.\r\n\r\nMoney related subtleties were not unveiled.\r\n\r\nNetanyahu included that Israel would proceed with its own endeavors to build up a COVID-19 antibody through the Israel Institute for Biological Research.\r\n\r\nIsrael - with a populace of 9 million - has detailed 19,783 novel coronavirus cases and 303 passings. It has seen a spike in new diseases since reviving schools, cafés and numerous organizations a month ago.\r\n\r\nDifferent nations, including France, Germany and Italy, have marked gracefully manages British drugmaker AstraZeneca for its potential COVID-19 immunization.','Israel consents to arrangement with Moderna for potential COVID-19 antibody','','inherit','closed','closed','','6216-revision-v1','','','2020-06-18 09:27:20','2020-06-18 09:27:20','',6216,'https://microbiozindia.com/uncategorized/6216-revision-v1/',0,'revision','',0),(6218,2,'2020-06-18 12:53:51','2020-06-18 12:53:51','Mumbai 18th June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as \"Cipla\") and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).\r\nRoche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.\r\n\r\n<em>Commenting on the partnership, Nikhil Chopra, Executive Vice President &amp; CEO - India Business, Cipla said, “Enabling access to high quality life-saving treatments is core to our purpose of ‘Caring for Life’. We are pleased to strengthen our partnership with Roche towards bringing innovative oncology medications to India. This represents our unwavering commitment to address the unmet needs of cancer patients through an enhanced portfolio of offerings in this space. We look forward to leveraging our solid marketing and distribution strengths in India to provide broader access to such transformative treatments in the country.</em>\r\n\r\n<em>”We have been working as a partner with Cipla for some of our products and it has been a great journey working with them in ensuring access to our innovations in India. We hope to extend the same support to patients in India through this new agreement”, said V. Simpson Emmanuel, General Manager, Roche Products (India) Pvt. Ltd. “This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in Indian healthcare system to ensure better outcomes for patients.”</em>','Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines','','publish','open','open','','cipla-expands-partnership-with-roche-pharma-india-to-further-improve-access-to-key-oncology-medicines','','','2020-06-18 12:53:51','2020-06-18 12:53:51','',0,'https://microbiozindia.com/?p=6218',0,'post','',0),(6219,2,'2020-06-18 12:53:51','2020-06-18 12:53:51','Mumbai 18th June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as \"Cipla\") and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for marketing and distribution of Roche Pharma’s key trademark oncology drugs viz.,Trastuzumab (Herclon), Bevacizumab (Avastin) and Rituximab (Ristova).\r\nRoche and Cipla had previously entered into a similar agreement in February 2018 for promotion and distribution of Tocilizumab (Actemra) and other products.\r\n\r\n<em>Commenting on the partnership, Nikhil Chopra, Executive Vice President &amp; CEO - India Business, Cipla said, “Enabling access to high quality life-saving treatments is core to our purpose of ‘Caring for Life’. We are pleased to strengthen our partnership with Roche towards bringing innovative oncology medications to India. This represents our unwavering commitment to address the unmet needs of cancer patients through an enhanced portfolio of offerings in this space. We look forward to leveraging our solid marketing and distribution strengths in India to provide broader access to such transformative treatments in the country.</em>\r\n\r\n<em>”We have been working as a partner with Cipla for some of our products and it has been a great journey working with them in ensuring access to our innovations in India. We hope to extend the same support to patients in India through this new agreement”, said V. Simpson Emmanuel, General Manager, Roche Products (India) Pvt. Ltd. “This deal will ensure that our focus on providing Roche innovations in India remains steadfast in this portfolio and we will keep on collaborating with the relevant stakeholders in Indian healthcare system to ensure better outcomes for patients.”</em>','Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines','','inherit','closed','closed','','6218-revision-v1','','','2020-06-18 12:53:51','2020-06-18 12:53:51','',6218,'https://microbiozindia.com/uncategorized/6218-revision-v1/',0,'revision','',0),(6220,2,'2020-06-18 18:23:32','2020-06-18 18:23:32','Pharmaceutical firm, Kopran, on Thursday, got a green sign to grow its quality in the US advertise by providing its Atenolol item. The declaration was welcomed with great affection by financial specialists, as the stock finished at Rs39.40 per piece up by 6.06% on Sensex.\r\n\r\nKopran educated the trades that the organization had recorded the DMF of Atenolol which has now been endorsed by the USFDA and the organization can start supplies of the API Atenolol to the US advertise.\r\n\r\nA year ago in January, the USFDA conveyed investigation at the organization\'s Active Pharmaceutical fixings Manufacturing office at Mahad of Kopran Research Laboratories Limited.\r\n\r\nKopran Research is a 100% auxiliary of Kopran.\r\n\r\nAll through the exchanging meeting, Kopran stock flooded till an intraday high of Rs40.85 per piece.\r\n\r\nThe stock opened at Rs37.10 per piece on Sensex, marginally lower from the past shutting of Rs37.15 per piece.','USFDA gives green sign to Kopran for providing Atenolol in the US showcase; stock hops 6%','','publish','open','open','','usfda-gives-green-sign-to-kopran-for-providing-atenolol-in-the-us-showcase-stock-hops-6','','','2020-06-18 18:44:41','2020-06-18 18:44:41','',0,'https://microbiozindia.com/?p=6220',0,'post','',0),(6221,2,'2020-06-18 18:23:32','2020-06-18 18:23:32','Pharmaceutical firm, Kopran, on Thursday, got a green sign to grow its quality in the US advertise by providing its Atenolol item. The declaration was welcomed with great affection by financial specialists, as the stock finished at Rs39.40 per piece up by 6.06% on Sensex.\r\n\r\nKopran educated the trades that the organization had recorded the DMF of Atenolol which has now been endorsed by the USFDA and the organization can start supplies of the API Atenolol to the US advertise.\r\n\r\nA year ago in January, the USFDA conveyed investigation at the organization\'s Active Pharmaceutical fixings Manufacturing office at Mahad of Kopran Research Laboratories Limited.\r\n\r\nKopran Research is a 100% auxiliary of Kopran.\r\n\r\nAll through the exchanging meeting, Kopran stock flooded till an intraday high of Rs40.85 per piece.\r\n\r\nThe stock opened at Rs37.10 per piece on Sensex, marginally lower from the past shutting of Rs37.15 per piece.','USFDA gives green sign to Kopran for providing Atenolol in the US showcase; stock hops 6%','','inherit','closed','closed','','6220-revision-v1','','','2020-06-18 18:23:32','2020-06-18 18:23:32','',6220,'https://microbiozindia.com/uncategorized/6220-revision-v1/',0,'revision','',0),(6222,2,'2020-06-19 04:07:37','2020-06-19 04:07:37','Researchers have additionally decoded how mammalian cerebrums see scents and recognize one smell from a great many others.\r\n\r\nIn tests in mice, NYU Grossman School of Medicine specialists have just because made an electrical mark that is seen as a scent in the cerebrum\'s smell-preparing focus, the olfactory bulb, despite the fact that the smell doesn\'t exist.\r\n\r\nSince the scent reenacting signal was humanmade, analysts could control the planning and request of related nerve flagging and distinguish which changes were generally imperative to the capacity of mice to precisely recognize the \"manufactured smell.\"\r\n<blockquote>\"Translating how the mind differentiates scents is confounded, to a limited extent, on the grounds that dissimilar to with different faculties, for example, vision, we don\'t yet know the most significant parts of individual scents,\" says study lead examiner Edmund Chong, MS, a doctoral understudy at NYU Langone Health. \"In facial acknowledgment, for instance, the cerebrum can perceive individuals dependent on viewable prompts, for example, the eyes, even without seeing somebody\'s nose and ears,\" says Chong. \"Be that as it may, these distinctive highlights, as recorded by the cerebrum, still can\'t seem to be found for each smell.\"</blockquote>\r\nThe current investigation results, distributed online in the diary Science on June 18, focus on the olfactory bulb, which is behind the nose in creatures and people. Past examinations have indicated that airborne particles connected to aromas trigger receptor cells covering the nose to impart electric signs to nerve-finishing groups in the bulb called glomeruli, and afterward to synapses (neurons).\r\n\r\nThe planning and request of glomeruli initiation is known to be extraordinary to each smell, analysts state, with signals at that point transmitted to the cerebrum\'s cortex, which controls how a creature sees, responds to, and recollects a smell. But since fragrances can differ after some time and blend with others, researchers have as of recently attempted to decisively follow a solitary smell signature over a few sorts of neurons.\r\n\r\nFor the new examination, the analysts planned tests dependent on the accessibility of mice hereditarily built by another lab with the goal that their synapses could be actuated by sparkling light on them - a strategy called optogenetics. Next they prepared the mice to perceive a sign produced by light actuation of six glomeruli - known to look like an example evoked by a scent - by giving them a water reward just when they saw the right \"smell\" and pushed a switch.\r\n\r\nOn the off chance that mice pushed the switch after actuation of an alternate arrangement of glomeruli (reproduction of an alternate smell), they got no water. Utilizing this model, the scientists changed the planning and blend of enacted glomeruli, taking note of how each change affected a mouse\'s observation as reflected in a conduct: the exactness with which it followed up on the engineered smell sign to get the prize.\r\n\r\nIn particular, scientists found that changing which of the glomeruli inside every smell characterizing set were initiated first prompted as much as a 30 percent drop in the capacity of a mouse to effectively detect a scent flag and get water. Changes in the last glomeruli in each set accompanied as meager as a 5 percent decline in precise scent detecting.\r\n\r\nThe planning of the glomeruli initiations cooperated \"like the notes in a song,\" state the specialists, with postponements or breaks in the early \"notes\" corrupting precision. Tight control in their model over when, what number of, and which receptors and glomeruli were initiated in the mice, empowered the group to filter through numerous factors and recognize which smell highlights stuck out.\r\n<blockquote>\"Since we have a model for separating the planning and request of glomeruli enactment, we can look at the base number and sort of receptors required by the olfactory bulb to recognize a specific smell,\" says study senior examiner and neurobiologist Dmitry Rinberg, PhD.</blockquote>\r\nRinberg, a partner teacher at NYU Langone and its Neuroscience Institute, says the human nose is known to have around 350 various types of scent receptors, while mice, whose feeling of smell is undeniably progressively specific, have more than 1,200.\r\n\r\n\"Our outcomes recognize just because a code for how the cerebrum changes over tactile data into view of something, for this situation a smell,\" includes Rinberg. \"This puts us closer to responding to the longstanding inquiry in our field of how the cerebrum separates tactile data to summon conduct.\"\r\n\r\nSubsidizing support for the investigation was given by National Institutes of Health award R01 NS109961.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">Materials</a></span> provided by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">NYU Langone Health / NYU School of Medicine</a></span> and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nEdmund Chong, Monica Moroni, Christopher Wilson, Shy Shoham, Stefano Panzeri, Dmitry Rinberg. Manipulating Synthetic Optogenetic Odors Reveals the Coding Logic of Olfactory Perception. Science, 2020 <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">DOI: 10.1126/science.aba2357</a></span>','Researchers unravel how the brain detects smell','','publish','open','open','','researchers-unravel-how-the-brain-detects-smell','','','2020-06-19 04:07:37','2020-06-19 04:07:37','',0,'https://microbiozindia.com/?p=6222',0,'post','',0),(6223,2,'2020-06-19 04:06:54','2020-06-19 04:06:54','','adult-19033_640','','inherit','open','closed','','adult-19033_640','','','2020-06-19 04:06:54','2020-06-19 04:06:54','',6222,'https://microbiozindia.com/wp-content/uploads/2020/06/adult-19033_640.jpg',0,'attachment','image/jpeg',0),(6224,2,'2020-06-19 04:07:37','2020-06-19 04:07:37','Researchers have additionally decoded how mammalian cerebrums see scents and recognize one smell from a great many others.\r\n\r\nIn tests in mice, NYU Grossman School of Medicine specialists have just because made an electrical mark that is seen as a scent in the cerebrum\'s smell-preparing focus, the olfactory bulb, despite the fact that the smell doesn\'t exist.\r\n\r\nSince the scent reenacting signal was humanmade, analysts could control the planning and request of related nerve flagging and distinguish which changes were generally imperative to the capacity of mice to precisely recognize the \"manufactured smell.\"\r\n<blockquote>\"Translating how the mind differentiates scents is confounded, to a limited extent, on the grounds that dissimilar to with different faculties, for example, vision, we don\'t yet know the most significant parts of individual scents,\" says study lead examiner Edmund Chong, MS, a doctoral understudy at NYU Langone Health. \"In facial acknowledgment, for instance, the cerebrum can perceive individuals dependent on viewable prompts, for example, the eyes, even without seeing somebody\'s nose and ears,\" says Chong. \"Be that as it may, these distinctive highlights, as recorded by the cerebrum, still can\'t seem to be found for each smell.\"</blockquote>\r\nThe current investigation results, distributed online in the diary Science on June 18, focus on the olfactory bulb, which is behind the nose in creatures and people. Past examinations have indicated that airborne particles connected to aromas trigger receptor cells covering the nose to impart electric signs to nerve-finishing groups in the bulb called glomeruli, and afterward to synapses (neurons).\r\n\r\nThe planning and request of glomeruli initiation is known to be extraordinary to each smell, analysts state, with signals at that point transmitted to the cerebrum\'s cortex, which controls how a creature sees, responds to, and recollects a smell. But since fragrances can differ after some time and blend with others, researchers have as of recently attempted to decisively follow a solitary smell signature over a few sorts of neurons.\r\n\r\nFor the new examination, the analysts planned tests dependent on the accessibility of mice hereditarily built by another lab with the goal that their synapses could be actuated by sparkling light on them - a strategy called optogenetics. Next they prepared the mice to perceive a sign produced by light actuation of six glomeruli - known to look like an example evoked by a scent - by giving them a water reward just when they saw the right \"smell\" and pushed a switch.\r\n\r\nOn the off chance that mice pushed the switch after actuation of an alternate arrangement of glomeruli (reproduction of an alternate smell), they got no water. Utilizing this model, the scientists changed the planning and blend of enacted glomeruli, taking note of how each change affected a mouse\'s observation as reflected in a conduct: the exactness with which it followed up on the engineered smell sign to get the prize.\r\n\r\nIn particular, scientists found that changing which of the glomeruli inside every smell characterizing set were initiated first prompted as much as a 30 percent drop in the capacity of a mouse to effectively detect a scent flag and get water. Changes in the last glomeruli in each set accompanied as meager as a 5 percent decline in precise scent detecting.\r\n\r\nThe planning of the glomeruli initiations cooperated \"like the notes in a song,\" state the specialists, with postponements or breaks in the early \"notes\" corrupting precision. Tight control in their model over when, what number of, and which receptors and glomeruli were initiated in the mice, empowered the group to filter through numerous factors and recognize which smell highlights stuck out.\r\n<blockquote>\"Since we have a model for separating the planning and request of glomeruli enactment, we can look at the base number and sort of receptors required by the olfactory bulb to recognize a specific smell,\" says study senior examiner and neurobiologist Dmitry Rinberg, PhD.</blockquote>\r\nRinberg, a partner teacher at NYU Langone and its Neuroscience Institute, says the human nose is known to have around 350 various types of scent receptors, while mice, whose feeling of smell is undeniably progressively specific, have more than 1,200.\r\n\r\n\"Our outcomes recognize just because a code for how the cerebrum changes over tactile data into view of something, for this situation a smell,\" includes Rinberg. \"This puts us closer to responding to the longstanding inquiry in our field of how the cerebrum separates tactile data to summon conduct.\"\r\n\r\nSubsidizing support for the investigation was given by National Institutes of Health award R01 NS109961.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">Materials</a></span> provided by <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">NYU Langone Health / NYU School of Medicine</a></span> and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nEdmund Chong, Monica Moroni, Christopher Wilson, Shy Shoham, Stefano Panzeri, Dmitry Rinberg. Manipulating Synthetic Optogenetic Odors Reveals the Coding Logic of Olfactory Perception. Science, 2020 <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://nyulangone.org/news/scientists-decode-how-brain-senses-smell\">DOI: 10.1126/science.aba2357</a></span>','Researchers unravel how the brain detects smell','','inherit','closed','closed','','6222-revision-v1','','','2020-06-19 04:07:37','2020-06-19 04:07:37','',6222,'https://microbiozindia.com/uncategorized/6222-revision-v1/',0,'revision','',0),(6225,2,'2020-06-19 09:02:02','2020-06-19 09:02:02','Gilead Sciences is set to direct a Phase II/III clinical preliminary of its investigational antiviral medication remdesivir to treat pediatric patients hospitalized with Covid-19.\r\n\r\nThe open-name, single-arm has been structured in a joint effort with the US Food and Drug Administration (FDA). Tolerant enrolment will start soon.\r\n\r\nIt will survey the security, averageness, pharmacokinetics and viability of remdesivir in around 50 pediatric patients experiencing moderate-to-extreme Covid-19, including babies and teenagers, at in excess of 30 destinations over the US and Europe.\r\n\r\nThe essential result proportions of the preliminary will be the extent of patients with treatment-developing unfavorable occasions and reviewed research center anomalies, alongside plasma convergences of remdesivir and metabolites.\r\n\r\nIn the interim, auxiliary results will incorporate oxygenation use, mechanical ventilation, clinical improvement, and time to release from medical clinic.\r\n\r\nThe preliminary is relied upon to be finished in December this year.\r\n\r\nGilead Sciences boss clinical official Merdad Parsey said in an announcement: \"From the beginning of the pandemic, Gilead has propelled the improvement of our investigational antiviral remdesivir for the treatment of Covid-19, in corresponding with developing information about the sickness.','Gilead to evaluate remdesivir in pediatric Covid-19 patients','','publish','open','open','','gilead-to-evaluate-remdesivir-in-pediatric-covid-19-patients','','','2020-06-19 09:02:02','2020-06-19 09:02:02','',0,'https://microbiozindia.com/?p=6225',0,'post','',0),(6226,2,'2020-06-19 09:01:37','2020-06-19 09:01:37','','download','','inherit','open','closed','','download-3','','','2020-06-19 09:01:37','2020-06-19 09:01:37','',6225,'https://microbiozindia.com/wp-content/uploads/2020/06/download.jpg',0,'attachment','image/jpeg',0),(6227,2,'2020-06-19 09:02:02','2020-06-19 09:02:02','Gilead Sciences is set to direct a Phase II/III clinical preliminary of its investigational antiviral medication remdesivir to treat pediatric patients hospitalized with Covid-19.\r\n\r\nThe open-name, single-arm has been structured in a joint effort with the US Food and Drug Administration (FDA). Tolerant enrolment will start soon.\r\n\r\nIt will survey the security, averageness, pharmacokinetics and viability of remdesivir in around 50 pediatric patients experiencing moderate-to-extreme Covid-19, including babies and teenagers, at in excess of 30 destinations over the US and Europe.\r\n\r\nThe essential result proportions of the preliminary will be the extent of patients with treatment-developing unfavorable occasions and reviewed research center anomalies, alongside plasma convergences of remdesivir and metabolites.\r\n\r\nIn the interim, auxiliary results will incorporate oxygenation use, mechanical ventilation, clinical improvement, and time to release from medical clinic.\r\n\r\nThe preliminary is relied upon to be finished in December this year.\r\n\r\nGilead Sciences boss clinical official Merdad Parsey said in an announcement: \"From the beginning of the pandemic, Gilead has propelled the improvement of our investigational antiviral remdesivir for the treatment of Covid-19, in corresponding with developing information about the sickness.','Gilead to evaluate remdesivir in pediatric Covid-19 patients','','inherit','closed','closed','','6225-revision-v1','','','2020-06-19 09:02:02','2020-06-19 09:02:02','',6225,'https://microbiozindia.com/uncategorized/6225-revision-v1/',0,'revision','',0),(6228,2,'2020-06-19 09:48:44','2020-06-19 09:48:44','Indian researchers have reacted mindfully to a proposal by worldwide specialists that the oral polio antibody be tried for COVID-19, saying it is a \"testable thought\" in view of a sound logical idea however may offer just restricted security against the contamination.\r\n\r\nWith an immunization for COVID-19 in any event a year away, researchers state repurposing effectively sheltered and successful antibodies is the best approach for sure fire help against COVID-19. The repurposed antibodies could incorporate the oral polio immunization (OPV) and the Bacillus Calmette–Guerin (BCG) utilized against tuberculosis, both piece of the vaccination given to Indian youngsters.\r\n\r\nIt merits leading a clinical preliminary, said Ram Vishwakarma, executive of the CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM) in Jammu.\r\n\r\nHe was reacting to an investigation a week ago by a global group of analysts in the diary Science. The analysts, including Shyamasundaran Kottili and Robert Gallo from the University of Maryland School of Medicine in the US, said the OPV ought to be tried to check whether it may shield individuals from the SARS-CoV-2 infection.\r\n\r\nThey noticed that the antibody used to forestall poliomyelitis contaminations has been around since the 1950s, and is found to give some security against other viral diseases.\r\n\r\nThe incitement of natural resistance by lessened antibodies - live however with considerably diminished harmfulness - by and large and OPV specifically could give impermanent security against COVID-19, the researchers noted.\r\n\r\nIntrinsic invulnerability is one of the two fundamental resistance systems found in vertebrates, including people.\r\n\r\nAs indicated by Vishwakarma, the thought proposed by Gallo, a globally eminent virologist who co-found that HIV causes AIDS, depends on the way that individuals who have experienced polio immunization help their intrinsic resistance.\r\n\r\n\"It is a sound logical idea however we don\'t have the foggiest idea what will in the end happen in light of the fact that this has various stages. It might help patients in the early stage, with mellow and moderate manifestations however may not support genuine patients,\" Vishwakarma told PTI.\r\n\r\n\"It is a testable thought dependent on a logical theory that is thusly founded on the idea of what we call prepared resistance, a vague method to support natural insusceptibility for our safe framework to battle out the infection,\" Vishwakarma clarified.\r\n\r\nIndia has been executing a heartbeat polio program since 1995 with a plan to destroy polio, included virologist Upasana Ray. This is as per a goals passed by the World Health Assembly in 1988 for polio annihilation all inclusive.\r\n\r\n\"Consistently, youngsters between 0-5 years age are inoculated with polio antibody. It is an across the board and settled program,\" Ray, senior researcher at CSIR-IICB, Kolkata, told PTI.\r\n\r\nImmunologist Satyajit Rath added that it is ideal to remember that Gallo and his group are not discussing the capacity of the OPV as an \'\'immunization\'\' which produces a particular safe reaction.\r\n\r\n\"Rather, it is just giving individuals a viral disease, any popular contamination, so that there is initiation of natural antiviral and incendiary insusceptibility, which may diminish the odds of another infection (SARS-CoV-2) contamination which enters simultaneously,\" Rath, from the National Institute of Immunology (NII) in New Delhi, told PTI.\r\n\r\n\"Do I figure this may work? It may, to some unobtrusive degree, would be my theory, and insufficient to make it especially advantageous,\" he said.\r\n\r\nTaking note of that repurposing immunizations is a smart thought, Ray said there is an opportunity of cross assurance somewhat if the proteins of two pathogens have comparative successions even at certain epitopes.\r\n\r\nAn epitope is a piece of an antigen or a remote substance that is perceived by the resistant framework cells, explicitly by antibodies, B cells and T cells.\r\n\r\n\"For polio additionally, we first need to check whether any of the polio proteins show covering T or B cell epitopes when contrasted with that of SARS-COV-2. On the off chance that there are, it may give some assurance... How much? That needs approval,\" said Ray.\r\n\r\nVishwakarma said the Council of Scientific and Industrial Research (CSIR) is as of now testing a repurposed immunization against COVID-19 on the comparative lines of a polio antibody.\r\n\r\nIt is trying Cadila Pharmaceuticals\'\' Sepsivac against COVID-19 out of a Phase 2 clinical preliminary.\r\n\r\nThis immunotherapy treatment, which helps \"intrinsic invulnerability\", has been endorsed by the Drug Controller General of India (DCGI) for clinical preliminaries, he said.\r\n\r\nRath noticed that there are significant possible restrictions to utilizing the polio immunization for COVID-19.\r\n\r\nTo begin with, almost certainly, this \'\'assurance\'\' by continuous natural resistant enactment is probably going to be of brief term.\r\n\r\nSecond, the probability is that many individuals in India, especially youngsters, are resistant to polio, and accordingly won\'t really let the OPV \'\'work\'\' as a contamination, he said.\r\n\r\n\"Rather, polio-invulnerable people would be \'\'ensured\'\' against yet more antibody, which would crush the SARS-CoV-2-related reason,\" Rath noted.\r\n\r\n\"Indeed, even among the individuals who don\'t have current enemy of polio antibodies, this \'\'assurance\'\' would probably be a transient one-time impact for a couple of days which is probably not going to be repeatable since this first introduction would make them polio-insusceptible,\" he said.\r\n\r\nConcurring with Rath, Ray noticed that the vast majority in India are now immunized against polio in youth.\r\n\r\n\"Aren\'\'t those individuals getting tainted? State truly, still they are.......then the following inquiry could be, are they becoming ill like non-immunized ones?\" she said.\r\n\r\n\"Next, is it conceivable that for polio it is giving deep rooted insurance. Is it conceivable that in the event that a few epitopes are coordinating that inoculation could help? All these are vulnerable sides. Need time testing,\" said Ray.','Polio immunization for COVID-19 \'testable\', may offer constrained security: Scientists','','publish','open','open','','polio-immunization-for-covid-19-testable-may-offer-constrained-security-scientists','','','2020-06-19 09:48:44','2020-06-19 09:48:44','',0,'https://microbiozindia.com/?p=6228',0,'post','',0),(6229,2,'2020-06-19 09:47:58','2020-06-19 09:47:58','','ampoules-2045833_640','','inherit','open','closed','','ampoules-2045833_640-2','','','2020-06-19 09:47:58','2020-06-19 09:47:58','',6228,'https://microbiozindia.com/wp-content/uploads/2020/06/ampoules-2045833_640.jpg',0,'attachment','image/jpeg',0),(6230,2,'2020-06-19 09:48:44','2020-06-19 09:48:44','Indian researchers have reacted mindfully to a proposal by worldwide specialists that the oral polio antibody be tried for COVID-19, saying it is a \"testable thought\" in view of a sound logical idea however may offer just restricted security against the contamination.\r\n\r\nWith an immunization for COVID-19 in any event a year away, researchers state repurposing effectively sheltered and successful antibodies is the best approach for sure fire help against COVID-19. The repurposed antibodies could incorporate the oral polio immunization (OPV) and the Bacillus Calmette–Guerin (BCG) utilized against tuberculosis, both piece of the vaccination given to Indian youngsters.\r\n\r\nIt merits leading a clinical preliminary, said Ram Vishwakarma, executive of the CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM) in Jammu.\r\n\r\nHe was reacting to an investigation a week ago by a global group of analysts in the diary Science. The analysts, including Shyamasundaran Kottili and Robert Gallo from the University of Maryland School of Medicine in the US, said the OPV ought to be tried to check whether it may shield individuals from the SARS-CoV-2 infection.\r\n\r\nThey noticed that the antibody used to forestall poliomyelitis contaminations has been around since the 1950s, and is found to give some security against other viral diseases.\r\n\r\nThe incitement of natural resistance by lessened antibodies - live however with considerably diminished harmfulness - by and large and OPV specifically could give impermanent security against COVID-19, the researchers noted.\r\n\r\nIntrinsic invulnerability is one of the two fundamental resistance systems found in vertebrates, including people.\r\n\r\nAs indicated by Vishwakarma, the thought proposed by Gallo, a globally eminent virologist who co-found that HIV causes AIDS, depends on the way that individuals who have experienced polio immunization help their intrinsic resistance.\r\n\r\n\"It is a sound logical idea however we don\'t have the foggiest idea what will in the end happen in light of the fact that this has various stages. It might help patients in the early stage, with mellow and moderate manifestations however may not support genuine patients,\" Vishwakarma told PTI.\r\n\r\n\"It is a testable thought dependent on a logical theory that is thusly founded on the idea of what we call prepared resistance, a vague method to support natural insusceptibility for our safe framework to battle out the infection,\" Vishwakarma clarified.\r\n\r\nIndia has been executing a heartbeat polio program since 1995 with a plan to destroy polio, included virologist Upasana Ray. This is as per a goals passed by the World Health Assembly in 1988 for polio annihilation all inclusive.\r\n\r\n\"Consistently, youngsters between 0-5 years age are inoculated with polio antibody. It is an across the board and settled program,\" Ray, senior researcher at CSIR-IICB, Kolkata, told PTI.\r\n\r\nImmunologist Satyajit Rath added that it is ideal to remember that Gallo and his group are not discussing the capacity of the OPV as an \'\'immunization\'\' which produces a particular safe reaction.\r\n\r\n\"Rather, it is just giving individuals a viral disease, any popular contamination, so that there is initiation of natural antiviral and incendiary insusceptibility, which may diminish the odds of another infection (SARS-CoV-2) contamination which enters simultaneously,\" Rath, from the National Institute of Immunology (NII) in New Delhi, told PTI.\r\n\r\n\"Do I figure this may work? It may, to some unobtrusive degree, would be my theory, and insufficient to make it especially advantageous,\" he said.\r\n\r\nTaking note of that repurposing immunizations is a smart thought, Ray said there is an opportunity of cross assurance somewhat if the proteins of two pathogens have comparative successions even at certain epitopes.\r\n\r\nAn epitope is a piece of an antigen or a remote substance that is perceived by the resistant framework cells, explicitly by antibodies, B cells and T cells.\r\n\r\n\"For polio additionally, we first need to check whether any of the polio proteins show covering T or B cell epitopes when contrasted with that of SARS-COV-2. On the off chance that there are, it may give some assurance... How much? That needs approval,\" said Ray.\r\n\r\nVishwakarma said the Council of Scientific and Industrial Research (CSIR) is as of now testing a repurposed immunization against COVID-19 on the comparative lines of a polio antibody.\r\n\r\nIt is trying Cadila Pharmaceuticals\'\' Sepsivac against COVID-19 out of a Phase 2 clinical preliminary.\r\n\r\nThis immunotherapy treatment, which helps \"intrinsic invulnerability\", has been endorsed by the Drug Controller General of India (DCGI) for clinical preliminaries, he said.\r\n\r\nRath noticed that there are significant possible restrictions to utilizing the polio immunization for COVID-19.\r\n\r\nTo begin with, almost certainly, this \'\'assurance\'\' by continuous natural resistant enactment is probably going to be of brief term.\r\n\r\nSecond, the probability is that many individuals in India, especially youngsters, are resistant to polio, and accordingly won\'t really let the OPV \'\'work\'\' as a contamination, he said.\r\n\r\n\"Rather, polio-invulnerable people would be \'\'ensured\'\' against yet more antibody, which would crush the SARS-CoV-2-related reason,\" Rath noted.\r\n\r\n\"Indeed, even among the individuals who don\'t have current enemy of polio antibodies, this \'\'assurance\'\' would probably be a transient one-time impact for a couple of days which is probably not going to be repeatable since this first introduction would make them polio-insusceptible,\" he said.\r\n\r\nConcurring with Rath, Ray noticed that the vast majority in India are now immunized against polio in youth.\r\n\r\n\"Aren\'\'t those individuals getting tainted? State truly, still they are.......then the following inquiry could be, are they becoming ill like non-immunized ones?\" she said.\r\n\r\n\"Next, is it conceivable that for polio it is giving deep rooted insurance. Is it conceivable that in the event that a few epitopes are coordinating that inoculation could help? All these are vulnerable sides. Need time testing,\" said Ray.','Polio immunization for COVID-19 \'testable\', may offer constrained security: Scientists','','inherit','closed','closed','','6228-revision-v1','','','2020-06-19 09:48:44','2020-06-19 09:48:44','',6228,'https://microbiozindia.com/uncategorized/6228-revision-v1/',0,'revision','',0),(6231,2,'2020-06-19 10:13:38','2020-06-19 10:13:38','The COVID 19 pandemic has touched every aspect of human life including healthcare delivery for other chronic diseases. With the explosion of medical information on this pandemic, medical care for diseases like cancer is also evolving every day. Gone are the days when patients used to schedule day care chemotherapy appointments like any other regular appointments.\r\n\r\nThe challenges for a cancer patient are manifold. Most patients worry about exposure to the COVID 19 virus when they visit the hospital. Another worry is whether chemotherapy will lower their immunity making them more susceptible to COVID 19 infection. And patients on chemotherapy may require repeated hospitalizations making them more susceptible to contracting COVID 19 infection.\r\n\r\nThere is always a lingering doubt in the patient’s mind whether to delay cancer treatment or not. Another question being asked is whether the interval between each cycle can be increased or whether intravenous therapy can be converted to oral therapy to reduce the risk of exposure. Many are even unsure as to which is more dangerous and difficult to treat – Cancer or COVID 19.\r\n\r\nLANCET Oncology, a premier medical journal published a study on Cancer and COVID 19 infection on May 28th with some startling hypothesis which may lead to a radical change in cancer care during COVID 19. First, patients with cancer appear to be at an increased risk of mortality and severe illness due to SARS-CoV-2 infection, regardless of whether they have active cancer, are on anticancer treatment, or both.\r\n\r\nThe absence of an association between 30-day all-cause mortality and recent surgery, recent non-cytotoxic therapy, or recent cytotoxic systemic therapy suggests that curative surgical resections, adjuvant chemotherapy i.e. chemotherapy given with a curative intent, and maintenance chemotherapy could continue during the SARS-CoV-2 pandemic with extreme caution, although this finding should not be interpreted as a recommendation.\r\n\r\nIn elderly patients or patients with co-morbidities who are at a high risk of contracting the COVID 19 infection, non-chemotherapy options like targeted agents and immunotherapy can be explored. Especially in selected cancers like early stage breast cancer which express the oestrogen receptor and without overexpression of a high risk receptor like HER2, targeted agents like hormonal therapy can be used as an option for effective disease control, thereby mitigating the risks of immune suppressive chemotherapy. Advances in treatment have meant certain subset of patients with lung cancer can be treated with a chemotherapy free option like targeted therapy or immunotherapy.\r\n\r\nPatient suffering from advanced stage lung cancer with particular driver mutations can be treated with oral agents effectively as a first line treatment option. Some patients of stage 4 lung cancer can be treated with single agent immunotherapy with even superior results as compared to chemotherapy, at the same time reducing the immune suppression associated with chemotherapy and the attendant side effects.\r\n\r\nIn fact, immunotherapy alone has now been approved as first line therapy in certain types of cancers like metastatic lung cancer, metastatic kidney cancer, metastatic liver cancer, and metastatic genito-urinary cancers. With a view of reducing hospital visits during the COVID 19 pandemic, extended intervals (6 weekly vs the traditional 3 weekly) between each immunotherapy session of a drug called Pembrolizumab, has been extensively studied and approved by the USFDA.\r\n\r\nHistory has taught us that the only way to overcome an adversity by innovating and evolving. Like all other facets of society, health care delivery has also risen up to the challenge and is striving to maintain optimum outcomes for patients suffering from cancer during this COVID 19 pandemic.','Immunotherapy – Evolving cancer care during COVID 19 pandemic','','publish','open','open','','immunotherapy-evolving-cancer-care-during-covid-19-pandemic','','','2020-06-19 10:13:38','2020-06-19 10:13:38','',0,'https://microbiozindia.com/?p=6231',0,'post','',0),(6232,2,'2020-06-19 10:10:56','2020-06-19 10:10:56','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-8','','','2020-06-19 10:10:56','2020-06-19 10:10:56','',6231,'https://microbiozindia.com/wp-content/uploads/2020/06/Untitled-design-1-3.png',0,'attachment','image/png',0),(6233,2,'2020-06-19 10:13:38','2020-06-19 10:13:38','The COVID 19 pandemic has touched every aspect of human life including healthcare delivery for other chronic diseases. With the explosion of medical information on this pandemic, medical care for diseases like cancer is also evolving every day. Gone are the days when patients used to schedule day care chemotherapy appointments like any other regular appointments.\r\n\r\nThe challenges for a cancer patient are manifold. Most patients worry about exposure to the COVID 19 virus when they visit the hospital. Another worry is whether chemotherapy will lower their immunity making them more susceptible to COVID 19 infection. And patients on chemotherapy may require repeated hospitalizations making them more susceptible to contracting COVID 19 infection.\r\n\r\nThere is always a lingering doubt in the patient’s mind whether to delay cancer treatment or not. Another question being asked is whether the interval between each cycle can be increased or whether intravenous therapy can be converted to oral therapy to reduce the risk of exposure. Many are even unsure as to which is more dangerous and difficult to treat – Cancer or COVID 19.\r\n\r\nLANCET Oncology, a premier medical journal published a study on Cancer and COVID 19 infection on May 28th with some startling hypothesis which may lead to a radical change in cancer care during COVID 19. First, patients with cancer appear to be at an increased risk of mortality and severe illness due to SARS-CoV-2 infection, regardless of whether they have active cancer, are on anticancer treatment, or both.\r\n\r\nThe absence of an association between 30-day all-cause mortality and recent surgery, recent non-cytotoxic therapy, or recent cytotoxic systemic therapy suggests that curative surgical resections, adjuvant chemotherapy i.e. chemotherapy given with a curative intent, and maintenance chemotherapy could continue during the SARS-CoV-2 pandemic with extreme caution, although this finding should not be interpreted as a recommendation.\r\n\r\nIn elderly patients or patients with co-morbidities who are at a high risk of contracting the COVID 19 infection, non-chemotherapy options like targeted agents and immunotherapy can be explored. Especially in selected cancers like early stage breast cancer which express the oestrogen receptor and without overexpression of a high risk receptor like HER2, targeted agents like hormonal therapy can be used as an option for effective disease control, thereby mitigating the risks of immune suppressive chemotherapy. Advances in treatment have meant certain subset of patients with lung cancer can be treated with a chemotherapy free option like targeted therapy or immunotherapy.\r\n\r\nPatient suffering from advanced stage lung cancer with particular driver mutations can be treated with oral agents effectively as a first line treatment option. Some patients of stage 4 lung cancer can be treated with single agent immunotherapy with even superior results as compared to chemotherapy, at the same time reducing the immune suppression associated with chemotherapy and the attendant side effects.\r\n\r\nIn fact, immunotherapy alone has now been approved as first line therapy in certain types of cancers like metastatic lung cancer, metastatic kidney cancer, metastatic liver cancer, and metastatic genito-urinary cancers. With a view of reducing hospital visits during the COVID 19 pandemic, extended intervals (6 weekly vs the traditional 3 weekly) between each immunotherapy session of a drug called Pembrolizumab, has been extensively studied and approved by the USFDA.\r\n\r\nHistory has taught us that the only way to overcome an adversity by innovating and evolving. Like all other facets of society, health care delivery has also risen up to the challenge and is striving to maintain optimum outcomes for patients suffering from cancer during this COVID 19 pandemic.','Immunotherapy – Evolving cancer care during COVID 19 pandemic','','inherit','closed','closed','','6231-revision-v1','','','2020-06-19 10:13:38','2020-06-19 10:13:38','',6231,'https://microbiozindia.com/uncategorized/6231-revision-v1/',0,'revision','',0),(6234,2,'2020-06-19 15:07:05','2020-06-19 15:07:05','Clover Biopharmaceuticals turned into the 6th Chinese designer of a potential COVID-19 antibody to move into human preliminaries on Friday, propelling an investigation in Australia that will test its immunization with promoters.\r\n\r\nChina and the United States have gone head to head over the wellbeing emergency and are driving equal endeavors to get immunizations effectively affirmed and into enormous scope creation not long from now.\r\n\r\nThere are as of now no endorsed antibodies or medicines for the ailment brought about by the new coronavirus, yet around twelve immunizations are being trialed all inclusive.\r\n\r\nThe infection developed in the Chinese city of Wuhan before the end of last year and has since spread comprehensively, executing in excess of 450,000 individuals.\r\n\r\nAn expansion in cases in China\'s capital Beijing has constrained specialists to contemplate the genome of a potential new strain.\r\n\r\nClover\'s preliminary, which is selecting around 150 grown-up and old patients, will assess two distinct sponsors, or adjuvants, from Britain\'s GSK and US-based Dynavax in blend with its competitor shot, SCB-2019, the Chinese organization said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.fiercepharma.com/pharma/coronavirus-tracker-hydroxychloroquine-fails-va-study-fda-approves-at-home-sample-collection\">China\'s CanSino Biological, Sinopharm and the Wuhan Institute of Biological Products are among those previously testing antibodies, as are AstraZeneca, Moderna and Germany\'s CureVac.</a></span>\r\n\r\nClover said beginning wellbeing information from its investigation was normal in August this year, and it would intend to begin more extensive examinations by year end. Its antibody depends on proteins considered antigens that will be taken in blend with the adjuvants.\r\n\r\nGSK, the world\'s biggest antibody producer, has avoided building up its own immunization and has rather centered endeavors around contributing its adjuvant mastery in the worldwide race.\r\n\r\nAdjuvants, or viability promoters, are added to certain immunizations to help safe reaction with the point of making a more drawn out insusceptibility against a disease.\r\n\r\nDynavax\'s supporter CpG 1018, being tried with Clover\'s shot, was created as an adjuvant for the US organization\'s Hepatitis B antibody.','Clover Biopharmaceuticals dispatches 6th Chinese COVID-19 antibody preliminary','','publish','open','open','','clover-biopharmaceuticals-dispatches-6th-chinese-covid-19-antibody-preliminary','','','2020-06-19 15:07:05','2020-06-19 15:07:05','',0,'https://microbiozindia.com/?p=6234',0,'post','',0),(6235,2,'2020-06-19 15:07:05','2020-06-19 15:07:05','Clover Biopharmaceuticals turned into the 6th Chinese designer of a potential COVID-19 antibody to move into human preliminaries on Friday, propelling an investigation in Australia that will test its immunization with promoters.\r\n\r\nChina and the United States have gone head to head over the wellbeing emergency and are driving equal endeavors to get immunizations effectively affirmed and into enormous scope creation not long from now.\r\n\r\nThere are as of now no endorsed antibodies or medicines for the ailment brought about by the new coronavirus, yet around twelve immunizations are being trialed all inclusive.\r\n\r\nThe infection developed in the Chinese city of Wuhan before the end of last year and has since spread comprehensively, executing in excess of 450,000 individuals.\r\n\r\nAn expansion in cases in China\'s capital Beijing has constrained specialists to contemplate the genome of a potential new strain.\r\n\r\nClover\'s preliminary, which is selecting around 150 grown-up and old patients, will assess two distinct sponsors, or adjuvants, from Britain\'s GSK and US-based Dynavax in blend with its competitor shot, SCB-2019, the Chinese organization said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.fiercepharma.com/pharma/coronavirus-tracker-hydroxychloroquine-fails-va-study-fda-approves-at-home-sample-collection\">China\'s CanSino Biological, Sinopharm and the Wuhan Institute of Biological Products are among those previously testing antibodies, as are AstraZeneca, Moderna and Germany\'s CureVac.</a></span>\r\n\r\nClover said beginning wellbeing information from its investigation was normal in August this year, and it would intend to begin more extensive examinations by year end. Its antibody depends on proteins considered antigens that will be taken in blend with the adjuvants.\r\n\r\nGSK, the world\'s biggest antibody producer, has avoided building up its own immunization and has rather centered endeavors around contributing its adjuvant mastery in the worldwide race.\r\n\r\nAdjuvants, or viability promoters, are added to certain immunizations to help safe reaction with the point of making a more drawn out insusceptibility against a disease.\r\n\r\nDynavax\'s supporter CpG 1018, being tried with Clover\'s shot, was created as an adjuvant for the US organization\'s Hepatitis B antibody.','Clover Biopharmaceuticals dispatches 6th Chinese COVID-19 antibody preliminary','','inherit','closed','closed','','6234-revision-v1','','','2020-06-19 15:07:05','2020-06-19 15:07:05','',6234,'https://microbiozindia.com/uncategorized/6234-revision-v1/',0,'revision','',0),(6236,2,'2020-06-20 08:04:36','2020-06-20 08:04:36','There is a prominent name missing from the leaders in the race to test exploratory immunisations against the novel coronavirus: the world\'s biggest antibody producer GlaxoSmithKline .\r\n\r\nWhat\'s more, that is totally fine as indicated by the British gathering\'s main clinical official for antibodies Thomas Breuer, who says the organization inclines toward the gradual methodology of concentrating on a set up innovation that has the most obvious opportunity with regards to arriving at the vastest conceivable segment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.fiercepharma.com/pharma/coronavirus-tracker-hydroxychloroquine-fails-va-study-fda-approves-at-home-sample-collection\">Moderna , the University of Oxford as a team with AstraZeneca , and a coalition of BioNTech and Pfizer got features by moving to human preliminaries from as ahead of schedule as March.</a></span>\r\n\r\nGSK, which is in seven coordinated efforts with organizations or firms all around, just entered the clinical preliminary stage with one anticipate on Friday.\r\n\r\n\"We need to be top tier, and in the event that others are a little quicker I will praise them since they can deal with perhaps the social insurance laborers in chose nations, however the world needs billions of portions and we will add to this exertion,\" Breuer told Reuters.\r\n\r\nGSK plans to contribute an alleged adjuvant, a viability supporter that is joined with progressively conventional immunizations, while the most exceptional adversary ventures utilize novel hereditary advances and have been quickened through pre-clinical testing in labs and on creatures.\r\n\r\nBreuer said immunizations grew later, and adjuvant innovation, may have longer or better adequacy, particularly in the old. For instance he highlighted GSK\'s success Shingrix, a shingles immunization with an adjuvant for more established individuals that has quickly supplanted a built up rival item.\r\n\r\nThe organization spread out plans in May to deliver 1 billion dosages of the viability supporters for COVID-19 shots one year from now, contrasted with the 700 million or so immunization portions against a scope of illnesses it for the most part creates in a year.\r\n\r\nBreuer said building up a wide scope of associations was GSK\'s response to limiting the danger of disappointment and permitted it to concentrate assets on its most encouraging innovation against COVID-19, despite the fact that it has recently dealt with hereditary immunizations.\r\n\r\n\"The best thing GSK can offer is making the adjuvant accessible to more than one organization. We needed to open our innovation to have a few shots on objective,\" he said.\r\n\r\nGathering CEO Emma Walmsley said in April that an inoculation that works for and is accessible for the vast majority was probably not going to rise before the second 50% of one year from now.\r\n\r\n\"Activity Warp Speed\", a US push to build up an inoculation shot, on the other hand, needs to have an antibody accessible by January 2021.\r\n\r\nGSK is one of in excess of 100 worldwide players taking a shot at immunizations against COVID-19, which has murdered around 350,000 individuals.\r\n\r\nIt has contributed its adjuvant to collusions including Chinese biotech firms Clover Biopharmaceuticals, Xiamen Innovax and Chongqing Zhifei , just as the University of Queensland in Australia and Sanofi . Two additional joint efforts are in progress however have not been uncovered at this point, Breuer included.','GSK in mission to be ideal, not first, in race for COVID-19 antibody','','publish','open','open','','gsk-in-mission-to-be-ideal-not-first-in-race-for-covid-19-antibody','','','2020-06-20 08:04:36','2020-06-20 08:04:36','',0,'https://microbiozindia.com/?p=6236',0,'post','',0),(6237,2,'2020-06-20 08:04:36','2020-06-20 08:04:36','There is a prominent name missing from the leaders in the race to test exploratory immunisations against the novel coronavirus: the world\'s biggest antibody producer GlaxoSmithKline .\r\n\r\nWhat\'s more, that is totally fine as indicated by the British gathering\'s main clinical official for antibodies Thomas Breuer, who says the organization inclines toward the gradual methodology of concentrating on a set up innovation that has the most obvious opportunity with regards to arriving at the vastest conceivable segment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.fiercepharma.com/pharma/coronavirus-tracker-hydroxychloroquine-fails-va-study-fda-approves-at-home-sample-collection\">Moderna , the University of Oxford as a team with AstraZeneca , and a coalition of BioNTech and Pfizer got features by moving to human preliminaries from as ahead of schedule as March.</a></span>\r\n\r\nGSK, which is in seven coordinated efforts with organizations or firms all around, just entered the clinical preliminary stage with one anticipate on Friday.\r\n\r\n\"We need to be top tier, and in the event that others are a little quicker I will praise them since they can deal with perhaps the social insurance laborers in chose nations, however the world needs billions of portions and we will add to this exertion,\" Breuer told Reuters.\r\n\r\nGSK plans to contribute an alleged adjuvant, a viability supporter that is joined with progressively conventional immunizations, while the most exceptional adversary ventures utilize novel hereditary advances and have been quickened through pre-clinical testing in labs and on creatures.\r\n\r\nBreuer said immunizations grew later, and adjuvant innovation, may have longer or better adequacy, particularly in the old. For instance he highlighted GSK\'s success Shingrix, a shingles immunization with an adjuvant for more established individuals that has quickly supplanted a built up rival item.\r\n\r\nThe organization spread out plans in May to deliver 1 billion dosages of the viability supporters for COVID-19 shots one year from now, contrasted with the 700 million or so immunization portions against a scope of illnesses it for the most part creates in a year.\r\n\r\nBreuer said building up a wide scope of associations was GSK\'s response to limiting the danger of disappointment and permitted it to concentrate assets on its most encouraging innovation against COVID-19, despite the fact that it has recently dealt with hereditary immunizations.\r\n\r\n\"The best thing GSK can offer is making the adjuvant accessible to more than one organization. We needed to open our innovation to have a few shots on objective,\" he said.\r\n\r\nGathering CEO Emma Walmsley said in April that an inoculation that works for and is accessible for the vast majority was probably not going to rise before the second 50% of one year from now.\r\n\r\n\"Activity Warp Speed\", a US push to build up an inoculation shot, on the other hand, needs to have an antibody accessible by January 2021.\r\n\r\nGSK is one of in excess of 100 worldwide players taking a shot at immunizations against COVID-19, which has murdered around 350,000 individuals.\r\n\r\nIt has contributed its adjuvant to collusions including Chinese biotech firms Clover Biopharmaceuticals, Xiamen Innovax and Chongqing Zhifei , just as the University of Queensland in Australia and Sanofi . Two additional joint efforts are in progress however have not been uncovered at this point, Breuer included.','GSK in mission to be ideal, not first, in race for COVID-19 antibody','','inherit','closed','closed','','6236-revision-v1','','','2020-06-20 08:04:36','2020-06-20 08:04:36','',6236,'https://microbiozindia.com/uncategorized/6236-revision-v1/',0,'revision','',0),(6238,2,'2020-06-20 08:18:28','2020-06-20 08:18:28','The Drug Controller General of India (DCGI) has affirmed the utilization of hostile to viral medication Favipiravir for COVID-19 patients for confined use. The medication can be utilized distinctly if there should be an occurrence of a crisis and family assent of the patient is obligatory.\r\n\r\nThe term of the course is 14 days.\r\n\r\nGlenmark Pharma is at present directing preliminaries for Favipiravir for use on coronavirus licenses. While the preliminaries are as yet in progress, the DCGI affirmed the medication in the wake of seeing empowering results.\r\n\r\nThe medication controller said observation for the initial 1,000 patients will be required in the wake of regulating Favipiravir to them.\r\n\r\nWhile the medication is commonly utilized for flu around the world, Russia, China','DCGI supports Restricted Use of Anti-viral Drug Favipiravir for Coronavirus Patients','','publish','open','open','','dcgi-supports-restricted-use-of-anti-viral-drug-favipiravir-for-coronavirus-patients','','','2020-06-20 12:47:58','2020-06-20 12:47:58','',0,'https://microbiozindia.com/?p=6238',0,'post','',0),(6239,2,'2020-06-20 08:18:28','2020-06-20 08:18:28','The Drug Controller General of India (DCGI) has affirmed the utilization of hostile to viral medication Favipiravir for COVID-19 patients for confined use. The medication can be utilized distinctly if there should be an occurrence of a crisis and family assent of the patient is obligatory.\r\n\r\nThe term of the course is 14 days.\r\n\r\nGlenmark Pharma is at present directing preliminaries for Favipiravir for use on coronavirus licenses. While the preliminaries are as yet in progress, the DCGI affirmed the medication in the wake of seeing empowering results.\r\n\r\nThe medication controller said observation for the initial 1,000 patients will be required in the wake of regulating Favipiravir to them.\r\n\r\nWhile the medication is commonly utilized for flu around the world, Russia, China','DCGI suppots Restricted Use of Anti-viral Drug Favipiravir for Coronavirus Patients','','inherit','closed','closed','','6238-revision-v1','','','2020-06-20 08:18:28','2020-06-20 08:18:28','',6238,'https://microbiozindia.com/uncategorized/6238-revision-v1/',0,'revision','',0),(6240,2,'2020-06-20 12:39:00','2020-06-20 12:39:00','Directing the MMR (measles, mumps, rubella) antibody could fill in as a preventive measure to hose septic aggravation related with COVID-19 disease, state a group of specialists in the current week\'s mBio, a diary of the American Society for Microbiology. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://theweek.com/speedreads/921027/mmr-vaccine-could-boost-immunity-mitigate-coronavirus-effects-researchers-suggest\">Long-term colleagues and life partners Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry and Dr. Mairi Noverr Professor of Microbiology and Immunology at Tulane University School of Medicine in New Orleans co-composed the point of view article</a> </span>dependent on thoughts originating from research in their labs. Inoculation with MMR in immunocompetent people has no contraindications and might be particularly successful for medicinal services laborers who can without much of a stretch be presented to COVID-19, state the scientists.\r\n<blockquote>Live attenuated vaccines seemingly have some nonspecific benefits as well as immunity to the target pathogen. A clinical trial with MMR in high-risk populations may provide a low-risk-high-reward preventive measure in saving lives during the COVID-19 pandemic. While we are conducting the clinical trials, I don\'t think it\'s going to hurt anybody to have an MMR vaccine that would protect against the measles, mumps, and rubella with this potential added benefit of helping against COVID-19.\"\r\n<em>Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry</em></blockquote>\r\nMounting proof shows that live lessened antibodies give vague assurance against deadly contaminations inconsequential to the objective pathogen of the immunization by initiating prepared vague inborn safe cells for improved host reactions against resulting diseases. Live lessened immunizations initiate vague impacts speaking to \"prepared natural resistance\" via preparing leukocyte (insusceptible framework cells) forerunners in the bone marrow to work all the more adequately against more extensive irresistible put-down.\r\n\r\nIn Dr. Noverr\'s research center, in a joint effort with Dr. Fidel, immunization with a live weakened contagious strain-incited prepared natural assurance against deadly polymicrobial sepsis. The assurance was intervened by seemingly perpetual myeloid-determined silencer cells (MDSCs) recently revealed hindering septic aggravation and mortality in a few exploratory models. The specialists state that a MMR immunization ought to have the option to instigate MDSCs that can hinder or lessen the serious lung aggravation/sepsis related with COVID-19. Mortality in COVID-19 cases is firmly connected with dynamic lung irritation and inevitable sepsis.\r\n\r\nLate occasions offer help for the specialists\' theory. The milder side effects found in the 955 mariners on the U.S.S Roosevelt who tried positive for COVID-19 (just a single hospitalization) may have been a result of the way that the MMR inoculations are given to all U.S. Naval force initiates. Also, epidemiological information propose a connection between\'s kin in geological areas who routinely get the MMR immunization and decreased COVID-19 passing rates. COVID-19 has not bigly affected kids, and the specialists estimate that one explanation kids are secured against viral contaminations that incite sepsis is their later and increasingly visit exposures to live lessened immunizations that can likewise actuate the prepared suppressive MDSCs that limit aggravation and sepsis.\r\n\r\nThe specialists propose a clinical preliminary to test whether the MMR antibody can ensure against COVID-19, however meanwhile, they recommend that all grown-ups, particularly medicinal services laborers and people in nursing homes get the MMR immunization. \"In the event that grown-ups got the MMR as a kid they likely despite everything have some degree of antibodies against measles, mumps, and rubella, yet most likely not the myeloid-determined silencer cells,\" said Dr. Fidel. \"While the MDSCs are extensive, they are not deep rooted cells. Along these lines, a supporter MMR would upgrade the antibodies to measles, mumps, and rubella and reinitiate the MDSCs. We would trust that the MDSCs instigated by the MMR would have a genuinely decent life expectancy to traverse the crucial time of the pandemic.\"\r\n\r\nDr. Noverr was as of late granted a \"Quick Grant\" (some portion of Emergent Ventures at the Mercatus Center, George Mason University) to test the viability of MMR straightforwardly in a nonhuman primate model of COVID-19 contamination.','MMR immunization could offer assurance against COVID-19','','publish','open','open','','mmr-immunization-could-offer-assurance-against-covid-19','','','2020-06-20 12:39:00','2020-06-20 12:39:00','',0,'https://microbiozindia.com/?p=6240',0,'post','',0),(6241,2,'2020-06-20 12:36:17','2020-06-20 12:36:17','','drape-5224847_640','','inherit','open','closed','','drape-5224847_640','','','2020-06-20 12:36:17','2020-06-20 12:36:17','',6240,'https://microbiozindia.com/wp-content/uploads/2020/06/drape-5224847_640.jpg',0,'attachment','image/jpeg',0),(6242,2,'2020-06-20 12:39:00','2020-06-20 12:39:00','Directing the MMR (measles, mumps, rubella) antibody could fill in as a preventive measure to hose septic aggravation related with COVID-19 disease, state a group of specialists in the current week\'s mBio, a diary of the American Society for Microbiology. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://theweek.com/speedreads/921027/mmr-vaccine-could-boost-immunity-mitigate-coronavirus-effects-researchers-suggest\">Long-term colleagues and life partners Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry and Dr. Mairi Noverr Professor of Microbiology and Immunology at Tulane University School of Medicine in New Orleans co-composed the point of view article</a> </span>dependent on thoughts originating from research in their labs. Inoculation with MMR in immunocompetent people has no contraindications and might be particularly successful for medicinal services laborers who can without much of a stretch be presented to COVID-19, state the scientists.\r\n<blockquote>Live attenuated vaccines seemingly have some nonspecific benefits as well as immunity to the target pathogen. A clinical trial with MMR in high-risk populations may provide a low-risk-high-reward preventive measure in saving lives during the COVID-19 pandemic. While we are conducting the clinical trials, I don\'t think it\'s going to hurt anybody to have an MMR vaccine that would protect against the measles, mumps, and rubella with this potential added benefit of helping against COVID-19.\"\r\n<em>Dr. Paul Fidel, Jr., Department Chair, Oral and Craniofacial Biology, and Associate Dean for Research, Louisiana State University Health School of Dentistry</em></blockquote>\r\nMounting proof shows that live lessened antibodies give vague assurance against deadly contaminations inconsequential to the objective pathogen of the immunization by initiating prepared vague inborn safe cells for improved host reactions against resulting diseases. Live lessened immunizations initiate vague impacts speaking to \"prepared natural resistance\" via preparing leukocyte (insusceptible framework cells) forerunners in the bone marrow to work all the more adequately against more extensive irresistible put-down.\r\n\r\nIn Dr. Noverr\'s research center, in a joint effort with Dr. Fidel, immunization with a live weakened contagious strain-incited prepared natural assurance against deadly polymicrobial sepsis. The assurance was intervened by seemingly perpetual myeloid-determined silencer cells (MDSCs) recently revealed hindering septic aggravation and mortality in a few exploratory models. The specialists state that a MMR immunization ought to have the option to instigate MDSCs that can hinder or lessen the serious lung aggravation/sepsis related with COVID-19. Mortality in COVID-19 cases is firmly connected with dynamic lung irritation and inevitable sepsis.\r\n\r\nLate occasions offer help for the specialists\' theory. The milder side effects found in the 955 mariners on the U.S.S Roosevelt who tried positive for COVID-19 (just a single hospitalization) may have been a result of the way that the MMR inoculations are given to all U.S. Naval force initiates. Also, epidemiological information propose a connection between\'s kin in geological areas who routinely get the MMR immunization and decreased COVID-19 passing rates. COVID-19 has not bigly affected kids, and the specialists estimate that one explanation kids are secured against viral contaminations that incite sepsis is their later and increasingly visit exposures to live lessened immunizations that can likewise actuate the prepared suppressive MDSCs that limit aggravation and sepsis.\r\n\r\nThe specialists propose a clinical preliminary to test whether the MMR antibody can ensure against COVID-19, however meanwhile, they recommend that all grown-ups, particularly medicinal services laborers and people in nursing homes get the MMR immunization. \"In the event that grown-ups got the MMR as a kid they likely despite everything have some degree of antibodies against measles, mumps, and rubella, yet most likely not the myeloid-determined silencer cells,\" said Dr. Fidel. \"While the MDSCs are extensive, they are not deep rooted cells. Along these lines, a supporter MMR would upgrade the antibodies to measles, mumps, and rubella and reinitiate the MDSCs. We would trust that the MDSCs instigated by the MMR would have a genuinely decent life expectancy to traverse the crucial time of the pandemic.\"\r\n\r\nDr. Noverr was as of late granted a \"Quick Grant\" (some portion of Emergent Ventures at the Mercatus Center, George Mason University) to test the viability of MMR straightforwardly in a nonhuman primate model of COVID-19 contamination.','MMR immunization could offer assurance against COVID-19','','inherit','closed','closed','','6240-revision-v1','','','2020-06-20 12:39:00','2020-06-20 12:39:00','',6240,'https://microbiozindia.com/uncategorized/6240-revision-v1/',0,'revision','',0),(6243,2,'2020-06-20 12:47:58','2020-06-20 12:47:58','The Drug Controller General of India (DCGI) has affirmed the utilization of hostile to viral medication Favipiravir for COVID-19 patients for confined use. The medication can be utilized distinctly if there should be an occurrence of a crisis and family assent of the patient is obligatory.\r\n\r\nThe term of the course is 14 days.\r\n\r\nGlenmark Pharma is at present directing preliminaries for Favipiravir for use on coronavirus licenses. While the preliminaries are as yet in progress, the DCGI affirmed the medication in the wake of seeing empowering results.\r\n\r\nThe medication controller said observation for the initial 1,000 patients will be required in the wake of regulating Favipiravir to them.\r\n\r\nWhile the medication is commonly utilized for flu around the world, Russia, China','DCGI supports Restricted Use of Anti-viral Drug Favipiravir for Coronavirus Patients','','inherit','closed','closed','','6238-revision-v1','','','2020-06-20 12:47:58','2020-06-20 12:47:58','',6238,'https://microbiozindia.com/uncategorized/6238-revision-v1/',0,'revision','',0),(6244,2,'2020-06-20 12:52:35','2020-06-20 12:52:35','Alembic Pharmaceuticals on Friday said it has gotten foundation examination report (EIR) from the US wellbeing controller for its Panelav office in Gujarat.\r\n\r\nThe organization has gotten EIR from the US Food and Drug Administration (USFDA) for the investigation completed by them on its general oral strong detailing office at Panelav, from March 9 to March 13, Alembic Pharmaceuticals said in a recording to the BSE.\r\n\r\n\"With this, EIR is set up for all our assembling offices for worldwide markets,\" it included.\r\n\r\nPortions of Alembic Pharmaceuticals were exchanging at Rs 940.05 per scrip on the BSE, up 3.50 percent from its past close. PTI AKT HRS','Alembic Pharma gets EIR from USFDA for its Panelav unit','','publish','open','open','','alembic-pharma-gets-eir-from-usfda-for-its-panelav-unit','','','2020-06-20 12:52:35','2020-06-20 12:52:35','',0,'https://microbiozindia.com/?p=6244',0,'post','',0),(6245,2,'2020-06-20 12:52:35','2020-06-20 12:52:35','Alembic Pharmaceuticals on Friday said it has gotten foundation examination report (EIR) from the US wellbeing controller for its Panelav office in Gujarat.\r\n\r\nThe organization has gotten EIR from the US Food and Drug Administration (USFDA) for the investigation completed by them on its general oral strong detailing office at Panelav, from March 9 to March 13, Alembic Pharmaceuticals said in a recording to the BSE.\r\n\r\n\"With this, EIR is set up for all our assembling offices for worldwide markets,\" it included.\r\n\r\nPortions of Alembic Pharmaceuticals were exchanging at Rs 940.05 per scrip on the BSE, up 3.50 percent from its past close. PTI AKT HRS','Alembic Pharma gets EIR from USFDA for its Panelav unit','','inherit','closed','closed','','6244-revision-v1','','','2020-06-20 12:52:35','2020-06-20 12:52:35','',6244,'https://microbiozindia.com/uncategorized/6244-revision-v1/',0,'revision','',0),(6246,2,'2020-06-20 16:58:44','2020-06-20 16:58:44','Laboratory Balances and Laboratory Scales from METTLER TOLEDO provide high quality solutions for Laboratory Weighing.When it comes to bringing you more, METTLER TOLEDO delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','publish','open','open','','fully-utilize-mettler-toledo-balances-to-enhance-your-laboratory','','','2020-06-20 17:08:34','2020-06-20 17:08:34','',0,'https://microbiozindia.com/?p=6246',0,'post','',0),(6247,2,'2020-06-20 16:45:03','2020-06-20 16:45:03','','4','','inherit','open','closed','','4-3','','','2020-06-20 16:45:03','2020-06-20 16:45:03','',6246,'https://microbiozindia.com/wp-content/uploads/2020/06/4.jpg',0,'attachment','image/jpeg',0),(6248,2,'2020-06-20 16:45:06','2020-06-20 16:45:06','','MT01','','inherit','open','closed','','mt01','','','2020-06-20 16:45:06','2020-06-20 16:45:06','',6246,'https://microbiozindia.com/wp-content/uploads/2020/06/MT01.png',0,'attachment','image/png',0),(6249,2,'2020-06-20 16:45:09','2020-06-20 16:45:09','','MT02','','inherit','open','closed','','mt02','','','2020-06-20 16:45:09','2020-06-20 16:45:09','',6246,'https://microbiozindia.com/wp-content/uploads/2020/06/MT02.png',0,'attachment','image/png',0),(6250,2,'2020-06-20 16:58:44','2020-06-20 16:58:44','When it comes to bringing you more, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-revision-v1','','','2020-06-20 16:58:44','2020-06-20 16:58:44','',6246,'https://microbiozindia.com/uncategorized/6246-revision-v1/',0,'revision','',0),(6251,2,'2020-06-20 17:00:04','2020-06-20 17:00:04','When it comes to bringing you more, <span style=\"text-decoration: underline; color: #000000;\"><span>METTLER TOLEDO</span></span> delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-revision-v1','','','2020-06-20 17:00:04','2020-06-20 17:00:04','',6246,'https://microbiozindia.com/uncategorized/6246-revision-v1/',0,'revision','',0),(6252,2,'2020-06-20 17:00:44','2020-06-20 17:00:44','When it comes to bringing you more, <span style=\"color: #000000;\">METTLER TOLEDO</span> delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-revision-v1','','','2020-06-20 17:00:44','2020-06-20 17:00:44','',6246,'https://microbiozindia.com/uncategorized/6246-revision-v1/',0,'revision','',0),(6253,2,'2020-06-20 17:03:19','2020-06-20 17:03:19','When it comes to bringing you more, delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-revision-v1','','','2020-06-20 17:03:19','2020-06-20 17:03:19','',6246,'https://microbiozindia.com/uncategorized/6246-revision-v1/',0,'revision','',0),(6254,2,'2020-06-20 17:05:37','2020-06-20 17:05:37','When it comes to bringing you more, METTLER TOLEDO delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\n\n<strong>The Most Complete Portfolio on the Market</strong>\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\n\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\n\n<strong>Glove Mode – Protect Yourself and Others</strong>\n\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\n\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\n\n<strong>About METTLER TOLEDO</strong>\n\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\n\nEmail us at – sales.mtin@mt.com\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-autosave-v1','','','2020-06-20 17:05:37','2020-06-20 17:05:37','',6246,'https://microbiozindia.com/uncategorized/6246-autosave-v1/',0,'revision','',0),(6255,2,'2020-06-20 17:08:34','2020-06-20 17:08:34','Laboratory Balances and Laboratory Scales from METTLER TOLEDO provide high quality solutions for Laboratory Weighing.When it comes to bringing you more, METTLER TOLEDO delivers.With the most complete portfolio of weighing equipment (Laboratory balances) on the market, we have been offering performance, quality and safety for 75 years. Learn more about our deep weighing experience and discover world-class instrumentation that fits your process and your budget.\r\n\r\n<strong>The Most Complete Portfolio on the Market</strong>\r\n<img class=\"alignnone size-medium wp-image-6248\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT01-300x201.png\" alt=\"\" width=\"300\" height=\"201\" />\r\n\r\nWith a broad range of sizes, readabilities, innovative features, and easy-to-connect accessories, our weighing instruments bring you the right combination of performance, reliability and ease-of-use.\r\n\r\n<strong>Glove Mode – Protect Yourself and Others</strong>\r\n\r\n<img class=\"alignnone size-medium wp-image-6249\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/MT02-300x202.png\" alt=\"\" width=\"300\" height=\"202\" />\r\n\r\nOur balances have features to provide additional user safety. With the function Glove Mode activated, the touch screen becomes easier to navigate when wearing gloves. This is especially important in the current situation, where users might want to protect themselves better by wearing gloves more regular, to reduce the risk of spreading Covid-19 – especially when the balances are shared.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://bit.ly/2MOT7Au\">Download the White Paper Now</a></span>\r\n\r\n<strong>About METTLER TOLEDO</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">METTLER TOLEDO</a></span> is available at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mt.com/in/en/home.html\">www.mt.com.</a></span>\r\n\r\nEmail us at – sales.mtin@mt.com\r\nCall us toll-free at – 1800 22 8884 &amp; 1800 1028 460','Fully Utilize METTLER TOLEDO Balances To Enhance Your laboratory','','inherit','closed','closed','','6246-revision-v1','','','2020-06-20 17:08:34','2020-06-20 17:08:34','',6246,'https://microbiozindia.com/uncategorized/6246-revision-v1/',0,'revision','',0),(6256,2,'2020-06-21 06:23:27','2020-06-21 06:23:27','India\'s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for \"confined crisis use\" on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed residential firm Glenmark Pharmaceuticals the authorization to fabricate and showcase favipiravir for \"confined crisis use\" in gentle to direct cases.\r\n\r\n\"The endorsement to Hetero and Cipla was given on Saturday,\" a source said.\r\n\r\nComposed educated assent regarding every patient is required before the utilization of remdesivir and consequences of extra clinical preliminaries, dynamic post-advertising reconnaissance information and detailing of genuine antagonistic occasions must be submitted.\r\n\r\nThe Union wellbeing service, in its \'Clinical Management Protocols for COVID-19\', suggested the utilization of the remdesivir on patients in moderate phase of the infection that is, those on oxygen. The medication has been incorporated as an \"investigational treatment\" just for confined crisis use purposes.\r\n\r\nIt isn\'t suggested for those with extreme renal debilitation and significant level of liver proteins, pregnant and lactating ladies, and those beneath 12 years, the report on \'Clinical Management Protocols for COVID-19\' expressed.\r\n\r\nThe medication, controlled as infusion, ought to be given at a portion of 200 mg on the very first moment followed by 100 mg day by day for five days.\r\n\r\nCipla and Hetero Labs have just gone into non-select authorizing concurrences with US pharma mammoth Gilead Sciences, which is the patent holder of the medication remdesivir.\r\n\r\nGilead Sciences had applied to the Indian Drug Regulatory Agency, CDSCO, for import and showcasing of Remdesivir on May 29. After due consultations, consent under crisis use approval was allowed by DCGI on June 1 in light of a legitimate concern for tolerant security and getting further information.\r\n\r\nOther than Hetero and Cipla, three different firms BDR, Jubilant, Mylan and DR Reddy\'s Labs have additionally applied to CDSCO for consent to produce and market the medication in India are as yet anticipating authorization.\r\n\r\nThese applications are being handled by the CDSCO as per the set down strategies. The organizations are at different moderate phases of review of assembling offices, check of information, steadiness testing, crisis research facility testing according to convention and so on, the wellbeing service had before said.\r\n\r\nBeing an injectable definition, testing for examine, personality, contaminations, bacterial endotoxin test and sterility become basic for understanding security and this information should be given by the organizations, the service had said.','Hetero, Cipla get gesture to make, market antiviral medication remdesivir','','publish','open','open','','hetero-cipla-get-gesture-to-make-market-antiviral-medication-remdesivir','','','2020-06-21 06:23:27','2020-06-21 06:23:27','',0,'https://microbiozindia.com/?p=6256',0,'post','',0),(6257,2,'2020-06-21 06:23:27','2020-06-21 06:23:27','India\'s Drug Regulator on June 20 allowed to Hetero and Cipla to produce and market antiviral medication remdesivir for \"confined crisis use\" on hospitalized COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), thinking about the crisis and neglected requirement for medications considering the coronavirus episode, allowed residential firm Glenmark Pharmaceuticals the authorization to fabricate and showcase favipiravir for \"confined crisis use\" in gentle to direct cases.\r\n\r\n\"The endorsement to Hetero and Cipla was given on Saturday,\" a source said.\r\n\r\nComposed educated assent regarding every patient is required before the utilization of remdesivir and consequences of extra clinical preliminaries, dynamic post-advertising reconnaissance information and detailing of genuine antagonistic occasions must be submitted.\r\n\r\nThe Union wellbeing service, in its \'Clinical Management Protocols for COVID-19\', suggested the utilization of the remdesivir on patients in moderate phase of the infection that is, those on oxygen. The medication has been incorporated as an \"investigational treatment\" just for confined crisis use purposes.\r\n\r\nIt isn\'t suggested for those with extreme renal debilitation and significant level of liver proteins, pregnant and lactating ladies, and those beneath 12 years, the report on \'Clinical Management Protocols for COVID-19\' expressed.\r\n\r\nThe medication, controlled as infusion, ought to be given at a portion of 200 mg on the very first moment followed by 100 mg day by day for five days.\r\n\r\nCipla and Hetero Labs have just gone into non-select authorizing concurrences with US pharma mammoth Gilead Sciences, which is the patent holder of the medication remdesivir.\r\n\r\nGilead Sciences had applied to the Indian Drug Regulatory Agency, CDSCO, for import and showcasing of Remdesivir on May 29. After due consultations, consent under crisis use approval was allowed by DCGI on June 1 in light of a legitimate concern for tolerant security and getting further information.\r\n\r\nOther than Hetero and Cipla, three different firms BDR, Jubilant, Mylan and DR Reddy\'s Labs have additionally applied to CDSCO for consent to produce and market the medication in India are as yet anticipating authorization.\r\n\r\nThese applications are being handled by the CDSCO as per the set down strategies. The organizations are at different moderate phases of review of assembling offices, check of information, steadiness testing, crisis research facility testing according to convention and so on, the wellbeing service had before said.\r\n\r\nBeing an injectable definition, testing for examine, personality, contaminations, bacterial endotoxin test and sterility become basic for understanding security and this information should be given by the organizations, the service had said.','Hetero, Cipla get gesture to make, market antiviral medication remdesivir','','inherit','closed','closed','','6256-revision-v1','','','2020-06-21 06:23:27','2020-06-21 06:23:27','',6256,'https://microbiozindia.com/uncategorized/6256-revision-v1/',0,'revision','',0),(6258,2,'2020-06-21 07:13:43','2020-06-21 07:13:43','In times of a global COVID 19 pandemic, many silent epidemics are being relegated to the background. The toll however due to these epidemics, rises unabated. Primary among them is the tobacco epidemic which continues to rage on as strongly as ever. As per the GLOBOCAN 2018 statistics, lung cancer has overtaken oral cancer and become the primary killer among men with cancers in India. The toll on families where tobacco use is prevalent is manifold including physical, psychological and economic hardship.\r\n\r\nWith that comes the role of fathers in the family who hold a special place in every child\'s life. Like mothers they are the pillars in the development of a child’s emotional, psychological and physical well-being. Children look to their fathers to lay down the rules and enforce them. They also look to their fathers to provide a feeling of security in both physical and mental ways. Children want to make their fathers proud, and an involved father promotes inner growth and strength. Studies have shown that when fathers are affectionate and supportive, it greatly affects a child’s cognitive and social development. It also instils an overall sense of well-being and self-confidence. Hence, they need to cut down on the illicit habits like smoking or vaping and drinking for the betterment of their family.\r\n\r\nAlso, for couples who are planning on family can get effected. As smoking relatively affects the fertility rate in men and may result in abnormal hormone levels, which can affect their fertility hence making it a difficult choice for them to become fathers. Also, at the same time studies have shown a possible decrease in female fertility when women are exposed to second-hand smoking. Smoking has been linked to an increased risk for many cancers, heart disease, emphysema, and a number of other health problems.\r\n\r\nCigarettes and beedis are known to contain over 4000 harmful chemicals including nearly 70 proven carcinogens. Tobacco use not only leads to cancer but it affects nearly every organ system in the body. In fact, as per the World Health Organisation fact sheet on tobacco in India released in 2018, 48% of tobacco related deaths are due to cardio-vascular diseases. A further 25% of mortality is due to chronic lung disease and 10% of tobacco related mortality is due to cancer.\r\n\r\nLung cancer is not the only cancer that tobacco causes. The list includes oral cancers, genito-urinary cancers, stomach cancers where tobacco use has been identified as the primary culprit. In India, tobacco takes 1 life every 8 seconds. Although the numbers just talk about the direct results of tobacco use, what gets lost in all the statistics is the untold misery and misfortune that this heaps on the whole family.\r\n\r\nChildren becoming exposed to smoking because of use by a parent has become an increasingly worrisome trend. Nearly 20-25% of the under 15 years population get exposed to second hand smoking at home. And since parents are the predominant role models for children, at this impressionable stage tobacco usage can be viewed as an acceptable habit and children may be encouraged to take up the same. In fact, some statistics state that in India, nearly 5000 children begin consuming tobacco every day while they must have got influenced by their parent smoking at some point of their life.\r\n\r\nSuccessive governments have taken up the issue of tobacco control and have come up with a host of measures. Some of them include, banning the advertisement of tobacco related products in public places, increasing the size of pictorial warnings and increasing the taxes on tobacco products substantially. In fact, the average expenditure on cigarettes nearly tripled between 2009 and 2017 and the expenditure on beedis doubled in the same period. This policy of economic deterrence is also bearing fruit with the number of tobacco users reducing by 8.1 million in 2017 compared to 2009 as reported by GATS surveys.\r\n\r\nThe benefit of stopping tobacco use starts on day 1 of stopping tobacco and these health benefits are sustained throughout the lifetime. Within 20 minutes of stopping smoking, the heart rate and blood pressure reduces. After 12 hours, the carbon monoxide levels in the blood normalises. After 2 weeks to 3 months of quitting, the circulation improves and lung function increases. After 1 year of quitting smoking, the excess risk of coronary heart disease is half that of someone who still smokes. After 5 years of quitting smoking, risk of cancers of the mouth, throat, oesophagus, and bladder is cut in half. In fact, within 10 years of stopping tobacco use, the risk of dying from lung cancer is reduced by 50% to that of a person who is still smoking.\r\n\r\nFor tobacco control measures to be successful, not only the young and impressionable, but people of all age groups need to be targeted. The best would be to never take up this dangerous habit, but it is never too late to quit. On the occasion of Father’s day, each and every parent must take a pledge to set a healthy precedent for the next generation. Taking this forward, every enlightened youth must also actively engage with the previous generation in convincing them that a tobacco free future is the best way to ensure that many more father’s days will be celebrated in the coming years.','How stopping smoking can make fathers the genuine legends of their youngsters!','','publish','open','open','','how-stopping-smoking-can-make-fathers-the-genuine-legends-of-their-youngsters','','','2020-06-21 07:13:43','2020-06-21 07:13:43','',0,'https://microbiozindia.com/?p=6258',0,'post','',0),(6259,2,'2020-06-21 07:13:32','2020-06-21 07:13:32','','stop-4036139_640','','inherit','open','closed','','stop-4036139_640','','','2020-06-21 07:13:32','2020-06-21 07:13:32','',6258,'https://microbiozindia.com/wp-content/uploads/2020/06/stop-4036139_640.jpg',0,'attachment','image/jpeg',0),(6260,2,'2020-06-21 07:13:43','2020-06-21 07:13:43','In times of a global COVID 19 pandemic, many silent epidemics are being relegated to the background. The toll however due to these epidemics, rises unabated. Primary among them is the tobacco epidemic which continues to rage on as strongly as ever. As per the GLOBOCAN 2018 statistics, lung cancer has overtaken oral cancer and become the primary killer among men with cancers in India. The toll on families where tobacco use is prevalent is manifold including physical, psychological and economic hardship.\r\n\r\nWith that comes the role of fathers in the family who hold a special place in every child\'s life. Like mothers they are the pillars in the development of a child’s emotional, psychological and physical well-being. Children look to their fathers to lay down the rules and enforce them. They also look to their fathers to provide a feeling of security in both physical and mental ways. Children want to make their fathers proud, and an involved father promotes inner growth and strength. Studies have shown that when fathers are affectionate and supportive, it greatly affects a child’s cognitive and social development. It also instils an overall sense of well-being and self-confidence. Hence, they need to cut down on the illicit habits like smoking or vaping and drinking for the betterment of their family.\r\n\r\nAlso, for couples who are planning on family can get effected. As smoking relatively affects the fertility rate in men and may result in abnormal hormone levels, which can affect their fertility hence making it a difficult choice for them to become fathers. Also, at the same time studies have shown a possible decrease in female fertility when women are exposed to second-hand smoking. Smoking has been linked to an increased risk for many cancers, heart disease, emphysema, and a number of other health problems.\r\n\r\nCigarettes and beedis are known to contain over 4000 harmful chemicals including nearly 70 proven carcinogens. Tobacco use not only leads to cancer but it affects nearly every organ system in the body. In fact, as per the World Health Organisation fact sheet on tobacco in India released in 2018, 48% of tobacco related deaths are due to cardio-vascular diseases. A further 25% of mortality is due to chronic lung disease and 10% of tobacco related mortality is due to cancer.\r\n\r\nLung cancer is not the only cancer that tobacco causes. The list includes oral cancers, genito-urinary cancers, stomach cancers where tobacco use has been identified as the primary culprit. In India, tobacco takes 1 life every 8 seconds. Although the numbers just talk about the direct results of tobacco use, what gets lost in all the statistics is the untold misery and misfortune that this heaps on the whole family.\r\n\r\nChildren becoming exposed to smoking because of use by a parent has become an increasingly worrisome trend. Nearly 20-25% of the under 15 years population get exposed to second hand smoking at home. And since parents are the predominant role models for children, at this impressionable stage tobacco usage can be viewed as an acceptable habit and children may be encouraged to take up the same. In fact, some statistics state that in India, nearly 5000 children begin consuming tobacco every day while they must have got influenced by their parent smoking at some point of their life.\r\n\r\nSuccessive governments have taken up the issue of tobacco control and have come up with a host of measures. Some of them include, banning the advertisement of tobacco related products in public places, increasing the size of pictorial warnings and increasing the taxes on tobacco products substantially. In fact, the average expenditure on cigarettes nearly tripled between 2009 and 2017 and the expenditure on beedis doubled in the same period. This policy of economic deterrence is also bearing fruit with the number of tobacco users reducing by 8.1 million in 2017 compared to 2009 as reported by GATS surveys.\r\n\r\nThe benefit of stopping tobacco use starts on day 1 of stopping tobacco and these health benefits are sustained throughout the lifetime. Within 20 minutes of stopping smoking, the heart rate and blood pressure reduces. After 12 hours, the carbon monoxide levels in the blood normalises. After 2 weeks to 3 months of quitting, the circulation improves and lung function increases. After 1 year of quitting smoking, the excess risk of coronary heart disease is half that of someone who still smokes. After 5 years of quitting smoking, risk of cancers of the mouth, throat, oesophagus, and bladder is cut in half. In fact, within 10 years of stopping tobacco use, the risk of dying from lung cancer is reduced by 50% to that of a person who is still smoking.\r\n\r\nFor tobacco control measures to be successful, not only the young and impressionable, but people of all age groups need to be targeted. The best would be to never take up this dangerous habit, but it is never too late to quit. On the occasion of Father’s day, each and every parent must take a pledge to set a healthy precedent for the next generation. Taking this forward, every enlightened youth must also actively engage with the previous generation in convincing them that a tobacco free future is the best way to ensure that many more father’s days will be celebrated in the coming years.','How stopping smoking can make fathers the genuine legends of their youngsters!','','inherit','closed','closed','','6258-revision-v1','','','2020-06-21 07:13:43','2020-06-21 07:13:43','',6258,'https://microbiozindia.com/uncategorized/6258-revision-v1/',0,'revision','',0),(6261,2,'2020-06-21 09:03:35','2020-06-21 09:03:35','The global Screw Threaded Glass Culture Tubes market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> Culture Tubes are widely used in Laboratories, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Microbiology\">Microbiology</a></span>, Pharmapackaging Industries and Educational Institutes.\r\n\r\n<strong>Here I am sharing you the significant facts of using about Glass Culture tubes:</strong>\r\n\r\n1. Glass is ubiquitous in the chemistry laboratory, but not all glass is the same. Glass Culture Tubes are made from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> having Coefficient of Liner <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Thermal_expansion\">Thermal Expansion</a></span> is 3.3 or 5.1.\r\n2. Mechanical Strength &amp; Thermal Shock resistance – Glass Culture Tubes are annealed in special chamber wherein the stress are developed during the manufacturing process is eliminated with a controlled heating and cooling process.\r\n3. Their round bottom and vertical sides reduce fluid and mass loss while pouring. Also, the round bottom makes it easier to wash out, and allow convenient monitoring of the contents.\r\n4. The slimness of the Glass culture tube efficiently reduces the spread of any vapors that may be produced by the reaction.\r\n5. Chemical Durability – Glass Culture Tubes are resistant to attack from acids,salt solutions and organic solvents.\r\n\r\n<strong>Hindustan Glass works, Ambala Haryana</strong> Based Manufacturer offers Glass Culture Tubes in Both CLE 3.3 and 5.1 Expansions that can be used for many laboratory applications. Biologically inert and exempt from mold release agents, these <strong>Hindustan Glass Works culture tubes</strong> prevent errors, contamination, and interferences in <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Radioimmunoassay\">RIA tests</a></span>. Designed with precise molding and uniforms in shape, these culture tubes are chemically clean and ready to use.\r\n\r\n“We constantly develop new technologies and understand the customer needs which differentiate us from our competitors. We use best quality raw material <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> CLE 3.3 and CLE 5.1 which is the backbone of our products. Quality consistency is very prominent for manufacturing our Glass Culture Tubes and Glass Vials,” says <strong>Sahil Jain, Managing Director, Hindustan Glass Works India.</strong>\r\nHindustan Glass works exports Glass Culture Tubes, EPA Vials, Injectable Vials to Saudi Arabia, Iran, Israel, USA, Canada and other countries.\r\n<blockquote>“Objectives are established so that we can always provide first class timely services to the demanding requirements of our customers. As a part of our commitment to continuous improvement, systems are established to ensure that we measure the performance of our process, review, and revise our policies when necessary,” signs off <strong>Sahil Jain.</strong></blockquote>\r\nFor more information:\r\n\r\n<strong>Hindustan Glass works India</strong>\r\n\r\n<strong>Email: sales@hgwindia.com</strong>\r\n\r\n<img class=\"alignnone  wp-image-6263\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/logo-300x172.png\" alt=\"\" width=\"234\" height=\"134\" />\r\n\r\n<strong><span style=\"text-decoration: underline;\">Tags;</span></strong>\r\n\r\n<span style=\"text-decoration: underline;\">glass culture tubes with caps glass culture tubes with caps,glass culture tubes with screw cap glass culture tubes with screw cap,glass culture tubes with screw caps glass culture tubes with screw caps</span>','5 Important Facts That You Should Know About Laboratory Glass Culture Tubes','','publish','open','open','','5-important-facts-that-you-should-know-about-laboratory-glass-culture-tubes','','','2020-06-21 09:03:35','2020-06-21 09:03:35','',0,'https://microbiozindia.com/?p=6261',0,'post','',0),(6262,2,'2020-06-21 08:52:12','2020-06-21 08:52:12','','HW','','inherit','open','closed','','hw','','','2020-06-21 08:52:12','2020-06-21 08:52:12','',6261,'https://microbiozindia.com/wp-content/uploads/2020/06/HW.png',0,'attachment','image/png',0),(6263,2,'2020-06-21 08:52:20','2020-06-21 08:52:20','','logo','','inherit','open','closed','','logo','','','2020-06-21 08:52:20','2020-06-21 08:52:20','',6261,'https://microbiozindia.com/wp-content/uploads/2020/06/logo.png',0,'attachment','image/png',0),(6264,2,'2020-06-21 09:03:35','2020-06-21 09:03:35','The global Screw Threaded Glass Culture Tubes market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> Culture Tubes are widely used in Laboratories, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Microbiology\">Microbiology</a></span>, Pharmapackaging Industries and Educational Institutes.\r\n\r\n<strong>Here I am sharing you the significant facts of using about Glass Culture tubes:</strong>\r\n\r\n1. Glass is ubiquitous in the chemistry laboratory, but not all glass is the same. Glass Culture Tubes are made from <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> having Coefficient of Liner <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Thermal_expansion\">Thermal Expansion</a></span> is 3.3 or 5.1.\r\n2. Mechanical Strength &amp; Thermal Shock resistance – Glass Culture Tubes are annealed in special chamber wherein the stress are developed during the manufacturing process is eliminated with a controlled heating and cooling process.\r\n3. Their round bottom and vertical sides reduce fluid and mass loss while pouring. Also, the round bottom makes it easier to wash out, and allow convenient monitoring of the contents.\r\n4. The slimness of the Glass culture tube efficiently reduces the spread of any vapors that may be produced by the reaction.\r\n5. Chemical Durability – Glass Culture Tubes are resistant to attack from acids,salt solutions and organic solvents.\r\n\r\n<strong>Hindustan Glass works, Ambala Haryana</strong> Based Manufacturer offers Glass Culture Tubes in Both CLE 3.3 and 5.1 Expansions that can be used for many laboratory applications. Biologically inert and exempt from mold release agents, these <strong>Hindustan Glass Works culture tubes</strong> prevent errors, contamination, and interferences in <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Radioimmunoassay\">RIA tests</a></span>. Designed with precise molding and uniforms in shape, these culture tubes are chemically clean and ready to use.\r\n\r\n“We constantly develop new technologies and understand the customer needs which differentiate us from our competitors. We use best quality raw material <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://en.wikipedia.org/wiki/Borosilicate_glass\">Borosilicate Glass</a></span> CLE 3.3 and CLE 5.1 which is the backbone of our products. Quality consistency is very prominent for manufacturing our Glass Culture Tubes and Glass Vials,” says <strong>Sahil Jain, Managing Director, Hindustan Glass Works India.</strong>\r\nHindustan Glass works exports Glass Culture Tubes, EPA Vials, Injectable Vials to Saudi Arabia, Iran, Israel, USA, Canada and other countries.\r\n<blockquote>“Objectives are established so that we can always provide first class timely services to the demanding requirements of our customers. As a part of our commitment to continuous improvement, systems are established to ensure that we measure the performance of our process, review, and revise our policies when necessary,” signs off <strong>Sahil Jain.</strong></blockquote>\r\nFor more information:\r\n\r\n<strong>Hindustan Glass works India</strong>\r\n\r\n<strong>Email: sales@hgwindia.com</strong>\r\n\r\n<img class=\"alignnone  wp-image-6263\" src=\"https://microbiozindia.com/wp-content/uploads/2020/06/logo-300x172.png\" alt=\"\" width=\"234\" height=\"134\" />\r\n\r\n<strong><span style=\"text-decoration: underline;\">Tags;</span></strong>\r\n\r\n<span style=\"text-decoration: underline;\">glass culture tubes with caps glass culture tubes with caps,glass culture tubes with screw cap glass culture tubes with screw cap,glass culture tubes with screw caps glass culture tubes with screw caps</span>','5 Important Facts That You Should Know About Laboratory Glass Culture Tubes','','inherit','closed','closed','','6261-revision-v1','','','2020-06-21 09:03:35','2020-06-21 09:03:35','',6261,'https://microbiozindia.com/uncategorized/6261-revision-v1/',0,'revision','',0),(6265,2,'2020-06-21 15:17:47','2020-06-21 15:17:47','Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.\r\n\r\nCipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need. As part of a risk management plan, Cipla will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients.\r\n<iframe src=\"https://www.youtube.com/embed/gA8m1ffz-cM\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nAccording to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study1, a randomized clinical trial conducted with remdesivir in 1063 patients over 60 centres across U.S., Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator. The mortality rates in the study were 7.1% in those given remdesivir and 11.9% in those who were given placebo.\r\n\r\nAs part of its efforts to enable speedy and equitable access to this treatment and in anticipation of demand, Cipla will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through Government and open market channels, to ensure equitable distribution.\r\n\r\nCommenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, “Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction. We will continue to collaborate with all stakeholders in the healthcare ecosystem towards providing access to such promising treatments in furtherance with our belief that no patient should be denied access to life-saving treatments.”','Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg','','publish','open','open','','cipla-launches-cipremiremdesivir-lyophilised-powder-for-injection-100-mg','','','2020-06-21 16:08:38','2020-06-21 16:08:38','',0,'https://microbiozindia.com/?p=6265',0,'post','',0),(6266,2,'2020-06-21 15:17:47','2020-06-21 15:17:47','Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.\r\n\r\nCipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need. As part of a risk management plan, Cipla will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients.\r\n\r\nAccording to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study1, a randomized clinical trial conducted with remdesivir in 1063 patients over 60 centres across U.S., Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator. The mortality rates in the study were 7.1% in those given remdesivir and 11.9% in those who were given placebo.\r\n\r\nAs part of its efforts to enable speedy and equitable access to this treatment and in anticipation of demand, Cipla will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through Government and open market channels, to ensure equitable distribution.\r\n\r\nCommenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, “Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction. We will continue to collaborate with all stakeholders in the healthcare ecosystem towards providing access to such promising treatments in furtherance with our belief that no patient should be denied access to life-saving treatments.”','Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg','','inherit','closed','closed','','6265-revision-v1','','','2020-06-21 15:17:47','2020-06-21 15:17:47','',6265,'https://microbiozindia.com/uncategorized/6265-revision-v1/',0,'revision','',0),(6267,2,'2020-06-21 16:08:38','2020-06-21 16:08:38','Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced the launch of remdesivir under its brand name CIPREMI. The U.S. FDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only U.S. FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.\r\n\r\nCipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need. As part of a risk management plan, Cipla will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients.\r\n<iframe src=\"https://www.youtube.com/embed/gA8m1ffz-cM\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\nAccording to a preliminary report from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study1, a randomized clinical trial conducted with remdesivir in 1063 patients over 60 centres across U.S., Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. Most of these patients were on oxygen therapy of which some were receiving high flow oxygen or non-invasive ventilation, and some were on a mechanical ventilator. The mortality rates in the study were 7.1% in those given remdesivir and 11.9% in those who were given placebo.\r\n\r\nAs part of its efforts to enable speedy and equitable access to this treatment and in anticipation of demand, Cipla will be commercialising remdesivir through its own facilities and partnered sites. The drug will be supplied through Government and open market channels, to ensure equitable distribution.\r\n\r\nCommenting on the launch, Mr. Umang Vohra (MD and Global CEO, Cipla Limited) said, “Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction. We will continue to collaborate with all stakeholders in the healthcare ecosystem towards providing access to such promising treatments in furtherance with our belief that no patient should be denied access to life-saving treatments.”','Cipla launches Cipremi:remdesivir lyophilised powder for injection 100 mg','','inherit','closed','closed','','6265-revision-v1','','','2020-06-21 16:08:38','2020-06-21 16:08:38','',6265,'https://microbiozindia.com/uncategorized/6265-revision-v1/',0,'revision','',0),(6268,2,'2020-06-22 09:24:55','2020-06-22 09:24:55','Porvair Sciences announce Microlute&#x2122; CP - a new generation of Solid Phase Extraction (SPE) 96-well microplates and cartridges that take SPE to a new level of performance by enhancing the reproducibility of analyte extraction and recovery from biological, environmental and chemical samples.\r\n\r\nUnlike traditional loose-packed SPE methods, Microlute CP uses a hybrid structure, a solid interconnected network of evenly distributed pores combined with the retentive media. This unique design enhances the flow-through of samples to maximise interactions between analytes and the solid phase to deliver an unmatched reproducible SPE method that excels in performance, cleanliness and sensitivity.\r\n\r\nMicrolute CP microplates and cartridges benefit from a recent technological development which enables immobilisation of active media within the structure of Vyon®, a porous plastic to form a structured interconnected network of even distributed pores. This hybrid technology results in the formation of a chemically active porous filter, a unique structure that overcomes inconsistencies and variabilities often associated with loose-packed methods.\r\n\r\nThe porous properties of Microlute CP allows for consistent and controlled flow of samples throughout the filter leading to overall better extraction and recovery performance. Meanwhile, the single solid structure used in Microlute CP plates eliminates the need for multiple porous filters for media support which can further disrupt flow rates and lead to unwanted material breakthrough. These technological advances have given rise to a new SPE methodology that extracts and cleans up your samples with enhanced reproducibility (&lt; 4% RSD) meaning you can have greater confidence in results. With no flow-through or packing variability - Microlute CP is the perfect SPE sample preparation tool for high throughput analysis.\r\n\r\nOther benefits of the efficient sample clean-up and concentration provided by Microlute CP include cost savings due to reduced need for replicating results; reduced analysis time due to the even emptying of wells; less solvent use compared to LLE and SLE methods as well as increased limit of detection (LoD) and quantification (LoQ). In addition, Microlute CP delivers cleaner samples thereby enabling you to achieve longer column life and reduced system downtime.\r\n\r\nFor further information about the Microlute&#x2122; CP range of Solid Phase Extraction (SPE) 96-well microplates and cartridges please visit https://www.microplates.com/microlute-cp/ or contact Porvair Sciences Ltd on +44-1978-661144 / enquiries@porvairsciences.com.\r\n\r\nPorvair Sciences are global leaders and original manufacturers and developers of cutting-edge porous plastics technologies. With patents dating back to the 1950\'s, our porous plastics continue to evolve, adapt and respond to changes in technologies, markets and customer needs. Empowered by 50 years of industrial experience, we strive to continue delivering world class, high performing products while providing superior customer service, every step of the way. Our diverse team of scientists, engineers and creative thinkers are committed to providing expert solutions that brings value and integrity to our customers.','Highly Reproducible Solid Phase Extraction','','publish','open','open','','highly-reproducible-solid-phase-extraction','','','2020-06-22 09:24:55','2020-06-22 09:24:55','',0,'https://microbiozindia.com/?p=6268',0,'post','',0),(6269,2,'2020-06-22 09:24:22','2020-06-22 09:24:22','','porvairpr547-image','','inherit','open','closed','','porvairpr547-image','','','2020-06-22 09:24:22','2020-06-22 09:24:22','',6268,'https://microbiozindia.com/wp-content/uploads/2020/06/porvairpr547-image.jpg',0,'attachment','image/jpeg',0),(6270,2,'2020-06-22 09:24:55','2020-06-22 09:24:55','Porvair Sciences announce Microlute&#x2122; CP - a new generation of Solid Phase Extraction (SPE) 96-well microplates and cartridges that take SPE to a new level of performance by enhancing the reproducibility of analyte extraction and recovery from biological, environmental and chemical samples.\r\n\r\nUnlike traditional loose-packed SPE methods, Microlute CP uses a hybrid structure, a solid interconnected network of evenly distributed pores combined with the retentive media. This unique design enhances the flow-through of samples to maximise interactions between analytes and the solid phase to deliver an unmatched reproducible SPE method that excels in performance, cleanliness and sensitivity.\r\n\r\nMicrolute CP microplates and cartridges benefit from a recent technological development which enables immobilisation of active media within the structure of Vyon®, a porous plastic to form a structured interconnected network of even distributed pores. This hybrid technology results in the formation of a chemically active porous filter, a unique structure that overcomes inconsistencies and variabilities often associated with loose-packed methods.\r\n\r\nThe porous properties of Microlute CP allows for consistent and controlled flow of samples throughout the filter leading to overall better extraction and recovery performance. Meanwhile, the single solid structure used in Microlute CP plates eliminates the need for multiple porous filters for media support which can further disrupt flow rates and lead to unwanted material breakthrough. These technological advances have given rise to a new SPE methodology that extracts and cleans up your samples with enhanced reproducibility (&lt; 4% RSD) meaning you can have greater confidence in results. With no flow-through or packing variability - Microlute CP is the perfect SPE sample preparation tool for high throughput analysis.\r\n\r\nOther benefits of the efficient sample clean-up and concentration provided by Microlute CP include cost savings due to reduced need for replicating results; reduced analysis time due to the even emptying of wells; less solvent use compared to LLE and SLE methods as well as increased limit of detection (LoD) and quantification (LoQ). In addition, Microlute CP delivers cleaner samples thereby enabling you to achieve longer column life and reduced system downtime.\r\n\r\nFor further information about the Microlute&#x2122; CP range of Solid Phase Extraction (SPE) 96-well microplates and cartridges please visit https://www.microplates.com/microlute-cp/ or contact Porvair Sciences Ltd on +44-1978-661144 / enquiries@porvairsciences.com.\r\n\r\nPorvair Sciences are global leaders and original manufacturers and developers of cutting-edge porous plastics technologies. With patents dating back to the 1950\'s, our porous plastics continue to evolve, adapt and respond to changes in technologies, markets and customer needs. Empowered by 50 years of industrial experience, we strive to continue delivering world class, high performing products while providing superior customer service, every step of the way. Our diverse team of scientists, engineers and creative thinkers are committed to providing expert solutions that brings value and integrity to our customers.','Highly Reproducible Solid Phase Extraction','','inherit','closed','closed','','6268-revision-v1','','','2020-06-22 09:24:55','2020-06-22 09:24:55','',6268,'https://microbiozindia.com/uncategorized/6268-revision-v1/',0,'revision','',0),(6271,2,'2020-06-22 09:34:43','2020-06-22 09:34:43','A group of researchers in Singapore has found 5 antibodies that can square coronavirus and ensure against the key changes created in the infection during the pandemic, as indicated by the nation\'s protection innovative work association, Defense Science Organization (DSO). PTI revealed that the human preliminaries for the lead immune response, AOD01 will start in the up and coming a long time in the wake of getting endorsement from the Health Sciences Authority.\r\n\r\nResearchers at the DSO have screened \"many thousands\" of B cells from the blood tests of the novel coronavirus patients who have recuperated since March this year. B cells are the cells that produce antibodies to target pathogens. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.financialexpress.com/lifestyle/health/singapore-scientists-discover-5-antibodies-that-can-combat-covid-19/1994515/\">The researchers figured out how to disconnect the initial two antibodies for testing inside a month of getting these blood tests from the National Center for Infectious Diseases and Singapore General Hospital.</a></span>\r\n\r\nAnother three compelling antibodies were, be that as it may, distinguished three months after the fact through a procedure wherein B cells are screened at the same time with the live infection, permitting antibodies with successful infection killing properties to be recognized. As per a Channel News Asia report, this method was grown mutually by the DSO, National University of Singapore\'s Yong Loo Lin School of Medicine and Life Sciences Institute in the course of recent years.\r\n\r\nResults demonstrate that these five antibodies \"show balance\" against coronavirus, the DSO said. It further included that these antibodies are \"all powerful in blocking disease and viable against key transformations that have developed in the infection during the pandemic.\"\r\n\r\nAs per Dr Conrad Chan, a senior researcher at DSO, the examination stage is presently finished and the investigation is currently changing into the preclinical stage, where the group is setting up this counter acting agent for creation. Dr Chan further said that this will permit clinical preliminaries to be directed and assembling will be increase if human preliminaries are fruitful.','Singapore researchers find 5 antibodies that can battle COVID-19','','publish','open','open','','singapore-researchers-find-5-antibodies-that-can-battle-covid-19','','','2020-06-22 09:34:43','2020-06-22 09:34:43','',0,'https://microbiozindia.com/?p=6271',0,'post','',0),(6272,2,'2020-06-22 09:34:43','2020-06-22 09:34:43','A group of researchers in Singapore has found 5 antibodies that can square coronavirus and ensure against the key changes created in the infection during the pandemic, as indicated by the nation\'s protection innovative work association, Defense Science Organization (DSO). PTI revealed that the human preliminaries for the lead immune response, AOD01 will start in the up and coming a long time in the wake of getting endorsement from the Health Sciences Authority.\r\n\r\nResearchers at the DSO have screened \"many thousands\" of B cells from the blood tests of the novel coronavirus patients who have recuperated since March this year. B cells are the cells that produce antibodies to target pathogens. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.financialexpress.com/lifestyle/health/singapore-scientists-discover-5-antibodies-that-can-combat-covid-19/1994515/\">The researchers figured out how to disconnect the initial two antibodies for testing inside a month of getting these blood tests from the National Center for Infectious Diseases and Singapore General Hospital.</a></span>\r\n\r\nAnother three compelling antibodies were, be that as it may, distinguished three months after the fact through a procedure wherein B cells are screened at the same time with the live infection, permitting antibodies with successful infection killing properties to be recognized. As per a Channel News Asia report, this method was grown mutually by the DSO, National University of Singapore\'s Yong Loo Lin School of Medicine and Life Sciences Institute in the course of recent years.\r\n\r\nResults demonstrate that these five antibodies \"show balance\" against coronavirus, the DSO said. It further included that these antibodies are \"all powerful in blocking disease and viable against key transformations that have developed in the infection during the pandemic.\"\r\n\r\nAs per Dr Conrad Chan, a senior researcher at DSO, the examination stage is presently finished and the investigation is currently changing into the preclinical stage, where the group is setting up this counter acting agent for creation. Dr Chan further said that this will permit clinical preliminaries to be directed and assembling will be increase if human preliminaries are fruitful.','Singapore researchers find 5 antibodies that can battle COVID-19','','inherit','closed','closed','','6271-revision-v1','','','2020-06-22 09:34:43','2020-06-22 09:34:43','',6271,'https://microbiozindia.com/uncategorized/6271-revision-v1/',0,'revision','',0),(6273,2,'2020-06-22 17:19:08','2020-06-22 17:19:08','Cannabidivarinic Acid (CBDVA) is a non-psychoactive cannabinoid answered to have mitigating properties. While its therapeutic advantages are as yet being explored, evaluating this compound in cannabis tests is significant for getting a genuine estimation of strength and chemovar distinguishing proof. Restek now offers another CBDVA confirmed reference material (CRM) to assist labs with propelling their examination of cannabis.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.restek.com/news/view/?tag=reference-standards\">Restek\'s new CBDVA standard is perfect for making multipoint (5-point least recommended) alignment bends for LC investigation.</a> </span>With confirmed piece and strength, this readied stock item takes out the requirement for in-house measures groundwork for more prominent comfort and lower work necessities. As it\'s rejected from U.S. DEA Controlled Substances Act (CSA) administrative controls, no client allows or permitting required to buy inside the U.S., and in light of the fact that it\'s produced and QC tried in Restek\'s ISO-certify labs, this new CBDVA standard qualifies as a confirmed reference material (CRM) that fulfills your ISO prerequisites.\r\n\r\nFor CBDVA and other reference norms, Raptor LC sections, test readiness items, and the master meeting your cannabis lab needs.\r\n\r\nFor more information:<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.restek.com/news/view/?tag=reference-standards\">https://www.restek.com/news/view/?tag=reference-standards </a></span>','Advance your examination of cannabis with Restek\'s new Cannabidivarinic Acid norm','','publish','open','open','','advance-your-examination-of-cannabis-with-resteks-new-cannabidivarinic-acid-norm','','','2020-06-22 17:19:08','2020-06-22 17:19:08','',0,'https://microbiozindia.com/?p=6273',0,'post','',0),(6274,2,'2020-06-22 17:16:28','2020-06-22 17:16:28','','cannabis-2152604_640','','inherit','open','closed','','cannabis-2152604_640','','','2020-06-22 17:16:28','2020-06-22 17:16:28','',6273,'https://microbiozindia.com/wp-content/uploads/2020/06/cannabis-2152604_640.jpg',0,'attachment','image/jpeg',0),(6275,2,'2020-06-22 17:19:08','2020-06-22 17:19:08','Cannabidivarinic Acid (CBDVA) is a non-psychoactive cannabinoid answered to have mitigating properties. While its therapeutic advantages are as yet being explored, evaluating this compound in cannabis tests is significant for getting a genuine estimation of strength and chemovar distinguishing proof. Restek now offers another CBDVA confirmed reference material (CRM) to assist labs with propelling their examination of cannabis.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.restek.com/news/view/?tag=reference-standards\">Restek\'s new CBDVA standard is perfect for making multipoint (5-point least recommended) alignment bends for LC investigation.</a> </span>With confirmed piece and strength, this readied stock item takes out the requirement for in-house measures groundwork for more prominent comfort and lower work necessities. As it\'s rejected from U.S. DEA Controlled Substances Act (CSA) administrative controls, no client allows or permitting required to buy inside the U.S., and in light of the fact that it\'s produced and QC tried in Restek\'s ISO-certify labs, this new CBDVA standard qualifies as a confirmed reference material (CRM) that fulfills your ISO prerequisites.\r\n\r\nFor CBDVA and other reference norms, Raptor LC sections, test readiness items, and the master meeting your cannabis lab needs.\r\n\r\nFor more information:<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.restek.com/news/view/?tag=reference-standards\">https://www.restek.com/news/view/?tag=reference-standards </a></span>','Advance your examination of cannabis with Restek\'s new Cannabidivarinic Acid norm','','inherit','closed','closed','','6273-revision-v1','','','2020-06-22 17:19:08','2020-06-22 17:19:08','',6273,'https://microbiozindia.com/uncategorized/6273-revision-v1/',0,'revision','',0),(6277,2,'2020-06-23 07:01:30','2020-06-23 07:01:30','French drugmaker Sanofi SA, said on June 23, it hopes to get endorsement for the potential COVID-19 antibody it is creating with Britain\'s GlaxoSmithKline Plc by the primary portion of one year from now, quicker than recently envisioned.\r\n\r\nSanofi, which is facilitating a virtual innovative work occasion, and GSK had said in April the immunization, if fruitful, would be accessible in the second 50% of 2021.\r\n\r\n\"We are being guided by our discourse with administrative specialists,\" Sanofi research boss John Reed outlined for columnists, when gotten some information about the quickened time period.\r\n\r\nThere are right now no antibodies to forestall the coronavirus that has contaminated in excess of 90 lakh individuals and slaughtered over 4.6 lakh all around, and just two or three drugs that have shown advantage in hospitalized COVID-19 patients in clinical preliminaries.\r\n\r\nNumerous drugmakers have set out in a race to concoct a protected and successful antibody that can be delivered everywhere scale.\r\n\r\nModerna Inc, the University of Oxford in a joint effort with AstraZeneca Plc, and a union of BioNTech and Pfizer Inc snatched features by moving to human preliminaries as ahead of schedule as March.\r\n\r\nSanofi Chief Executive Paul Hudson said the firsts in the race presently were not guaranteed of making sure about triumph.\r\n\r\n\"There are organizations moving quicker, however let us be mercilessly clear, speed has three drawbacks,\" he said of rivalry.\r\n\r\n\"They are utilizing existing work, much of the time accomplished for SARS; it is likely not to be as effective; and there is no assurance on gracefully in enormous volumes,\" Hudson said.\r\n\r\nAdditionally read: COVID-19 treatment | Gilead to start clinical preliminaries of breathed in rendition of remdesivir\r\n\r\nThe likelihood of progress for Sanofi is \"higher than any other individual,\" the CEO said.\r\n\r\nThe remarks resounded those of GSK, whose central clinical official for immunizations told Reuters on June 19 the organization was focusing on quality before speed.\r\n\r\nSanofi, whose Pasteur immunizations division has a since quite a while ago settled notoriety, remarkably in influenza, is as of now chipping away at two antibody ventures.\r\n\r\nOne uses an adjuvant made by GSK to conceivably help its viability. It has gotten monetary help from the U.S. Biomedical Advanced Research and Development Authority (BARDA).\r\n\r\nThe other, being created with U.S. organization Translate Bio Inc, depends on an alternate innovation known as mRNA, like the Moderna approach.\r\n\r\nClinical preliminaries of the immunization created with GSK, portrayed as a recombinant antibody due to the utilization of GSK\'s boosting adjuvant, are to begin in September. Preliminaries of the mRNA antibody up-and-comer should start around the year\'s end, the organization said.\r\n\r\nSanofi said it had ability to deliver up to 1 billion dosages per year of its recombinant antibody, and that it is ready to gracefully up to 360 million portions of its mRNA immunization every year.\r\n\r\nIn April, Sanofi said it had fabricating limit with respect to 600 million portions for its recombinant antibody, with the aspiration to twofold creation by mid-2021.','Sanofi eyes endorsement of COVID-19 immunization by first 50% of 2021','','publish','open','open','','sanofi-eyes-endorsement-of-covid-19-immunization-by-first-50-of-2021','','','2020-06-23 07:01:30','2020-06-23 07:01:30','',0,'https://microbiozindia.com/?p=6277',0,'post','',0),(6278,2,'2020-06-23 07:01:30','2020-06-23 07:01:30','French drugmaker Sanofi SA, said on June 23, it hopes to get endorsement for the potential COVID-19 antibody it is creating with Britain\'s GlaxoSmithKline Plc by the primary portion of one year from now, quicker than recently envisioned.\r\n\r\nSanofi, which is facilitating a virtual innovative work occasion, and GSK had said in April the immunization, if fruitful, would be accessible in the second 50% of 2021.\r\n\r\n\"We are being guided by our discourse with administrative specialists,\" Sanofi research boss John Reed outlined for columnists, when gotten some information about the quickened time period.\r\n\r\nThere are right now no antibodies to forestall the coronavirus that has contaminated in excess of 90 lakh individuals and slaughtered over 4.6 lakh all around, and just two or three drugs that have shown advantage in hospitalized COVID-19 patients in clinical preliminaries.\r\n\r\nNumerous drugmakers have set out in a race to concoct a protected and successful antibody that can be delivered everywhere scale.\r\n\r\nModerna Inc, the University of Oxford in a joint effort with AstraZeneca Plc, and a union of BioNTech and Pfizer Inc snatched features by moving to human preliminaries as ahead of schedule as March.\r\n\r\nSanofi Chief Executive Paul Hudson said the firsts in the race presently were not guaranteed of making sure about triumph.\r\n\r\n\"There are organizations moving quicker, however let us be mercilessly clear, speed has three drawbacks,\" he said of rivalry.\r\n\r\n\"They are utilizing existing work, much of the time accomplished for SARS; it is likely not to be as effective; and there is no assurance on gracefully in enormous volumes,\" Hudson said.\r\n\r\nAdditionally read: COVID-19 treatment | Gilead to start clinical preliminaries of breathed in rendition of remdesivir\r\n\r\nThe likelihood of progress for Sanofi is \"higher than any other individual,\" the CEO said.\r\n\r\nThe remarks resounded those of GSK, whose central clinical official for immunizations told Reuters on June 19 the organization was focusing on quality before speed.\r\n\r\nSanofi, whose Pasteur immunizations division has a since quite a while ago settled notoriety, remarkably in influenza, is as of now chipping away at two antibody ventures.\r\n\r\nOne uses an adjuvant made by GSK to conceivably help its viability. It has gotten monetary help from the U.S. Biomedical Advanced Research and Development Authority (BARDA).\r\n\r\nThe other, being created with U.S. organization Translate Bio Inc, depends on an alternate innovation known as mRNA, like the Moderna approach.\r\n\r\nClinical preliminaries of the immunization created with GSK, portrayed as a recombinant antibody due to the utilization of GSK\'s boosting adjuvant, are to begin in September. Preliminaries of the mRNA antibody up-and-comer should start around the year\'s end, the organization said.\r\n\r\nSanofi said it had ability to deliver up to 1 billion dosages per year of its recombinant antibody, and that it is ready to gracefully up to 360 million portions of its mRNA immunization every year.\r\n\r\nIn April, Sanofi said it had fabricating limit with respect to 600 million portions for its recombinant antibody, with the aspiration to twofold creation by mid-2021.','Sanofi eyes endorsement of COVID-19 immunization by first 50% of 2021','','inherit','closed','closed','','6277-revision-v1','','','2020-06-23 07:01:30','2020-06-23 07:01:30','',6277,'https://microbiozindia.com/uncategorized/6277-revision-v1/',0,'revision','',0),(6279,2,'2020-06-23 08:59:52','2020-06-23 08:59:52','Postnova Analytics have published an informative new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.\r\n\r\nViruses are the scientific story of 2020 with the global Coronavirus (COVID-19) pandemic thrusting them to the forefront of almost every person’s consciousness around the world. Development of antibodies to specific viruses form the core of future immune response. Characterization of viruses, the development of vaccines, and the quantification of antibodies, has become the most important scientific pursuit for many leading labs.\r\n\r\nVaccines can be complex and may contain many species which span a large size range from antibodies, virus fragments such as proteins and nucleic acids, polysaccharide-protein complexes, up to large aggregates often over 100 nm in diameter. This means such samples are challenging to separate and characterize using column-based chromatography techniques. The new white paper explains and illustrates how AF4 techniques can help researchers in this field as it is a stationary-phase-free separation technique for characterization of polydisperse samples from about 1 nanometre to 1 micron in diameter. The AF4 technique has already been cited in a growing number of papers focusing on characterization of viruses and virus-like particles as well as antibodies, antigens, and their aggregates and agglomerates.\r\n\r\nThe white paper presents three applications using multi-detector AF4 and EAF4: Separation and characterization of Adeno-Associated Virus (AAV) monomers and their fragments or aggregates; The aggregation of two AAV serotypes after exposure to heat stress and the separation of monoclonal antibodies (mAb) and quantification of mAb aggregates.\r\n\r\nThe authors of this new white paper conclude that the open channel design of Postnova Analytics’ AF4 system has advantages over chromatographic techniques, as the absence of a stationary phase results in less sample loss due to interaction with, or filtration by, the column packing material. Further, from the data presented, it can be seen that AF4 can separate a wide range of sizes using a single method, from virus fragments less than 10 nm in radius, to large aggregates above 100 nm in radius. The powerful yet versatile AF4 technique can be equally applied to any or all the components in virus and vaccine research from small antibodies of only a few nm in size, up to large protein-polysaccharide complexes or virus particles and aggregates of well over 100 nm.\r\n\r\nFor a copy of the new white paper please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.postnova.com/news-and-events/press-releases/256-white-paper-separation-and-characterization-of-viruses-and-antibodies.html\">https://www.postnova.com/news-and-events/press-releases/256-white-paper-separation-and-characterization-of-viruses-and-antibodies.html</a></span> or contact Postnova Analytics on +49-8191-985-6880 / +44-1885-475007 / +1-801-521-2004 or info@postnova.com.','White Paper:  Separation and Characterization of Viruses and Antibodies','','publish','open','open','','white-paper-separation-and-characterization-of-viruses-and-antibodies','','','2020-06-23 08:59:52','2020-06-23 08:59:52','',0,'https://microbiozindia.com/?p=6279',0,'post','',0),(6280,2,'2020-06-23 08:56:46','2020-06-23 08:56:46','','postnova-launch-temperature-controlled-flow-field-flow-fractionation-mals-system-287823','','inherit','open','closed','','postnova-launch-temperature-controlled-flow-field-flow-fractionation-mals-system-287823','','','2020-06-23 08:56:46','2020-06-23 08:56:46','',6279,'https://microbiozindia.com/wp-content/uploads/2020/06/postnova-launch-temperature-controlled-flow-field-flow-fractionation-mals-system-287823.jpg',0,'attachment','image/jpeg',0),(6281,2,'2020-06-23 08:59:52','2020-06-23 08:59:52','Postnova Analytics have published an informative new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.\r\n\r\nViruses are the scientific story of 2020 with the global Coronavirus (COVID-19) pandemic thrusting them to the forefront of almost every person’s consciousness around the world. Development of antibodies to specific viruses form the core of future immune response. Characterization of viruses, the development of vaccines, and the quantification of antibodies, has become the most important scientific pursuit for many leading labs.\r\n\r\nVaccines can be complex and may contain many species which span a large size range from antibodies, virus fragments such as proteins and nucleic acids, polysaccharide-protein complexes, up to large aggregates often over 100 nm in diameter. This means such samples are challenging to separate and characterize using column-based chromatography techniques. The new white paper explains and illustrates how AF4 techniques can help researchers in this field as it is a stationary-phase-free separation technique for characterization of polydisperse samples from about 1 nanometre to 1 micron in diameter. The AF4 technique has already been cited in a growing number of papers focusing on characterization of viruses and virus-like particles as well as antibodies, antigens, and their aggregates and agglomerates.\r\n\r\nThe white paper presents three applications using multi-detector AF4 and EAF4: Separation and characterization of Adeno-Associated Virus (AAV) monomers and their fragments or aggregates; The aggregation of two AAV serotypes after exposure to heat stress and the separation of monoclonal antibodies (mAb) and quantification of mAb aggregates.\r\n\r\nThe authors of this new white paper conclude that the open channel design of Postnova Analytics’ AF4 system has advantages over chromatographic techniques, as the absence of a stationary phase results in less sample loss due to interaction with, or filtration by, the column packing material. Further, from the data presented, it can be seen that AF4 can separate a wide range of sizes using a single method, from virus fragments less than 10 nm in radius, to large aggregates above 100 nm in radius. The powerful yet versatile AF4 technique can be equally applied to any or all the components in virus and vaccine research from small antibodies of only a few nm in size, up to large protein-polysaccharide complexes or virus particles and aggregates of well over 100 nm.\r\n\r\nFor a copy of the new white paper please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.postnova.com/news-and-events/press-releases/256-white-paper-separation-and-characterization-of-viruses-and-antibodies.html\">https://www.postnova.com/news-and-events/press-releases/256-white-paper-separation-and-characterization-of-viruses-and-antibodies.html</a></span> or contact Postnova Analytics on +49-8191-985-6880 / +44-1885-475007 / +1-801-521-2004 or info@postnova.com.','White Paper:  Separation and Characterization of Viruses and Antibodies','','inherit','closed','closed','','6279-revision-v1','','','2020-06-23 08:59:52','2020-06-23 08:59:52','',6279,'https://microbiozindia.com/uncategorized/6279-revision-v1/',0,'revision','',0),(6282,2,'2020-06-23 11:50:53','2020-06-23 11:50:53','Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/\">preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.</a> </span>The preclinical information exhibited that JBI-802 has solid viability in numerous in vivo malignant growth models interceded by LSD1 and HDAC6 restraint, while showing fantastic selectivity against different HDACs and better in vivo adequacy looked at than single specialists focusing on LSD1 or HDAC6.\r\n\r\n<em>We are excited to reveal these new data from our study of JBI-802 whose first-in-class dual mechanism of action targets the overexpression of two proteins, while exhibiting a favorable tolerability profile.\"</em>\r\nSyed Kazmi, President and Chief Executive Officer\r\n\r\n&nbsp;','Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020','','publish','open','open','','jubilant-therapeutics-reports-preclinical-information-of-double-lsd1-and-hdac6-at-aacr-2020','','','2020-06-23 11:50:53','2020-06-23 11:50:53','',0,'https://microbiozindia.com/?p=6282',0,'post','',0),(6283,2,'2020-06-23 11:47:00','2020-06-23 11:47:00','','Jubilant-Therapeutics Logo','Jubilant Therapeutics Logo','inherit','open','closed','','jubilant-therapeutics-logo','','','2020-06-23 11:47:00','2020-06-23 11:47:00','',6282,'https://microbiozindia.com/wp-content/uploads/2020/06/100.jpg',0,'attachment','image/jpeg',0),(6284,2,'2020-06-23 11:50:53','2020-06-23 11:50:53','Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.aacr.org/meeting/aacr-annual-meeting-2020/coronavirus-information/\">preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.</a> </span>The preclinical information exhibited that JBI-802 has solid viability in numerous in vivo malignant growth models interceded by LSD1 and HDAC6 restraint, while showing fantastic selectivity against different HDACs and better in vivo adequacy looked at than single specialists focusing on LSD1 or HDAC6.\r\n\r\n<em>We are excited to reveal these new data from our study of JBI-802 whose first-in-class dual mechanism of action targets the overexpression of two proteins, while exhibiting a favorable tolerability profile.\"</em>\r\nSyed Kazmi, President and Chief Executive Officer\r\n\r\n&nbsp;','Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020','','inherit','closed','closed','','6282-revision-v1','','','2020-06-23 11:50:53','2020-06-23 11:50:53','',6282,'https://microbiozindia.com/uncategorized/6282-revision-v1/',0,'revision','',0),(6286,2,'2020-06-23 11:55:43','2020-06-23 11:55:43','Nicoya, a main supplier of cutting edge expository instruments for the biotechnology and pharmaceutical businesses, will get warning administrations and up to $299,190 in innovative work subsidizing from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to build up a compact COVID-19 demonstrative test called Atlas.\r\n\r\nThis financing comes as a major aspect of a joint test gave by the Public Health Agency of Canada (PHAC) and the National Research Council of Canada (NRC) through the Innovative Solutions Canada (ISC) program. The spit based test will have the option to identify COVID-19 disease in under 20 minutes, with a simple to-utilize gadget that can be utilized in an assortment of settings.\r\n\r\n<em>Accessibility continues to be a large barrier in achieving population testing goals. There is an urgent need for diagnostic kits that can provide users with immediate results, rather than having to rely on testing labs that can take two to five days. Delays increase the possibility of infected people spreading the virus further, or uninfected people facing unnecessary quarantine. Atlas will fill an important void in the current testing space, as a portable COVID-19 test that can fit seamlessly into economic re-opening strategies.”</em>\r\nRyan Denomme, Co-founder and CEO of Nicoya\r\n\r\nChart book will be a solitary use, dispensable gadget that will recognize dynamic disease by testing for SARS-CoV-2 viral proteins. To make the test as open as could be expected under the circumstances, Nicoya is driving it with cell phone innovation so it can convey lab-quality outcomes to an application in less than 20 minutes. The test will be performed with a salivation test, as opposed to the more typical nasopharyngeal swab tests. With Atlas, Nicoya plans to make testing increasingly accessible all over the place, from remote networks to cutting edge screening techniques.\r\n\r\nAs indicated by the World Health Organization, analytic testing for COVID-19 is basic to following the infection, understanding its the study of disease transmission, advising case the executives and smothering transmission. The NRC IRAP-ISC COVID-19 Challenge Program is assisting answers for fast testing in decentralized and purpose of-care settings.\r\n\r\n<em>Our government is mobilizing resources to combat COVID-19 and I’m proud that Nicoya was one of four Phase I funding recipients of the Point-of-Care Diagnostic Test Kit Challenge. Nicoya is an exemplary company already working hard on pioneering innovative research and finding solutions together, and this approach is a pillar to ensuring we have both short and long-term solutions to fight the COVID-19 pandemic.”</em>Raj Saini, Member of Parliament for Kitchener Centre\r\n\r\nWith regards to their main goal to improve human life, Nicoya\'s biosensor arrangements have been empowering progressed logical exploration for quite a long time. The Nicoya group is presently utilizing its profound aptitude in territories, for example, nanotechnology, microfluidics and natural chemistry to create Atlas as a suitable answer for containing COVID-19 and forestalling the spread of future viral maladies.\r\n\r\nThe improvement of an Atlas model is in progress for Nicoya. \"With this financing and backing, we have the chance to speed up innovative work of Atlas, and we\'re striving to carry it to general society as fast as could be expected under the circumstances,\" Denomme clarified.','Nicoya gets NRC IRAP financing to create salivation based indicative test for COVID-19','','publish','open','open','','nicoya-gets-nrc-irap-financing-to-create-salivation-based-indicative-test-for-covid-19','','','2020-06-23 11:55:43','2020-06-23 11:55:43','',0,'https://microbiozindia.com/?p=6286',0,'post','',0),(6287,2,'2020-06-23 11:55:43','2020-06-23 11:55:43','Nicoya, a main supplier of cutting edge expository instruments for the biotechnology and pharmaceutical businesses, will get warning administrations and up to $299,190 in innovative work subsidizing from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to build up a compact COVID-19 demonstrative test called Atlas.\r\n\r\nThis financing comes as a major aspect of a joint test gave by the Public Health Agency of Canada (PHAC) and the National Research Council of Canada (NRC) through the Innovative Solutions Canada (ISC) program. The spit based test will have the option to identify COVID-19 disease in under 20 minutes, with a simple to-utilize gadget that can be utilized in an assortment of settings.\r\n\r\n<em>Accessibility continues to be a large barrier in achieving population testing goals. There is an urgent need for diagnostic kits that can provide users with immediate results, rather than having to rely on testing labs that can take two to five days. Delays increase the possibility of infected people spreading the virus further, or uninfected people facing unnecessary quarantine. Atlas will fill an important void in the current testing space, as a portable COVID-19 test that can fit seamlessly into economic re-opening strategies.”</em>\r\nRyan Denomme, Co-founder and CEO of Nicoya\r\n\r\nChart book will be a solitary use, dispensable gadget that will recognize dynamic disease by testing for SARS-CoV-2 viral proteins. To make the test as open as could be expected under the circumstances, Nicoya is driving it with cell phone innovation so it can convey lab-quality outcomes to an application in less than 20 minutes. The test will be performed with a salivation test, as opposed to the more typical nasopharyngeal swab tests. With Atlas, Nicoya plans to make testing increasingly accessible all over the place, from remote networks to cutting edge screening techniques.\r\n\r\nAs indicated by the World Health Organization, analytic testing for COVID-19 is basic to following the infection, understanding its the study of disease transmission, advising case the executives and smothering transmission. The NRC IRAP-ISC COVID-19 Challenge Program is assisting answers for fast testing in decentralized and purpose of-care settings.\r\n\r\n<em>Our government is mobilizing resources to combat COVID-19 and I’m proud that Nicoya was one of four Phase I funding recipients of the Point-of-Care Diagnostic Test Kit Challenge. Nicoya is an exemplary company already working hard on pioneering innovative research and finding solutions together, and this approach is a pillar to ensuring we have both short and long-term solutions to fight the COVID-19 pandemic.”</em>Raj Saini, Member of Parliament for Kitchener Centre\r\n\r\nWith regards to their main goal to improve human life, Nicoya\'s biosensor arrangements have been empowering progressed logical exploration for quite a long time. The Nicoya group is presently utilizing its profound aptitude in territories, for example, nanotechnology, microfluidics and natural chemistry to create Atlas as a suitable answer for containing COVID-19 and forestalling the spread of future viral maladies.\r\n\r\nThe improvement of an Atlas model is in progress for Nicoya. \"With this financing and backing, we have the chance to speed up innovative work of Atlas, and we\'re striving to carry it to general society as fast as could be expected under the circumstances,\" Denomme clarified.','Nicoya gets NRC IRAP financing to create salivation based indicative test for COVID-19','','inherit','closed','closed','','6286-revision-v1','','','2020-06-23 11:55:43','2020-06-23 11:55:43','',6286,'https://microbiozindia.com/uncategorized/6286-revision-v1/',0,'revision','',0),(6288,2,'2020-06-24 08:17:58','2020-06-24 08:17:58','Rotavirus is answerable for in excess of 130,000 passings in newborn children and little youngsters more youthful than five years, consistently. The infection causes serious, getting dried out loose bowels as it duplicates in viral manufacturing plants called viroplasms that structure inside tainted cells. Viroplasms have been hard to contemplate in light of the fact that they regularly structure rapidly, however a fortunate perception drove scientists at Baylor College of Medicine to reveal new experiences into the development of viroplasms.\r\n\r\n<strong><span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">The specialists made a freak rotavirus that out of the blue repeated much more slow than the first infection, permitting them to watch the initial steps of viral get together.</a></span></strong> The discoveries, distributed in the Journal of Virology, open additional opportunities for rewarding and forestalling this viral malady and for seeing how comparative industrial facilities of different infections work.\r\n\r\n\"The development of viroplasms is basic for an effective rotavirus disease. They structure rapidly inside tainted cells and are made of both viral and cell proteins that cooperate with lipid beads, however the subtleties of how the parts are assembled are as yet not satisfactory,\" said first creator Dr. Jeanette M. Criglar, a previous postdoctoral student and now staff researcher in the Department of Molecular Virology and Microbiology at Baylor in Dr. Mary Estes\' lab.\r\n\r\nTo get new bits of knowledge into the development of viroplasms, Criglar and her partners considered NSP2, one of the viral proteins that is required for the infection to duplicate. Without it, neither viroplasms nor new infections would frame.\r\n\r\nLike all proteins, NSP2 is made of amino acids hung together like dabs on an accessory. \'Globule\' 313 is the amino corrosive serine. Significantly, serine 313 is phosphorylated - it has a phosphate compound gathering appended to it. Protein phosphorylation is a component cells use to manage protein movement. It works like an on-and-off switch, enacting or deactivating a protein. Here, the analysts assessed the job NSP2\'s phosphorylation of serine 313 plays on viroplasm development.\r\n\r\n<strong>A fortunate finding</strong>\r\n\r\nUtilizing an as of late created turn around hereditary qualities framework, Criglar and her partners produced a rotavirus conveying a NSP2 protein with a transformation in amino corrosive 313, called a phosphomimetic change, by changing serine to aspartic corrosive. The name phosphomimetic demonstrates that the freak protein copies the phosphorylated protein in the first rotavirus. Switch hereditary qualities begins with a protein and works in reverse to make the freak quality, which at that point is made piece of the infection to contemplate the capacity of the protein on viral conduct.\r\n\r\n\"In research center tests, our phosphomimetic freak protein crystalized quicker than the first, inside hours rather than days,\" Criglar said. \"Be that as it may, shockingly, when contrasted with non-freak rotavirus, the phosphomimetic infection was delayed to make viroplasms and to recreate.\"\r\n\r\n\"This isn\'t what we anticipated. We believed that rotavirus with the freak protein likewise would reproduce quicker,\" said Estes, Cullen Foundation Endowed Chair and Distinguished Service Professor of atomic virology and microbiology at Baylor. \"We exploited the deferral in viroplasm arrangement to watch early occasions that have been hard to consider.\"\r\n\r\n<strong>Early advances: NSP2 and lipid beads meet up</strong>\r\n\r\nThe scientists found that one of the initial phases in viroplasm development is the relationship of NSP2 with lipid beads, demonstrating that NSP2 phosphorylated on position 313 alone can cooperate with the drops, without connecting with different segments of the viroplasm.\r\n\r\nLipid beads are a fundamental piece of viroplasms. It is realized that rotavirus cajoles tainted cells to create the beads, however how it does it is obscure. The new discoveries recommend that rotavirus might be utilizing phosphorylated NSP2 to trigger lipid bead development.\r\n\r\n\"It was energizing to see that simply changing a solitary amino corrosive in the NSP2 protein influenced the replication of the entire infection,\" Criglar said. \"The phosphomimetic change adjusted the elements of viral replication without murdering the infection. We can utilize this freak rotavirus to keep researching the succession of occasions prompting viroplasm arrangement, including a long-standing inquiry in cell science about how lipid beads structure.\"\r\n\r\n\"This is the primary investigation in our lab that has utilized the opposite hereditary qualities framework produced for rotavirus by Kanai and partners in Japan, and that is energizing for me,\" Estes said. \"There have been not very many papers that utilization the framework to pose a natural inquiry, and our own is one of them.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">Materials</a></span> provided by Baylor College of Medicine. Original written by Ana María Rodríguez, Ph.D.. and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nJeanette M. Criglar, Sue E. Crawford, Boyang Zhao, Hunter G. Smith, Fabio Stossi, Mary K. Estes. <strong><a href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">A genetically engineered rotavirus NSP2 phosphorylation mutant impaired in viroplasm formation and replication shows an early interaction between vNSP2 and cellular lipid droplets. Journal of Virology,</a> </strong>2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">DOI: 10.1128/JVI.00972-20</a></span>','Slow-developing rotavirus freak uncovers early strides of viral get together','','publish','open','open','','slow-developing-rotavirus-freak-uncovers-early-strides-of-viral-get-together','','','2020-06-24 08:18:07','2020-06-24 08:18:07','',0,'https://microbiozindia.com/?p=6288',0,'post','',0),(6289,2,'2020-06-24 08:17:47','2020-06-24 08:17:47','','Rotavirus Cells - in fluid','','inherit','open','closed','','rotavirus-cells-in-fluid','','','2020-06-24 08:17:47','2020-06-24 08:17:47','',6288,'https://microbiozindia.com/wp-content/uploads/2020/06/Rotavirus.jpg',0,'attachment','image/jpeg',0),(6290,2,'2020-06-24 08:17:58','2020-06-24 08:17:58','Rotavirus is answerable for in excess of 130,000 passings in newborn children and little youngsters more youthful than five years, consistently. The infection causes serious, getting dried out loose bowels as it duplicates in viral manufacturing plants called viroplasms that structure inside tainted cells. Viroplasms have been hard to contemplate in light of the fact that they regularly structure rapidly, however a fortunate perception drove scientists at Baylor College of Medicine to reveal new experiences into the development of viroplasms.\r\n\r\n<strong><span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">The specialists made a freak rotavirus that out of the blue repeated much more slow than the first infection, permitting them to watch the initial steps of viral get together.</a></span></strong> The discoveries, distributed in the Journal of Virology, open additional opportunities for rewarding and forestalling this viral malady and for seeing how comparative industrial facilities of different infections work.\r\n\r\n\"The development of viroplasms is basic for an effective rotavirus disease. They structure rapidly inside tainted cells and are made of both viral and cell proteins that cooperate with lipid beads, however the subtleties of how the parts are assembled are as yet not satisfactory,\" said first creator Dr. Jeanette M. Criglar, a previous postdoctoral student and now staff researcher in the Department of Molecular Virology and Microbiology at Baylor in Dr. Mary Estes\' lab.\r\n\r\nTo get new bits of knowledge into the development of viroplasms, Criglar and her partners considered NSP2, one of the viral proteins that is required for the infection to duplicate. Without it, neither viroplasms nor new infections would frame.\r\n\r\nLike all proteins, NSP2 is made of amino acids hung together like dabs on an accessory. \'Globule\' 313 is the amino corrosive serine. Significantly, serine 313 is phosphorylated - it has a phosphate compound gathering appended to it. Protein phosphorylation is a component cells use to manage protein movement. It works like an on-and-off switch, enacting or deactivating a protein. Here, the analysts assessed the job NSP2\'s phosphorylation of serine 313 plays on viroplasm development.\r\n\r\n<strong>A fortunate finding</strong>\r\n\r\nUtilizing an as of late created turn around hereditary qualities framework, Criglar and her partners produced a rotavirus conveying a NSP2 protein with a transformation in amino corrosive 313, called a phosphomimetic change, by changing serine to aspartic corrosive. The name phosphomimetic demonstrates that the freak protein copies the phosphorylated protein in the first rotavirus. Switch hereditary qualities begins with a protein and works in reverse to make the freak quality, which at that point is made piece of the infection to contemplate the capacity of the protein on viral conduct.\r\n\r\n\"In research center tests, our phosphomimetic freak protein crystalized quicker than the first, inside hours rather than days,\" Criglar said. \"Be that as it may, shockingly, when contrasted with non-freak rotavirus, the phosphomimetic infection was delayed to make viroplasms and to recreate.\"\r\n\r\n\"This isn\'t what we anticipated. We believed that rotavirus with the freak protein likewise would reproduce quicker,\" said Estes, Cullen Foundation Endowed Chair and Distinguished Service Professor of atomic virology and microbiology at Baylor. \"We exploited the deferral in viroplasm arrangement to watch early occasions that have been hard to consider.\"\r\n\r\n<strong>Early advances: NSP2 and lipid beads meet up</strong>\r\n\r\nThe scientists found that one of the initial phases in viroplasm development is the relationship of NSP2 with lipid beads, demonstrating that NSP2 phosphorylated on position 313 alone can cooperate with the drops, without connecting with different segments of the viroplasm.\r\n\r\nLipid beads are a fundamental piece of viroplasms. It is realized that rotavirus cajoles tainted cells to create the beads, however how it does it is obscure. The new discoveries recommend that rotavirus might be utilizing phosphorylated NSP2 to trigger lipid bead development.\r\n\r\n\"It was energizing to see that simply changing a solitary amino corrosive in the NSP2 protein influenced the replication of the entire infection,\" Criglar said. \"The phosphomimetic change adjusted the elements of viral replication without murdering the infection. We can utilize this freak rotavirus to keep researching the succession of occasions prompting viroplasm arrangement, including a long-standing inquiry in cell science about how lipid beads structure.\"\r\n\r\n\"This is the primary investigation in our lab that has utilized the opposite hereditary qualities framework produced for rotavirus by Kanai and partners in Japan, and that is energizing for me,\" Estes said. \"There have been not very many papers that utilization the framework to pose a natural inquiry, and our own is one of them.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">Materials</a></span> provided by Baylor College of Medicine. Original written by Ana María Rodríguez, Ph.D.. and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nJeanette M. Criglar, Sue E. Crawford, Boyang Zhao, Hunter G. Smith, Fabio Stossi, Mary K. Estes. <strong><a href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">A genetically engineered rotavirus NSP2 phosphorylation mutant impaired in viroplasm formation and replication shows an early interaction between vNSP2 and cellular lipid droplets. Journal of Virology,</a> </strong>2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://blogs.bcm.edu/2020/06/23/from-the-labs-slow-growing-rotavirus-mutant-reveals-early-steps-of-viral-assembly/\">DOI: 10.1128/JVI.00972-20</a></span>','Slow-developing rotavirus freak uncovers early strides of viral get together','','inherit','closed','closed','','6288-revision-v1','','','2020-06-24 08:17:58','2020-06-24 08:17:58','',6288,'https://microbiozindia.com/uncategorized/6288-revision-v1/',0,'revision','',0),(6291,2,'2020-06-24 10:13:20','2020-06-24 10:13:20','Freeman Technology, a Micromeritics company and the global leader in powder characterisation technology, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.freemantech.co.uk/news\">has released a new eBook focusing on the application of powder flow testing in Additive Manufacturing (AM). Powders used for AM, or 3D printing, range from metals and polymers through to pharmaceutical formulations.</a> </span>‘Powder Flow Testing for Additive Manufacturing’ focuses on the measurement of bulk powder properties, notably flowability via dynamic testing, that are being used by industry pioneers to enhance throughput and printed product quality. Including a range of case studies, it provides valuable, expert guidance for materials scientists and engineers looking to optimise the application and performance of AM.\r\n\r\nThe application of AM is growing rapidly, in industries as diverse as aerospace and automotive, energy and medical. The robust specification of feedstocks is critical for commercial success, to secure consistency in the powder supply chain and to develop new materials for printing. Choosing between supplies, establishing effective powder recycling strategies, and selecting the best material for a specific application all rely on understanding which properties define performance. Bulk flow properties are important within this context. They impact powder discharge from the feed hopper into the process and spreadability, the ease and consistency of powder dispersion across the build platform. Powder flowability can also directly influence the quality of finished components.\r\n\r\nWritten in clear, easy-to-understand language, the new eBook summarises Freeman Technology’s understanding and expertise in this area, gathered over many years working with academic and industrial leaders. Readers can learn about:\r\n\r\n1.Which powder properties are most relevant to AM performance and why?\r\n2.The strengths and limitations of different techniques for powder flow measurement.\r\n3.The benefits of multi-faceted powder testing, via a series of case studies from in-house research and industrial collaborations.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.micromeritics.com/Product-Showcase/additive-manufacturing.aspx\">The robust specification of powders for AM is challenging with subtle differences distinguishing powders that perform well from those that will be economically or technically inferior.</a></span> Multi-faceted powder characterisation, based on the measurement of dynamic, bulk and shear properties, provides valuable insight into powder behaviour with the exemplary sensitivity and established relevance of dynamic testing often proving critical.\r\n\r\nDownload this complimentary new eBook today and learn how to improve your analytical strategy for AM powder selection and management.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.freemantech.co.uk/learn/ebooks\">https://www.freemantech.co.uk/learn/ebooks</a></span>\r\n\r\nFreeman Technology and Powder Rheometer are registered trademarks of Freeman Technology Ltd\r\n\r\n<strong>About Freeman Technology:</strong>\r\n\r\nFreeman Technology, a Micromeritics company, specialises in systems for measuring the flow properties of powders and has over 15 years’ experience in powder flow and powder characterisation. Expert teams provide comprehensive support alongside the company’s range of products.\r\n\r\nSystems are installed around the world across a diverse range of industries. They deliver data that maximise process and product understanding, accelerating R&amp;D and formulation towards successful commercialisation, and supporting the long term optimisation of powder processes.\r\n\r\nFreeman Technology is headquartered in Gloucestershire, UK, with operations and distribution partners in key global territories.\r\n\r\nIn 2007 the company received the Queen’s Award for Enterprise in Innovation and in 2012 the Queen’s Award for Enterprise in International Trade. www.freemantech.co.uk\r\n\r\n<strong>Tags:</strong>\r\n\r\n<span style=\"text-decoration: underline;\">testing powder,powdered glass test ,baking powder pregnancy test ,baking powder gender test accuracy ,</span>\r\n<span style=\"text-decoration: underline;\">soap powder pregnancy test,how to test turmeric powder,how to test whey protein powder ,what is testing powder ,how to test detergent powder ,how to make testing powder</span>','New eBook from Freeman Technology addresses the critical issue of powder flow testing for Additive Manufacturing','','publish','open','open','','new-ebook-from-freeman-technology-addresses-the-critical-issue-of-powder-flow-testing-for-additive-manufacturing','','','2020-06-24 10:13:20','2020-06-24 10:13:20','',0,'https://microbiozindia.com/?p=6291',0,'post','',0),(6292,2,'2020-06-24 08:57:32','2020-06-24 08:57:32','{{unknown}}','','','publish','closed','closed','','99de49cee797311fb819675b9e936633','','','2020-06-24 08:57:32','2020-06-24 08:57:32','',0,'https://microbiozindia.com/uncategorized/99de49cee797311fb819675b9e936633/',0,'oembed_cache','',0),(6293,2,'2020-06-24 08:59:22','2020-06-24 08:59:22','','GLPR05_Powder Flow Testing for Additive Manufacturing','','inherit','open','closed','','glpr05_powder-flow-testing-for-additive-manufacturing','','','2020-06-24 08:59:22','2020-06-24 08:59:22','',6291,'https://microbiozindia.com/wp-content/uploads/2020/06/GLPR05_Powder-Flow-Testing-for-Additive-Manufacturing.png',0,'attachment','image/png',0),(6294,2,'2020-06-24 10:13:20','2020-06-24 10:13:20','Freeman Technology, a Micromeritics company and the global leader in powder characterisation technology, <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.freemantech.co.uk/news\">has released a new eBook focusing on the application of powder flow testing in Additive Manufacturing (AM). Powders used for AM, or 3D printing, range from metals and polymers through to pharmaceutical formulations.</a> </span>‘Powder Flow Testing for Additive Manufacturing’ focuses on the measurement of bulk powder properties, notably flowability via dynamic testing, that are being used by industry pioneers to enhance throughput and printed product quality. Including a range of case studies, it provides valuable, expert guidance for materials scientists and engineers looking to optimise the application and performance of AM.\r\n\r\nThe application of AM is growing rapidly, in industries as diverse as aerospace and automotive, energy and medical. The robust specification of feedstocks is critical for commercial success, to secure consistency in the powder supply chain and to develop new materials for printing. Choosing between supplies, establishing effective powder recycling strategies, and selecting the best material for a specific application all rely on understanding which properties define performance. Bulk flow properties are important within this context. They impact powder discharge from the feed hopper into the process and spreadability, the ease and consistency of powder dispersion across the build platform. Powder flowability can also directly influence the quality of finished components.\r\n\r\nWritten in clear, easy-to-understand language, the new eBook summarises Freeman Technology’s understanding and expertise in this area, gathered over many years working with academic and industrial leaders. Readers can learn about:\r\n\r\n1.Which powder properties are most relevant to AM performance and why?\r\n2.The strengths and limitations of different techniques for powder flow measurement.\r\n3.The benefits of multi-faceted powder testing, via a series of case studies from in-house research and industrial collaborations.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.micromeritics.com/Product-Showcase/additive-manufacturing.aspx\">The robust specification of powders for AM is challenging with subtle differences distinguishing powders that perform well from those that will be economically or technically inferior.</a></span> Multi-faceted powder characterisation, based on the measurement of dynamic, bulk and shear properties, provides valuable insight into powder behaviour with the exemplary sensitivity and established relevance of dynamic testing often proving critical.\r\n\r\nDownload this complimentary new eBook today and learn how to improve your analytical strategy for AM powder selection and management.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.freemantech.co.uk/learn/ebooks\">https://www.freemantech.co.uk/learn/ebooks</a></span>\r\n\r\nFreeman Technology and Powder Rheometer are registered trademarks of Freeman Technology Ltd\r\n\r\n<strong>About Freeman Technology:</strong>\r\n\r\nFreeman Technology, a Micromeritics company, specialises in systems for measuring the flow properties of powders and has over 15 years’ experience in powder flow and powder characterisation. Expert teams provide comprehensive support alongside the company’s range of products.\r\n\r\nSystems are installed around the world across a diverse range of industries. They deliver data that maximise process and product understanding, accelerating R&amp;D and formulation towards successful commercialisation, and supporting the long term optimisation of powder processes.\r\n\r\nFreeman Technology is headquartered in Gloucestershire, UK, with operations and distribution partners in key global territories.\r\n\r\nIn 2007 the company received the Queen’s Award for Enterprise in Innovation and in 2012 the Queen’s Award for Enterprise in International Trade. www.freemantech.co.uk\r\n\r\n<strong>Tags:</strong>\r\n\r\n<span style=\"text-decoration: underline;\">testing powder,powdered glass test ,baking powder pregnancy test ,baking powder gender test accuracy ,</span>\r\n<span style=\"text-decoration: underline;\">soap powder pregnancy test,how to test turmeric powder,how to test whey protein powder ,what is testing powder ,how to test detergent powder ,how to make testing powder</span>','New eBook from Freeman Technology addresses the critical issue of powder flow testing for Additive Manufacturing','','inherit','closed','closed','','6291-revision-v1','','','2020-06-24 10:13:20','2020-06-24 10:13:20','',6291,'https://microbiozindia.com/uncategorized/6291-revision-v1/',0,'revision','',0),(6296,2,'2020-06-24 10:57:26','2020-06-24 10:57:26','Syracuse University science educator Dr. Robert P. Doyle has built up another medication lead to treat type 2 diabetes in a great many patients who are looking to all the more likely control their glucose without the basic symptoms of queasiness, spewing, and in select cases, undesired weight reduction.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.x-mol.com/paper/1273037091114610688\">Doyle\'s examination article, \"Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,\" was distributed as of late in the friend assessed logical diary Cell Reports.</a></span>\r\n\r\nA typical gathering of medications used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do bring down glucose levels in diabetic patients, their symptoms incorporate sickness, spewing, and weight reduction.\r\n\r\nThrough awards from the National Institutes of Health (NIH), Doyle and his colleagues figured out how to consolidate two atoms into another substance that brings down glucose without those undesired symptoms.\r\n\r\nIn specialized terms, Doyle\'s group built up another zone of bioconjugation, a compound strategy used to join two particles. By restricting together exendin-4 (Ex4), a FDA-affirmed GLP-1R agonist, to dicyanocobinamide (Cbi), which is a little bit of the unpredictable nutrient B12 atom, they created Cbi-Ex4 in a method they call \"corrination\" - a play, obviously, on \"royal celebration.\"\r\n\r\nInformation gathered from testing Cbi-Ex4 in the musk wench (Suncus murinus) - the well evolved creature utilized in this examination because of its capacity to upchuck (rodents and numerous warm blooded animals come up short on that capacity) - uncovered advantageous impacts as prove by improved glucose levels during glucose resilience tests and a significant decrease in heaving contrasted with Ex4. Significantly, no weight reduction was noted, again as a distinct difference to the right now endorsed GLP-1R agonist, making this new medication perfect for patients who require glucoregulation without influencing their weight record (BMI) levels.\r\n\r\nThis medication could along these lines advantage diabetes patients who likewise live with cystic fibrosis, COPD, sarcopenia, malignancy, or HIV, where weight reduction is counter-demonstrated.\r\n\r\nThe following stage in the advancement of this momentous medication is to move it through the pre-clinical stage into stage I human examinations. Doyle and his group have presented another award proposition to the NIH to subsidize this exertion.\r\n\r\nNearby this work, Doyle has likewise been granted a three-year, $3 million award through the government Department of Defense (DoD) to assist military veterans with comorbid diabetes and weight. Almost 25 percent of veterans accepting consideration at VA clinical focuses are determined to have diabetes (contrasted with around 9 percent of everybody).\r\n<span style=\"text-decoration: underline;\"><em>This is what the military would call dual-use technology, applicable to all civilians if it works. The grant is specifically aimed at making researchers look at major problems within the veteran community, and the hope is that we would see a significant weight loss method that is better than what is currently available.\"</em></span>\r\n<strong>Dr. Robert P. Doyle, Chemistry Professor, Syracuse University</strong>\r\n<blockquote>\"There\'s no treatment out there now that can keep weight off for a long period of time without illness behaviors such as nausea,\" Doyle added. \"So, my group is pushing to expand on GLP-1R agonists to treat diabetes with obesity (DoD project) and then separately to treat diabetes without affecting nutritional status (\'corrination\').\"</blockquote>','Scientist grows new medication to treat type 2 diabetes without undesired reactions','','publish','open','open','','scientist-grows-new-medication-to-treat-type-2-diabetes-without-undesired-reactions','','','2020-06-24 10:57:26','2020-06-24 10:57:26','',0,'https://microbiozindia.com/?p=6296',0,'post','',0),(6297,2,'2020-06-24 10:43:12','2020-06-24 10:43:12','','diabetes-528678_640','','inherit','open','closed','','diabetes-528678_640','','','2020-06-24 10:43:12','2020-06-24 10:43:12','',6296,'https://microbiozindia.com/wp-content/uploads/2020/06/diabetes-528678_640.jpg',0,'attachment','image/jpeg',0),(6298,2,'2020-06-24 10:57:26','2020-06-24 10:57:26','Syracuse University science educator Dr. Robert P. Doyle has built up another medication lead to treat type 2 diabetes in a great many patients who are looking to all the more likely control their glucose without the basic symptoms of queasiness, spewing, and in select cases, undesired weight reduction.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.x-mol.com/paper/1273037091114610688\">Doyle\'s examination article, \"Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis,\" was distributed as of late in the friend assessed logical diary Cell Reports.</a></span>\r\n\r\nA typical gathering of medications used to treat type 2 diabetes are glucagon-like peptide-1 receptor (GLP-1R) agonists. While they do bring down glucose levels in diabetic patients, their symptoms incorporate sickness, spewing, and weight reduction.\r\n\r\nThrough awards from the National Institutes of Health (NIH), Doyle and his colleagues figured out how to consolidate two atoms into another substance that brings down glucose without those undesired symptoms.\r\n\r\nIn specialized terms, Doyle\'s group built up another zone of bioconjugation, a compound strategy used to join two particles. By restricting together exendin-4 (Ex4), a FDA-affirmed GLP-1R agonist, to dicyanocobinamide (Cbi), which is a little bit of the unpredictable nutrient B12 atom, they created Cbi-Ex4 in a method they call \"corrination\" - a play, obviously, on \"royal celebration.\"\r\n\r\nInformation gathered from testing Cbi-Ex4 in the musk wench (Suncus murinus) - the well evolved creature utilized in this examination because of its capacity to upchuck (rodents and numerous warm blooded animals come up short on that capacity) - uncovered advantageous impacts as prove by improved glucose levels during glucose resilience tests and a significant decrease in heaving contrasted with Ex4. Significantly, no weight reduction was noted, again as a distinct difference to the right now endorsed GLP-1R agonist, making this new medication perfect for patients who require glucoregulation without influencing their weight record (BMI) levels.\r\n\r\nThis medication could along these lines advantage diabetes patients who likewise live with cystic fibrosis, COPD, sarcopenia, malignancy, or HIV, where weight reduction is counter-demonstrated.\r\n\r\nThe following stage in the advancement of this momentous medication is to move it through the pre-clinical stage into stage I human examinations. Doyle and his group have presented another award proposition to the NIH to subsidize this exertion.\r\n\r\nNearby this work, Doyle has likewise been granted a three-year, $3 million award through the government Department of Defense (DoD) to assist military veterans with comorbid diabetes and weight. Almost 25 percent of veterans accepting consideration at VA clinical focuses are determined to have diabetes (contrasted with around 9 percent of everybody).\r\n<span style=\"text-decoration: underline;\"><em>This is what the military would call dual-use technology, applicable to all civilians if it works. The grant is specifically aimed at making researchers look at major problems within the veteran community, and the hope is that we would see a significant weight loss method that is better than what is currently available.\"</em></span>\r\n<strong>Dr. Robert P. Doyle, Chemistry Professor, Syracuse University</strong>\r\n<blockquote>\"There\'s no treatment out there now that can keep weight off for a long period of time without illness behaviors such as nausea,\" Doyle added. \"So, my group is pushing to expand on GLP-1R agonists to treat diabetes with obesity (DoD project) and then separately to treat diabetes without affecting nutritional status (\'corrination\').\"</blockquote>','Scientist grows new medication to treat type 2 diabetes without undesired reactions','','inherit','closed','closed','','6296-revision-v1','','','2020-06-24 10:57:26','2020-06-24 10:57:26','',6296,'https://microbiozindia.com/uncategorized/6296-revision-v1/',0,'revision','',0),(6299,2,'2020-06-24 11:16:58','2020-06-24 11:16:58','Herd immunity to COVID-19, which happens when such huge numbers of individuals in a network become safe to the illness that it quits spreading, could be accomplished with less individuals being contaminated than recently assessed, as per another examination.\r\n\r\nResearchers, including those from the University of Nottingham in the UK, noticed that group resistance creates when people getting the malady develop common invulnerability, and by individuals accepting an immunization.\r\n\r\nThey clarified that when a huge level of the populace gets safe to a sickness, the spread of the malady eases back down or stops and the chain of transmission is broken.\r\n\r\nIn the ebb and flow study, distributed in the diary Science, the scientists formulated a numerical model classifying individuals into bunches reflecting age and social movement level to decide the edge of the populace that should have been resistant for group invulnerability to create.\r\n\r\nAt the point when they calculated in contrasts in age and social movement in the model, they found that the group insusceptibility level decreased from 60 to 43 percent.\r\n\r\nThe 43 percent figure, as indicated by the researchers, ought to be deciphered as a representation instead of a careful worth, or even a best gauge.\r\n\r\nFor COVID-19, they said crowd invulnerability is regularly expressed as around 60 percent, a figure got from the portion of the populace that must be inoculated ahead of time of a plague to forestall an enormous flare-up.\r\n\r\nThis figure expect that every person in the populace is similarly prone to be immunized, and henceforth resistant, the researchers clarified.\r\n\r\nIn any case, they said this isn\'t the situation if insusceptibility emerges because of sickness spreading in a populace comprising of individuals with a wide range of practices.\r\n\r\n\"By adopting this new scientific strategy to assessing the level for group resistance to be accomplished we discovered it might be decreased to 43 percent and that this decrease is chiefly because of movement level as opposed to age structure,\" clarified study co-creator Frank Ball from the University of Nottingham.\r\n\r\nAs indicated by the researchers, the more socially dynamic people are, the almost certain they are to get contaminated, than the less socially dynamic ones - and they are likewise bound to taint individuals on the off chance that they become tainted.\r\n\r\nThe specialists said the crowd insusceptibility level is lower when invulnerability is brought about by illness spreading than when resistance originates from immunization.\r\n\r\nThey accept that the discoveries have likely ramifications for the arrival of lockdown measures over the world, and recommended that singular variety is a significant element to remember for models that direct strategy.','Herd immunity limit could be lower than recently suspected: Study','','publish','open','open','','herd-immunity-limit-could-be-lower-than-recently-suspected-study','','','2020-06-24 11:16:58','2020-06-24 11:16:58','',0,'https://microbiozindia.com/?p=6299',0,'post','',0),(6300,2,'2020-06-24 11:06:51','2020-06-24 11:06:51','','businessmen-5243087_640','','inherit','open','closed','','businessmen-5243087_640','','','2020-06-24 11:06:51','2020-06-24 11:06:51','',6299,'https://microbiozindia.com/wp-content/uploads/2020/06/businessmen-5243087_640.jpg',0,'attachment','image/jpeg',0),(6301,2,'2020-06-24 11:16:58','2020-06-24 11:16:58','Herd immunity to COVID-19, which happens when such huge numbers of individuals in a network become safe to the illness that it quits spreading, could be accomplished with less individuals being contaminated than recently assessed, as per another examination.\r\n\r\nResearchers, including those from the University of Nottingham in the UK, noticed that group resistance creates when people getting the malady develop common invulnerability, and by individuals accepting an immunization.\r\n\r\nThey clarified that when a huge level of the populace gets safe to a sickness, the spread of the malady eases back down or stops and the chain of transmission is broken.\r\n\r\nIn the ebb and flow study, distributed in the diary Science, the scientists formulated a numerical model classifying individuals into bunches reflecting age and social movement level to decide the edge of the populace that should have been resistant for group invulnerability to create.\r\n\r\nAt the point when they calculated in contrasts in age and social movement in the model, they found that the group insusceptibility level decreased from 60 to 43 percent.\r\n\r\nThe 43 percent figure, as indicated by the researchers, ought to be deciphered as a representation instead of a careful worth, or even a best gauge.\r\n\r\nFor COVID-19, they said crowd invulnerability is regularly expressed as around 60 percent, a figure got from the portion of the populace that must be inoculated ahead of time of a plague to forestall an enormous flare-up.\r\n\r\nThis figure expect that every person in the populace is similarly prone to be immunized, and henceforth resistant, the researchers clarified.\r\n\r\nIn any case, they said this isn\'t the situation if insusceptibility emerges because of sickness spreading in a populace comprising of individuals with a wide range of practices.\r\n\r\n\"By adopting this new scientific strategy to assessing the level for group resistance to be accomplished we discovered it might be decreased to 43 percent and that this decrease is chiefly because of movement level as opposed to age structure,\" clarified study co-creator Frank Ball from the University of Nottingham.\r\n\r\nAs indicated by the researchers, the more socially dynamic people are, the almost certain they are to get contaminated, than the less socially dynamic ones - and they are likewise bound to taint individuals on the off chance that they become tainted.\r\n\r\nThe specialists said the crowd insusceptibility level is lower when invulnerability is brought about by illness spreading than when resistance originates from immunization.\r\n\r\nThey accept that the discoveries have likely ramifications for the arrival of lockdown measures over the world, and recommended that singular variety is a significant element to remember for models that direct strategy.','Herd immunity limit could be lower than recently suspected: Study','','inherit','closed','closed','','6299-revision-v1','','','2020-06-24 11:16:58','2020-06-24 11:16:58','',6299,'https://microbiozindia.com/uncategorized/6299-revision-v1/',0,'revision','',0),(6302,2,'2020-06-24 11:31:26','2020-06-24 11:31:26','Zydus Cadila has gotten last endorsement from the USFDA to showcase <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rxlist.com/antivert-drug.htm\">Meclizine Hydrochloride Tablets (US RLD: Antivert Tablets) in the qualities of 12.5 mg and 25 mg.</a></span>\r\n\r\nThe medication will be produced at the gathering\'s assembling office at SEZ, Ahmedabad, Cadila said in the recording.\r\n\r\nMeclizine is an antihistamine that is utilized to forestall and treat queasiness, spewing, and discombobulation brought about by movement ailment. It might likewise be utilized to decrease discombobulation and loss of parity (vertigo) brought about by inward ear issues.\r\n\r\nThe gathering presently has 292 endorsements and has so far documented more than 390 ANDAs since the beginning of the recording procedure in FY2003-04.\r\n\r\nCadila Healthcare Ltd is as of now exchanging at Rs367.35, up by Rs0.4 or 0.11% from its past shutting of Rs366.95 on the BSE.\r\n\r\nThe scrip opened at Rs370 and has contacted a high and low of Rs373.35 and Rs363.15 separately.','Zydus Cadila gets last endorsement from USFDA for Meclizine Hydrochloride Tablets','','publish','open','open','','zydus-cadila-gets-last-endorsement-from-usfda-for-meclizine-hydrochloride-tablets','','','2020-06-24 11:31:26','2020-06-24 11:31:26','',0,'https://microbiozindia.com/?p=6302',0,'post','',0),(6303,2,'2020-06-24 11:31:26','2020-06-24 11:31:26','Zydus Cadila has gotten last endorsement from the USFDA to showcase <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.rxlist.com/antivert-drug.htm\">Meclizine Hydrochloride Tablets (US RLD: Antivert Tablets) in the qualities of 12.5 mg and 25 mg.</a></span>\r\n\r\nThe medication will be produced at the gathering\'s assembling office at SEZ, Ahmedabad, Cadila said in the recording.\r\n\r\nMeclizine is an antihistamine that is utilized to forestall and treat queasiness, spewing, and discombobulation brought about by movement ailment. It might likewise be utilized to decrease discombobulation and loss of parity (vertigo) brought about by inward ear issues.\r\n\r\nThe gathering presently has 292 endorsements and has so far documented more than 390 ANDAs since the beginning of the recording procedure in FY2003-04.\r\n\r\nCadila Healthcare Ltd is as of now exchanging at Rs367.35, up by Rs0.4 or 0.11% from its past shutting of Rs366.95 on the BSE.\r\n\r\nThe scrip opened at Rs370 and has contacted a high and low of Rs373.35 and Rs363.15 separately.','Zydus Cadila gets last endorsement from USFDA for Meclizine Hydrochloride Tablets','','inherit','closed','closed','','6302-revision-v1','','','2020-06-24 11:31:26','2020-06-24 11:31:26','',6302,'https://microbiozindia.com/uncategorized/6302-revision-v1/',0,'revision','',0),(6304,2,'2020-06-24 11:34:08','2020-06-24 11:34:08','Ipca Laboratories Limited had before declared about USFDA exclusion from import alert for APls Chloroquine Phosphate and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.outlookindia.com/newsscroll/usfda-has-removed-partial-lifting-of-import-alert-on-apis-mfg-facility-at-ratlam-ipca-lab/1875665\">Hydroxycholoroquine Sulfate produced from Company\'s APIs fabricating office arranged at Ratlam (M.P).</a></span>\r\n\r\nThe US FDA vide its email dated 23rd June 2020 has conveyed to the Company that lack suggestions for Chloroquine Phosphate API has changed and Chloroquine Phosphate tranquilize item is no longer in deficiency and in this way, no shipment of API Chloroquine Phosphate will be prohibited from the import alert.\r\n\r\nUSFDA has additionally educated that because of potential lack suggestions as well as clinical need, special case to the import alert has been made for API Hydroxychloroquine Sulfate. US FDA has additionally educated that this exemption will be re-thought of if the lack suggestions change.\r\n\r\nPortions of IPCA LABORATORIES LTD. was last exchanging BSE at Rs.1671.85 when contrasted with the past close of Rs. 1640. The complete number of offers exchanged during the day was 16843 in more than 2117 exchanges.\r\n\r\nThe stock hit an intraday high of Rs. 1675 and intraday low of 1644.9. The net turnover during the day was Rs. 28006534.','USFDA changes import alert on Ipca Laboratories Limited\'s Ratlam Unit','','publish','open','open','','usfda-changes-import-alert-on-ipca-laboratories-limiteds-ratlam-unit','','','2020-06-24 11:34:31','2020-06-24 11:34:31','',0,'https://microbiozindia.com/?p=6304',0,'post','',0),(6305,2,'2020-06-24 11:34:08','2020-06-24 11:34:08','Ipca Laboratories Limited had before declared about USFDA exclusion from import alert for APls Chloroquine Phosphate and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.outlookindia.com/newsscroll/usfda-has-removed-partial-lifting-of-import-alert-on-apis-mfg-facility-at-ratlam-ipca-lab/1875665\">Hydroxycholoroquine Sulfate produced from Company\'s APIs fabricating office arranged at Ratlam (M.P).</a></span>\r\n\r\nThe US FDA vide its email dated 23rd June 2020 has conveyed to the Company that lack suggestions for Chloroquine Phosphate API has changed and Chloroquine Phosphate tranquilize item is no longer in deficiency and in this way, no shipment of API Chloroquine Phosphate will be prohibited from the import alert.\r\n\r\nUSFDA has additionally educated that because of potential lack suggestions as well as clinical need, special case to the import alert has been made for API Hydroxychloroquine Sulfate. US FDA has additionally educated that this exemption will be re-thought of if the lack suggestions change.\r\n\r\nPortions of IPCA LABORATORIES LTD. was last exchanging BSE at Rs.1671.85 when contrasted with the past close of Rs. 1640. The complete number of offers exchanged during the day was 16843 in more than 2117 exchanges.\r\n\r\nThe stock hit an intraday high of Rs. 1675 and intraday low of 1644.9. The net turnover during the day was Rs. 28006534.','USFDA changes import alert on Ipca Laboratories Limited\'s Ratlam office','','inherit','closed','closed','','6304-revision-v1','','','2020-06-24 11:34:08','2020-06-24 11:34:08','',6304,'https://microbiozindia.com/uncategorized/6304-revision-v1/',0,'revision','',0),(6306,2,'2020-06-24 11:34:31','2020-06-24 11:34:31','Ipca Laboratories Limited had before declared about USFDA exclusion from import alert for APls Chloroquine Phosphate and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.outlookindia.com/newsscroll/usfda-has-removed-partial-lifting-of-import-alert-on-apis-mfg-facility-at-ratlam-ipca-lab/1875665\">Hydroxycholoroquine Sulfate produced from Company\'s APIs fabricating office arranged at Ratlam (M.P).</a></span>\r\n\r\nThe US FDA vide its email dated 23rd June 2020 has conveyed to the Company that lack suggestions for Chloroquine Phosphate API has changed and Chloroquine Phosphate tranquilize item is no longer in deficiency and in this way, no shipment of API Chloroquine Phosphate will be prohibited from the import alert.\r\n\r\nUSFDA has additionally educated that because of potential lack suggestions as well as clinical need, special case to the import alert has been made for API Hydroxychloroquine Sulfate. US FDA has additionally educated that this exemption will be re-thought of if the lack suggestions change.\r\n\r\nPortions of IPCA LABORATORIES LTD. was last exchanging BSE at Rs.1671.85 when contrasted with the past close of Rs. 1640. The complete number of offers exchanged during the day was 16843 in more than 2117 exchanges.\r\n\r\nThe stock hit an intraday high of Rs. 1675 and intraday low of 1644.9. The net turnover during the day was Rs. 28006534.','USFDA changes import alert on Ipca Laboratories Limited\'s Ratlam Unit','','inherit','closed','closed','','6304-revision-v1','','','2020-06-24 11:34:31','2020-06-24 11:34:31','',6304,'https://microbiozindia.com/uncategorized/6304-revision-v1/',0,'revision','',0),(6307,2,'2020-06-25 05:10:31','2020-06-25 05:10:31','The world faces a deficiency of oxygen concentrators as the quantity of overall instances of coronavirus contamination approaches the 10 million imprint, the World Health Organization head said on Wednesday.\r\n\r\n\"Numerous nations are currently encountering challenges getting oxygen concentrators,\" WHO Director General Tedros Adhanom Ghebreyesus told a news gathering. \"Request is presently overwhelming gracefully.\"\r\n\r\nThe new coronavirus has hit 9.3 million individuals and executed more than 480,000 up until this point and is ascending by around 1 million cases for each week. This has pushed oxygen request to 88,000 huge chambers for each day, or 620,000 cubic meters of oxygen, Tedros said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nytimes.com/2020/06/23/health/coronavirus-oxygen-africa.html\">The unexpected ascent has made a deficiency of oxygen concentrators expected to help breathing of COVID-19 patients experiencing respiratory pain.</a></span>\r\n\r\nThe wellbeing office has bought 14,000 oxygen concentrators from makers and plans to send them to 120 nations in coming weeks, Tedros said. A further 170,000 concentrators - esteemed at some $100 million - will be possibly accessible throughout the following a half year.\r\n\r\nThe leader of the WHO crises program, Dr Mike Ryan, in the mean time said the pandemic in numerous Latin American nations was as yet extraordinary as passings in the district outperformed 100,000 this week. Numerous nations had encountered 25-half increments in cases in the previous week, he said.\r\n\r\n\"I would portray the circumstance in the Americas all in all as yet developing, not having arrived at its pinnacle yet, and prone to bring about supported quantities of cases and proceeded with passings,\" he said.\r\n\r\nThe United States has condemned WHO\'s treatment of the pandemic, calling the office \"China-driven\". President Donald Trump requested a prompt survey and changes and has promised to stop the Geneva-based body.\r\n\r\nEuropean governments are additionally working with the United States on an update plan.\r\n\r\nWhile Tedros has swore responsibility and a post-pandemic audit, Ryan said on Wednesday the organization was holding inner talks over its activities including what it has found out about controlling the infection.','WHO cautions of oxygen lack as COVID cases set to top 10 million','','publish','open','open','','who-cautions-of-oxygen-lack-as-covid-cases-set-to-top-10-million','','','2020-06-25 05:10:31','2020-06-25 05:10:31','',0,'https://microbiozindia.com/?p=6307',0,'post','',0),(6308,2,'2020-06-25 05:10:31','2020-06-25 05:10:31','The world faces a deficiency of oxygen concentrators as the quantity of overall instances of coronavirus contamination approaches the 10 million imprint, the World Health Organization head said on Wednesday.\r\n\r\n\"Numerous nations are currently encountering challenges getting oxygen concentrators,\" WHO Director General Tedros Adhanom Ghebreyesus told a news gathering. \"Request is presently overwhelming gracefully.\"\r\n\r\nThe new coronavirus has hit 9.3 million individuals and executed more than 480,000 up until this point and is ascending by around 1 million cases for each week. This has pushed oxygen request to 88,000 huge chambers for each day, or 620,000 cubic meters of oxygen, Tedros said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nytimes.com/2020/06/23/health/coronavirus-oxygen-africa.html\">The unexpected ascent has made a deficiency of oxygen concentrators expected to help breathing of COVID-19 patients experiencing respiratory pain.</a></span>\r\n\r\nThe wellbeing office has bought 14,000 oxygen concentrators from makers and plans to send them to 120 nations in coming weeks, Tedros said. A further 170,000 concentrators - esteemed at some $100 million - will be possibly accessible throughout the following a half year.\r\n\r\nThe leader of the WHO crises program, Dr Mike Ryan, in the mean time said the pandemic in numerous Latin American nations was as yet extraordinary as passings in the district outperformed 100,000 this week. Numerous nations had encountered 25-half increments in cases in the previous week, he said.\r\n\r\n\"I would portray the circumstance in the Americas all in all as yet developing, not having arrived at its pinnacle yet, and prone to bring about supported quantities of cases and proceeded with passings,\" he said.\r\n\r\nThe United States has condemned WHO\'s treatment of the pandemic, calling the office \"China-driven\". President Donald Trump requested a prompt survey and changes and has promised to stop the Geneva-based body.\r\n\r\nEuropean governments are additionally working with the United States on an update plan.\r\n\r\nWhile Tedros has swore responsibility and a post-pandemic audit, Ryan said on Wednesday the organization was holding inner talks over its activities including what it has found out about controlling the infection.','WHO cautions of oxygen lack as COVID cases set to top 10 million','','inherit','closed','closed','','6307-revision-v1','','','2020-06-25 05:10:31','2020-06-25 05:10:31','',6307,'https://microbiozindia.com/uncategorized/6307-revision-v1/',0,'revision','',0),(6309,2,'2020-06-25 11:03:44','2020-06-25 11:03:44','An inhabitant from the rambling Black township of Soweto, south of here, has gotten the principal South African to be infused with a preliminary immunization for COVID-19 as researchers look for a treatment for the infection which has tainted millions and slaughtered several thousands over the globe.\r\n\r\nMhlongo (24), is one of around 2,000 South Africans who will partake in the worldwide investigation after the potential antibody was created at the Oxford Jenner Institute in the UK.\r\n\r\nIn the wake of getting an infusion during the preliminary on Tuesday from Shabir Madhi, head of vaccinology at Wits University and executive of the South Africa Medical Research Council\'s\' antibodies and irresistible illnesses investigation research unit, Mholongo said he needed to find out about COVID-19 and assist specialists with finding a solution for the infection.\r\n\r\nMadhi is likewise an individual from the board exhorting the South African government on the pandemic.\r\n\r\n\"This is a milestone second for South Africa and Africa at this phase of the COVID-19 pandemic. As we enter winter in South Africa and weight increments on open clinics, we need an immunization now like never before,\" said Madhi at the virtual dispatch of the preliminary, which is being run at numerous destinations in South Africa.\r\n\r\nThe South African members will be joined by 5,000 in Brazil, 4,000 in the UK, with an extra 10,000 members arranged, and up to 30,000 expected to be taken on the US.\r\n\r\nFormally known as the Ox1Cov-19 Vaccine VIDA-preliminary, the South African segment of the preliminary is likewise a first for the African mainland.\r\n\r\nIn the midst of the positive thinking, specialists called attention to that the antibody being tried is one among the in excess of 100 that are at present being investigated everywhere throughout the world.\r\n\r\nIn South Africa, at any rate 1,00,000 individuals have been determined to have COVID-19 and more than 2,000 have kicked the bucket from infection since March when the President proclaimed a condition of debacle and national lockdown which is proceeding at Level 3 of a five-level vital way to deal with battle the pandemic.\r\n<blockquote>\"Antibodies are among the most useful assets to relieve hazardous ailments. Without an immunization against COVID-19, there will probably be progressing virus, causing serious ailment and demise,\" said Zeblon Vilakazi, Vice Principal and Deputy Vice Chancellor of Research and Postgraduate Affairs at Wits University.</blockquote>\r\nHe said his establishment was resolved to help out Oxford University in the preliminary.\r\n\r\nBefore the dispatch, the South African examination was dependent upon thorough surveys and was endorsed by both the South African Health Products Regulatory Authority (SAHPRA) and the Human Research Ethics Committee of Wits University.\r\n\r\n\"It is basic that immunization considers are acted in southern side of the equator nations, remembering for the African area, simultaneously with concentrates in northern half of the globe nations,\" said Helen Rees, Chair of SAHPRA and Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI).\r\n<blockquote>\"This permits assessment of the adequacy and wellbeing of applicant antibodies to be surveyed in a worldwide setting, bombing which the presentation of numerous life-sparing immunizations into open vaccination programs for low-center pay nations much of the time lingers behind those in high-salary nations.\"</blockquote>\r\nThere has been a lot of discussion globally, including at the World Health Organization, that the antibody, when it is found, be made accessible to all nations at low or even no expense to creating nations, and not exclusively be sold in rich and created countries as it were.\r\n<blockquote>\"As the world assemblies to discover wellbeing arrangements, a South African undertaking for the improvement of a viable COVID-19 immunization is demonstration of our dedication of supporting medicinal services advancement to spare lives,\" said Glenda Gray, President and CEO of the South African Medical Research Council, which is subsidizing the venture with help from the Bill and Melinda Gates Foundation.</blockquote>\r\nThe venture additionally has the help of the South African government.\r\n\r\n\"The National Department of Health is energized at the dispatch of this immunization preliminary, which will go far to solidify South Africa\'s\' authority in the logical space,\" Sandile Buthelezi, the Director General of Health in the National Department of Health.\r\n\r\n\"With COVID-19 diseases expanding each day, the improvement of the immunization will be the keep going arrangement in the long haul, and we are completely behind the group driving this preliminary,\" said Buthelezi.','S Africa starts mainland\'s first preliminaries for COVID-19 antibody','','publish','open','open','','s-africa-starts-mainlands-first-preliminaries-for-covid-19-antibody','','','2020-06-25 11:03:44','2020-06-25 11:03:44','',0,'https://microbiozindia.com/?p=6309',0,'post','',0),(6310,2,'2020-06-25 11:03:44','2020-06-25 11:03:44','An inhabitant from the rambling Black township of Soweto, south of here, has gotten the principal South African to be infused with a preliminary immunization for COVID-19 as researchers look for a treatment for the infection which has tainted millions and slaughtered several thousands over the globe.\r\n\r\nMhlongo (24), is one of around 2,000 South Africans who will partake in the worldwide investigation after the potential antibody was created at the Oxford Jenner Institute in the UK.\r\n\r\nIn the wake of getting an infusion during the preliminary on Tuesday from Shabir Madhi, head of vaccinology at Wits University and executive of the South Africa Medical Research Council\'s\' antibodies and irresistible illnesses investigation research unit, Mholongo said he needed to find out about COVID-19 and assist specialists with finding a solution for the infection.\r\n\r\nMadhi is likewise an individual from the board exhorting the South African government on the pandemic.\r\n\r\n\"This is a milestone second for South Africa and Africa at this phase of the COVID-19 pandemic. As we enter winter in South Africa and weight increments on open clinics, we need an immunization now like never before,\" said Madhi at the virtual dispatch of the preliminary, which is being run at numerous destinations in South Africa.\r\n\r\nThe South African members will be joined by 5,000 in Brazil, 4,000 in the UK, with an extra 10,000 members arranged, and up to 30,000 expected to be taken on the US.\r\n\r\nFormally known as the Ox1Cov-19 Vaccine VIDA-preliminary, the South African segment of the preliminary is likewise a first for the African mainland.\r\n\r\nIn the midst of the positive thinking, specialists called attention to that the antibody being tried is one among the in excess of 100 that are at present being investigated everywhere throughout the world.\r\n\r\nIn South Africa, at any rate 1,00,000 individuals have been determined to have COVID-19 and more than 2,000 have kicked the bucket from infection since March when the President proclaimed a condition of debacle and national lockdown which is proceeding at Level 3 of a five-level vital way to deal with battle the pandemic.\r\n<blockquote>\"Antibodies are among the most useful assets to relieve hazardous ailments. Without an immunization against COVID-19, there will probably be progressing virus, causing serious ailment and demise,\" said Zeblon Vilakazi, Vice Principal and Deputy Vice Chancellor of Research and Postgraduate Affairs at Wits University.</blockquote>\r\nHe said his establishment was resolved to help out Oxford University in the preliminary.\r\n\r\nBefore the dispatch, the South African examination was dependent upon thorough surveys and was endorsed by both the South African Health Products Regulatory Authority (SAHPRA) and the Human Research Ethics Committee of Wits University.\r\n\r\n\"It is basic that immunization considers are acted in southern side of the equator nations, remembering for the African area, simultaneously with concentrates in northern half of the globe nations,\" said Helen Rees, Chair of SAHPRA and Executive Director of the Wits Reproductive Health and HIV Institute (Wits RHI).\r\n<blockquote>\"This permits assessment of the adequacy and wellbeing of applicant antibodies to be surveyed in a worldwide setting, bombing which the presentation of numerous life-sparing immunizations into open vaccination programs for low-center pay nations much of the time lingers behind those in high-salary nations.\"</blockquote>\r\nThere has been a lot of discussion globally, including at the World Health Organization, that the antibody, when it is found, be made accessible to all nations at low or even no expense to creating nations, and not exclusively be sold in rich and created countries as it were.\r\n<blockquote>\"As the world assemblies to discover wellbeing arrangements, a South African undertaking for the improvement of a viable COVID-19 immunization is demonstration of our dedication of supporting medicinal services advancement to spare lives,\" said Glenda Gray, President and CEO of the South African Medical Research Council, which is subsidizing the venture with help from the Bill and Melinda Gates Foundation.</blockquote>\r\nThe venture additionally has the help of the South African government.\r\n\r\n\"The National Department of Health is energized at the dispatch of this immunization preliminary, which will go far to solidify South Africa\'s\' authority in the logical space,\" Sandile Buthelezi, the Director General of Health in the National Department of Health.\r\n\r\n\"With COVID-19 diseases expanding each day, the improvement of the immunization will be the keep going arrangement in the long haul, and we are completely behind the group driving this preliminary,\" said Buthelezi.','S Africa starts mainland\'s first preliminaries for COVID-19 antibody','','inherit','closed','closed','','6309-revision-v1','','','2020-06-25 11:03:44','2020-06-25 11:03:44','',6309,'https://microbiozindia.com/uncategorized/6309-revision-v1/',0,'revision','',0),(6311,2,'2020-06-25 11:05:49','2020-06-25 11:05:49','Sinovac Biotech Ltd. ( \"Sinovac\" or the \" Company\")(Nasdaq: SVA), a main supplier of biopharmaceutical items in China, today reported the China National Medical Products Administration (or NMPA) gave an item permit for its quadrivalent Influenza antibody (or QIV).\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.businesswire.com/news/home/20200624005762/en/Sinovac-Receives-Approval-China-Quadrivalent-Influenza-Vaccine\">Sinovac anticipates that its QIV should be accessible to the China advertise for the 2020-2021 flu season. QIV contains two A strains and two B strains, suggested by the WHO, and the antibody ensures an objective gathering of 3 years and more established against the flu malady.</a></span>\r\n\r\nMr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, \"The endorsement of QIV shows our progressing promise to create antibodies against influenza related illnesses. Notwithstanding the recently endorsed QIV, our authorized flu immunization portfolio comprises of Anflu®, China\'s first additive free trivalent flu infection split antibody; Panflu®, China\'s first pandemic flu infection (H5N1) inactivated antibody; and PANFLU.1®, the world\'s first flu A H1N1 flu infection split immunization. By utilizing our ability in flu immunization innovation, Sinovac can give an incredible assortment of arrangements against influenza related illness.\"\r\n\r\n<strong>About Sinovac</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.sinovac.com/\">Sinovac Biotech Ltd.</a></span> is a China-put together biopharmaceutical organization that concentrations with respect to the exploration, advancement, assembling and commercialization of antibodies that secure against human irresistible ailments.\r\n\r\nSinovac\'s item portfolio incorporates antibodies against enterovirus71 (EV71), hepatitis An and B, occasional flu, H5N1 pandemic flu (avian influenza), H1N1 flu (pig influenza), varicella immunization and mumps. Healive, the hepatitis An immunization fabricated by the Company, has passed the evaluation under WHO prequalification techniques in 2017. The EV71 immunization, an inventive antibody created by Sinovac against hand foot and mouth sickness brought about by EV71, was marketed in China in 2016. In 2009, Sinovac was the main organization worldwide to get endorsement for its H1N1 flu antibody, which it has provided to the Chinese Government\'s inoculation battle and storing program. The Company is likewise the main provider of the H5N1 pandemic flu immunization to the administration accumulating program.\r\n\r\nThe Company is building up various new items including a Sabin-strain inactivated polio immunization, pneumococcal polysaccharides antibody, a quadrivalent flu immunization and a SARS-CoV-2 (ordinarily alluded to as COVID-19) immunization. Sinovac essentially sells its antibodies in China, while likewise investigating development openings in global markets.\r\n\r\nThe Company is enlisting its items in more than 30 nations outside of China. For more data please observe the Company\'s site at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.sinovac.com/\">www.sinovac.com.</a></span>','Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine','','publish','open','open','','sinovac-receives-approval-from-china-for-its-quadrivalent-influenza-vaccine','','','2020-06-25 11:05:49','2020-06-25 11:05:49','',0,'https://microbiozindia.com/?p=6311',0,'post','',0),(6312,2,'2020-06-25 11:05:49','2020-06-25 11:05:49','Sinovac Biotech Ltd. ( \"Sinovac\" or the \" Company\")(Nasdaq: SVA), a main supplier of biopharmaceutical items in China, today reported the China National Medical Products Administration (or NMPA) gave an item permit for its quadrivalent Influenza antibody (or QIV).\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.businesswire.com/news/home/20200624005762/en/Sinovac-Receives-Approval-China-Quadrivalent-Influenza-Vaccine\">Sinovac anticipates that its QIV should be accessible to the China advertise for the 2020-2021 flu season. QIV contains two A strains and two B strains, suggested by the WHO, and the antibody ensures an objective gathering of 3 years and more established against the flu malady.</a></span>\r\n\r\nMr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, \"The endorsement of QIV shows our progressing promise to create antibodies against influenza related illnesses. Notwithstanding the recently endorsed QIV, our authorized flu immunization portfolio comprises of Anflu®, China\'s first additive free trivalent flu infection split antibody; Panflu®, China\'s first pandemic flu infection (H5N1) inactivated antibody; and PANFLU.1®, the world\'s first flu A H1N1 flu infection split immunization. By utilizing our ability in flu immunization innovation, Sinovac can give an incredible assortment of arrangements against influenza related illness.\"\r\n\r\n<strong>About Sinovac</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.sinovac.com/\">Sinovac Biotech Ltd.</a></span> is a China-put together biopharmaceutical organization that concentrations with respect to the exploration, advancement, assembling and commercialization of antibodies that secure against human irresistible ailments.\r\n\r\nSinovac\'s item portfolio incorporates antibodies against enterovirus71 (EV71), hepatitis An and B, occasional flu, H5N1 pandemic flu (avian influenza), H1N1 flu (pig influenza), varicella immunization and mumps. Healive, the hepatitis An immunization fabricated by the Company, has passed the evaluation under WHO prequalification techniques in 2017. The EV71 immunization, an inventive antibody created by Sinovac against hand foot and mouth sickness brought about by EV71, was marketed in China in 2016. In 2009, Sinovac was the main organization worldwide to get endorsement for its H1N1 flu antibody, which it has provided to the Chinese Government\'s inoculation battle and storing program. The Company is likewise the main provider of the H5N1 pandemic flu immunization to the administration accumulating program.\r\n\r\nThe Company is building up various new items including a Sabin-strain inactivated polio immunization, pneumococcal polysaccharides antibody, a quadrivalent flu immunization and a SARS-CoV-2 (ordinarily alluded to as COVID-19) immunization. Sinovac essentially sells its antibodies in China, while likewise investigating development openings in global markets.\r\n\r\nThe Company is enlisting its items in more than 30 nations outside of China. For more data please observe the Company\'s site at <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.sinovac.com/\">www.sinovac.com.</a></span>','Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine','','inherit','closed','closed','','6311-revision-v1','','','2020-06-25 11:05:49','2020-06-25 11:05:49','',6311,'https://microbiozindia.com/uncategorized/6311-revision-v1/',0,'revision','',0),(6313,2,'2020-06-25 12:21:49','2020-06-25 12:21:49','Neuroscientists of the University of Zurich shed another light on the instruments answerable for familial headache: They show that a hereditary brokenness in explicit synapses of the cingulate cortex territory firmly impacts head torment event.\r\n\r\nHeadache is one of the most crippling issue, influencing one of every seven individuals and causing an enormous social and financial weight. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/23/eaaz1584\">A few discoveries recommend that headache is a sickness influencing an enormous piece of the focal sensory system and portrayed by a worldwide brokenness in tangible data handling and joining, which additionally happens between headache scenes (interictal period).</a> </span>\r\nFor instance, patients with headache display expanded cortical reactions to tangible upgrades during the interictal period. At present, the cell systems liable for these modifications are to a great extent obscure.\r\n\r\n<strong>Malfunction of astrocytes in the cingulate cortex</strong>\r\nA group of neuroscientists drove by Mirko Santello at the Institute of Pharmacology and Toxicology of the University of Zurich, in a joint effort with the University of Padua, has distinguished another component ensnared in an exceptional type of headache brought about by hereditary change.\r\nThey report that this familial hemiplegic headache type 2 (FHM2) causes a breakdown of astrocytes in the cingulate cortex, a mind locale that is associated with the sentiment of torment.\r\nAstrocytes, explicit star-molded synapses, are fundamental supporters of neuronal capacity and strongly affect mind circuits and conduct.\"In spite of their plenitude, astrocytes have been generally disregarded by neuroscientists,\" says Mirko Santello, last creator of the investigation.\r\n\r\nHowever these cells are critical to clear transmitters discharged by neurons. In their examination the analysts had the option to show that in familial headache the astrocytes can\'t evacuate unnecessary transmitters discharged by neurons. The impairment in astrocytic glutamate uptake in the cingulate cortex strongly enhances cortical dendritic excitability and thus enhances firing of the neurons.\"\r\nMirko Santello, Study Last Author, University of Zurich\r\n\r\n<strong>Less migraine occurrence due to genetic manipulations</strong>\r\nMoreover, the examination revealed that the glitch of the cingulate cortex additionally impacts headache event. In a mouse model the specialists indicated that the mice showed expanded affectability to head torment triggers. \"By controlling astrocytes in the cingulate cortex, we had the option to turn around their brokenness. This forestalled an expansion in head torment in mice conveying the hereditary deformity,\" says Jennifer Romanos, first creator of the investigation.\r\n\r\nHeadache is a confused issue that influences some portion of the sensory system. \"Our outcomes give an away from of how astrocyte brokenness created by a hereditary imperfection influences neuronal action and affectability to head torment triggers,\" clarifies Mirko Santello. The discoveries help to all the more likely comprehend headache pathophysiology and propose that the cingulate cortex may speak to a basic center point in the ailment. The showing of the connection between brokenness of astrocytes in the cingulate cortex and familial headache could help in conceiving new headache treatment techniques.\r\n\r\n<strong>Source:</strong>\r\nUniversity of Zurich\r\n\r\n<strong>Journal reference:</strong>\r\nRomanos, J., et al. (2020) <strong>Astrocyte dysfunction increases cortical dendritic excitability and promotes cranial pain in familial migraine.</strong> Science Advances. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/23/eaaz1584\">doi.org/10.1126/sciadv.aaz1584.</a></span>\r\n\r\n&nbsp;','Neuroscientists reveals new insight into systems liable for familial headache','','publish','open','open','','neuroscientists-reveals-new-insight-into-systems-liable-for-familial-headache','','','2020-06-25 14:23:39','2020-06-25 14:23:39','',0,'https://microbiozindia.com/?p=6313',0,'post','',0),(6314,2,'2020-06-25 12:07:25','2020-06-25 12:07:25','','Headache','Young woman having headache','inherit','open','closed','','headache','','','2020-06-25 12:07:25','2020-06-25 12:07:25','',6313,'https://microbiozindia.com/wp-content/uploads/2020/06/SideHeadache-scaled-1.jpg',0,'attachment','image/jpeg',0),(6315,2,'2020-06-25 12:21:49','2020-06-25 12:21:49','Neuroscientists of the University of Zurich shed another light on the instruments answerable for familial headache: They show that a hereditary brokenness in explicit synapses of the cingulate cortex territory firmly impacts head torment event.\r\n\r\nHeadache is one of the most crippling issue, influencing one of every seven individuals and causing an enormous social and financial weight. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/23/eaaz1584\">A few discoveries recommend that headache is a sickness influencing an enormous piece of the focal sensory system and portrayed by a worldwide brokenness in tangible data handling and joining, which additionally happens between headache scenes (interictal period).</a> </span>\r\nFor instance, patients with headache display expanded cortical reactions to tangible upgrades during the interictal period. At present, the cell systems liable for these modifications are to a great extent obscure.\r\n\r\n<strong>Malfunction of astrocytes in the cingulate cortex</strong>\r\nA group of neuroscientists drove by Mirko Santello at the Institute of Pharmacology and Toxicology of the University of Zurich, in a joint effort with the University of Padua, has distinguished another component ensnared in an exceptional type of headache brought about by hereditary change.\r\nThey report that this familial hemiplegic headache type 2 (FHM2) causes a breakdown of astrocytes in the cingulate cortex, a mind locale that is associated with the sentiment of torment.\r\nAstrocytes, explicit star-molded synapses, are fundamental supporters of neuronal capacity and strongly affect mind circuits and conduct.\"In spite of their plenitude, astrocytes have been generally disregarded by neuroscientists,\" says Mirko Santello, last creator of the investigation.\r\n\r\nHowever these cells are critical to clear transmitters discharged by neurons. In their examination the analysts had the option to show that in familial headache the astrocytes can\'t evacuate unnecessary transmitters discharged by neurons. The impairment in astrocytic glutamate uptake in the cingulate cortex strongly enhances cortical dendritic excitability and thus enhances firing of the neurons.\"\r\nMirko Santello, Study Last Author, University of Zurich\r\n\r\n<strong>Less migraine occurrence due to genetic manipulations</strong>\r\nMoreover, the examination revealed that the glitch of the cingulate cortex additionally impacts headache event. In a mouse model the specialists indicated that the mice showed expanded affectability to head torment triggers. \"By controlling astrocytes in the cingulate cortex, we had the option to turn around their brokenness. This forestalled an expansion in head torment in mice conveying the hereditary deformity,\" says Jennifer Romanos, first creator of the investigation.\r\n\r\nHeadache is a confused issue that influences some portion of the sensory system. \"Our outcomes give an away from of how astrocyte brokenness created by a hereditary imperfection influences neuronal action and affectability to head torment triggers,\" clarifies Mirko Santello. The discoveries help to all the more likely comprehend headache pathophysiology and propose that the cingulate cortex may speak to a basic center point in the ailment. The showing of the connection between brokenness of astrocytes in the cingulate cortex and familial headache could help in conceiving new headache treatment techniques.\r\n\r\n<strong>Source:</strong>\r\nUniversity of Zurich\r\n\r\n<strong>Journal reference:</strong>\r\nRomanos, J., et al. (2020) <strong>Astrocyte dysfunction increases cortical dendritic excitability and promotes cranial pain in familial migraine.</strong> Science Advances. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/23/eaaz1584\">doi.org/10.1126/sciadv.aaz1584.</a></span>\r\n\r\n&nbsp;','Neuroscientists reveals new insight into systems liable for familial headache','','inherit','closed','closed','','6313-revision-v1','','','2020-06-25 12:21:49','2020-06-25 12:21:49','',6313,'https://microbiozindia.com/uncategorized/6313-revision-v1/',0,'revision','',0),(6316,2,'2020-06-25 12:35:00','2020-06-25 12:35:00','To assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy for dealing with the SARS-CoV-2 virus pandemic – Ziath has introduced two optimized packages for reliable tracking of patient samples submitted for Coronavirus (COVID-19) testing.\r\n\r\nFor large-scale, high-density Coronavirus (COVID-19) testing labs - Ziath has introduced an attractively priced package that brings their Mohawk tube selector, Mirage rack scanner and Samples Software together to provide a reliable, high throughput sample-tracking technology bundle.\r\n\r\nThe liquid handling needed for clean-up and extraction of RNA from COVID-19 patient samples can be done on robots with 4, 8 or 96 well pick up and dispense heads; or multi-channel pipettes of 4 or 8 channels can be used in manual mode. To keep track of these tubes, Ziath offers its 96-position tube selector, the Mohawk, which can automatically pop up tubes from within the rack as they are required, greatly simplifying retrieval and ensuring accurate tube selection under software control. With the co-ordination of Ziath\'s Samples software, a Mirage rack scanner and Mohawk tube picker are designed to work seamlessly to provide verification of original tube position in a rack and the location of any picked tube in a daughter or destination rack, updating the database with both pieces of information in real time.\r\n\r\nFor labs specializing in testing larger Coronavirus (COVID-19) patient sample swabs - Ziath offers its 2D-coded Cryovial sample storage tubes. These are available in a large variety of volumes, up to 10ml capacity, and heights, which can accommodate almost any swab. These Cryovial sample tubes can then be stored, sorted and handled in Cryoboxes. In combination with the Samples software, labs can use a Ziath Cube 2D rack scanner to quickly and accurately update tube position information in each sample entry, with the scanner being controlled from within the database software. A competitively priced bundled package that includes a cryoprotected Cube tube scanner, Samples sample tracking software and two cases of Cryoracks plus sufficient Cryotubes to fill these is now available.\r\n\r\nFor further information on these optimized packages for reliable tracking of Coronavirus (COVID-19) patient samples please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.ziath.com/ziath_downloads/ziath_coronavirus_datasheet.pdf\">www.ziath.com/ziath_downloads/ziath_coronavirus_datasheet.pdf </a></span>or contact Ziath on +44-1223-855021 / +1 858-880-6920 / info@ziath.com\r\n\r\nFounded in 2005, Ziath specialises in development of innovative instrumentation control and information management products using 2D DataMatrix bar-coded tubes to simplify automation processes in life science organisations, from academia, to the biotech and pharma industries. For further information please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.ziath.com\">http://www.ziath.com</a></span>','Coronavirus (COVID-19) Sample Tracking Packages','','publish','open','open','','coronavirus-covid-19-sample-tracking-packages','','','2020-06-25 12:35:00','2020-06-25 12:35:00','',0,'https://microbiozindia.com/?p=6316',0,'post','',0),(6317,2,'2020-06-25 12:28:52','2020-06-25 12:28:52','','ZiathPR19-imageA','','inherit','open','closed','','ziathpr19-imagea','','','2020-06-25 12:28:52','2020-06-25 12:28:52','',6316,'https://microbiozindia.com/wp-content/uploads/2020/06/ZiathPR19-imageA.jpg',0,'attachment','image/jpeg',0),(6318,2,'2020-06-25 12:35:00','2020-06-25 12:35:00','To assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy for dealing with the SARS-CoV-2 virus pandemic – Ziath has introduced two optimized packages for reliable tracking of patient samples submitted for Coronavirus (COVID-19) testing.\r\n\r\nFor large-scale, high-density Coronavirus (COVID-19) testing labs - Ziath has introduced an attractively priced package that brings their Mohawk tube selector, Mirage rack scanner and Samples Software together to provide a reliable, high throughput sample-tracking technology bundle.\r\n\r\nThe liquid handling needed for clean-up and extraction of RNA from COVID-19 patient samples can be done on robots with 4, 8 or 96 well pick up and dispense heads; or multi-channel pipettes of 4 or 8 channels can be used in manual mode. To keep track of these tubes, Ziath offers its 96-position tube selector, the Mohawk, which can automatically pop up tubes from within the rack as they are required, greatly simplifying retrieval and ensuring accurate tube selection under software control. With the co-ordination of Ziath\'s Samples software, a Mirage rack scanner and Mohawk tube picker are designed to work seamlessly to provide verification of original tube position in a rack and the location of any picked tube in a daughter or destination rack, updating the database with both pieces of information in real time.\r\n\r\nFor labs specializing in testing larger Coronavirus (COVID-19) patient sample swabs - Ziath offers its 2D-coded Cryovial sample storage tubes. These are available in a large variety of volumes, up to 10ml capacity, and heights, which can accommodate almost any swab. These Cryovial sample tubes can then be stored, sorted and handled in Cryoboxes. In combination with the Samples software, labs can use a Ziath Cube 2D rack scanner to quickly and accurately update tube position information in each sample entry, with the scanner being controlled from within the database software. A competitively priced bundled package that includes a cryoprotected Cube tube scanner, Samples sample tracking software and two cases of Cryoracks plus sufficient Cryotubes to fill these is now available.\r\n\r\nFor further information on these optimized packages for reliable tracking of Coronavirus (COVID-19) patient samples please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.ziath.com/ziath_downloads/ziath_coronavirus_datasheet.pdf\">www.ziath.com/ziath_downloads/ziath_coronavirus_datasheet.pdf </a></span>or contact Ziath on +44-1223-855021 / +1 858-880-6920 / info@ziath.com\r\n\r\nFounded in 2005, Ziath specialises in development of innovative instrumentation control and information management products using 2D DataMatrix bar-coded tubes to simplify automation processes in life science organisations, from academia, to the biotech and pharma industries. For further information please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.ziath.com\">http://www.ziath.com</a></span>','Coronavirus (COVID-19) Sample Tracking Packages','','inherit','closed','closed','','6316-revision-v1','','','2020-06-25 12:35:00','2020-06-25 12:35:00','',6316,'https://microbiozindia.com/uncategorized/6316-revision-v1/',0,'revision','',0);
